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     Abstract 
 
 
It is widely accepted that both osteoporosis (OP) and cardiovascular disease (CVD) are 
common conditions and are a major cause of morbidity and mortality within the ageing 
population. Traditionally they have been viewed as two separate conditions that increase 
with age and are therefore frequently seen in the same individual. In this large study of 
462 postmenopausal women the primary objective is to investigate the relationship 
between OP and aortic calcification (AC); investigating associations between AC, BMD 
and regulators of bone remodelling that have been implicated in the pathogenesis of 
vascular calcification (VC) such as the Wnt signalling pathway. A secondary objective is to 
investigate the effects of bisphosphonates (BPs) on VC in postmenopausal women with 
low BMD, in a 2-year randomised controlled trial. This research is clinically important 
since no therapies are available that can reverse VC. Results will provide valuable 
information on whether BPs can be used to prevent or decrease AC in addition to 
improving BMD and reducing fracture risk. An important aspect of this study is to evaluate 
the novel application of simple, non-invasive imaging techniques for quantifying AC. Two 
methods including pulse wave velocity (PWV), an ultrasound method of assessing arterial 
stiffness, and lateral vertebral fracture assessment (VFA) scanning; an imaging method 
previously validated for the quantification of AC, will be compared to the gold-standard of 
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1.1 Bone  
Bone is a dynamic connective tissue consisting of an inorganic and organic phase. 
Approximately 60% of bone tissue is inorganic matter, 8-10% is water and the remainder 
is organic matter [1]. The inorganic phase of bone tissue is an impure form of 
hydroxyapatite (Ca10[PO4]6[OH]2) – a naturally occurring calcium phosphate. The organic 
phase is predominately made up of type I collagen and a variety of non-collagenous 
proteins and cells [2]. The structure of bone and its composition reflect a balance between 
its two major functions; the provision of mechanical integrity for locomotion and protection, 
and involvement in the metabolic pathways associated with mineral homeostasis [1]. 
There are two types of bone within the body, cortical and trabecular bone. Cortical bone is 
dense and compact and forms the outer layer of bone whereas trabecular bone makes up 
the inner layer of bone and has a spongy, honeycomb-like structure (Figure1.1) Cortical 
bone constitutes approximately 80% of our skeletal mass and the remaining 20% is that of 
trabecular bone [3]. 
                                
Figure 1.1 The microscopic structure of bone. Accessed 
2010 (www.animusmedicalmindmaps.com).  
                          
1.1.1 Bone Remodelling 
To maintain the structure-function relationship, bone is constantly broken down and rebuilt 
in a process known as bone remodelling and this process leads to the replacement of 
between 4 and 10% of bone annually in the adult human [1]. Bone remodelling is a 





    
(resorption), and the replacement with newly formed bone (formation). There are four 
types of cell involved in bone remodelling which are responsible for the production, 
maintenance and resorption of bone: 
 
1. Osteoblasts are mononucleate cells that descend from mesenchymal stem cells in bone 
marrow [4] and are responsible for the production of the protein matrix of bone which is 
made up of type 1 collagen and several non-collagenous proteins. This protein matrix is 
known as osteoid which creates the template for mineralisation and the production of 
mature bone [1].  
2. Lining cells are flat inactive osteoblasts that form a membrane at the surface of the bone 
tissue.   
3. Osteoclasts are multinucleated cells that originate from monocytes and are responsible 
for the resorption of calcified bone and cartilage. During the process of bone resorption 
osteoclasts lie in small pits on the bone surface that are created by the digestion of 
underling bone. The pits (or Howship’s Lacunae) are formed in a sealing zone from the 
attachment of the cells plasma membrane to the underlying bone. A ruffled border 
secretes acid onto the lacunae thus acidifying and aiding dissolution of the mineralised 
bone matrix.  
4. Osteocytes are also from the mesenchymal cell lineage and are the most abundant 
cellular component of bone. They are mature bone cells and their primary role is the 
maintenance of cellular activity and the regulation of bone turnover. Osteocytes are 
thought to be cells that control osteoblastic and osteoclastic activity within a basic 
multicellular unit (BMU), where bone remodelling occurs [5]. Osteocytes generate an 
inhibitory signal that is passed through their cell processes to osteoblasts for recruitment 
to enable bone formation [6]. 
 
Bone remodelling is complex, requiring the balanced interaction between osteoblasts and 
osteoclasts that are regulated by biochemical as well as mechanical factors on trabecular 
bone surfaces and in harversian systems [7]. The bone remodelling cycle of resorption 
and formation can be summarised in five phases (Figure1.2): 
 
1. Activation begins as a result of mechanical or biochemical stimuli from quiescence. 
Under the influence of parathyroid hormone (PTH), calcitriol, or other bone marrow 
derived hormonal or cytokine signals osteocytes start to withdraw and swell. This action 
exposes the thin layer of unmineralised bone matrix or osteoid that encases the surface of 
bone. Newly activated epithelial or bone lining cells send chemical signals to pre-





    
recruited to the site and become fused to form differentiated, multinucleated osteoclasts 
[8].  
2. Resorption is initiated by the newly formed or mature osteoclast that attaches to the bone 
surface. In order to remove bone, osteoclasts must become polarised and form a ruffled 
membrane which enables adherence to the bone surface. Hydrogen ions generated by 
carbonic anhydrase II are pumped across the ruffled membrane by a proton pump which 
dissolves bone. Enzymes are then released in order to degrade bone matrix [8].  
3. Reversal represents the start of the repair process in which osteoclasts undergo 
apoptosis. Osteoclasts are replaced by mononucleated cells that smooth off the interior of 
the resorption pit and deposit a collagen poor binding layer that cements newly deposited 
bone to the old bone surface [1, 8].  
4. Formation is a process whereby osteoblasts are attracted to the area by bone derived 
growth factors and chemical signals released by dead osteoclasts [8]. Type I collagen is 
then secreted in layers by the osteoblasts together with osteocalcin and other proteins to 
fill in the cavity forming new bone matrix.  
5. The resting phase or quiescence or represents the end stage of the remodelling process. 
Following the matrix mineralisation osteoblasts flatten onto the new surface and then 
differentiate into bone lining cells. Some of the remaining osteoblasts become trapped in 
bone matrix to become osteocytes [8]. 
 
                                    
Figure 1.2 The bone remodelling cycle illustrating the 
cellular process of bone formation and resorption. 
Accessed 2010 (www.bioscience.org). 
                                             
Remodelling allows bone to respond and adapt to stresses and mechanical loading such 
as physical exercise and under normal circumstances bone remodelling follows the 
sequence of resorption and formation and the resorption and formation rates are equally 





    
remodelling for trabecular bone is much higher than cortical bone throughout life; it is 
remodelled 5 – 10 times more rapidly than cortical bone [8]. Histologically bone is 
composed of individual BMU’s [9] which are the coupled functional unit of osteoclasts and 
osteoblasts [10] and annually, the healthy adult may resorb and replace approximately 3 
million BMUs, each taking 3 to 4 months from activation to completion [11]. The bone 
remodelling cycle is regulated by local and systemic factors. At the earliest phase of 
remodelling, osteoblastic marker runt-related transcription factor (Runx2) is necessary for 
progenitor cell differentiation along the osteoblast lineage [12]. During the sequence of 
cellular proliferation, Runx2 regulates the expression of genes encoding osteocalcin, 
VEGF, RANKL and sclerostin [13]. A large number of paracrine, autocrine, and endocrine 
factors affect osteoblast development and maturation. For example, bone morphogenetic 
proteins (BMP’s), growth factors FGF and IGF, angiogenic factors endothelin-1, hormones 
such as parathyroid hormone (PTH) and prostaglandin agonists, all modulate osteoblast 
differentiation [14]. The fully differentiated osteoblast is characterised by its co-expression 
of alkaline phosphatase (ALP) and type I collagen (PINP), which are both essential for the 
synthesis of bone matrix and its subsequent mineralisation [15]. Mature osteoblasts also 
produce regulators of matrix mineralisation including osteocalcin, osteopontin (OPN) and 
osteonectin (ON) and RANKL which is necessary for osteoclast differentiation.  When 
osteoblasts reach the end of their lifespan they are transformed into either osteocytes or 
lining cells. Specific molecules expressed by osteocytes include fibroblast growth factor-
23 (FGF 23) and sclerostin, which control bone formation and phosphate metabolism [16]. 
Osteoclast differentiation is dominated by the RANKL/RANK/OPG pathway. This pathway 
is based on osteoblasts promoting osteoclast differentiation through the membranous 
secretion of RANKL and the binding of this factor to the membrane receptor RANK on 
osteoclast precursors [17]. The promotion of osteoclast differentiation by the receptor 
activator of nuclear factor kappa B ligand (RANKL) is inhibited by the decoy receptor 
osteoprotegerin (OPG), a glycoprotein and member of the tumour necrosis factor (TNF) 
receptor superfamily, which is also produced by osteoblasts [18]. Oestrogens increase 
OPG and decrease RANKL expression in osteoblasts, thus increasing bone formation. 
Postmenopausal bone loss is linked to reduced oestrogen levels resulting in increased 
resorption and subsequent bone loss [17]. 
 
             1.1.2 Mineral homeostasis 
 
Bone plays a vital role in human physiology. The word ‘homeostasis’ means steady-state 
where several ionic concentrations must be maintained at constant levels, one of which is 
calcium. Ninety nine percent of the body’s calcium is contained in the skeleton [8] and the 





    
muscle contraction, hormone secretion and enzyme activities such as blood clotting [19]. 
Approximately half the calcium in the bloodstream circulates as free, or ionized, calcium, 
and is available for use in these functions. The other half circulates while attached to 
proteins, and is less readily bioavailable [19]. In a healthy adult, calcium is maintained at a 
concentration of approximately 10mg/dL in blood serum. The mineral and organic 
composition of plasma, extracellular and intracellular fluid must be maintained within tight 
limits by the regulation and modulation of calciotropic hormones, including PTH, calcitonin 
and vitamin D [20, 21]. Calcium concentrations are maintained by a complex 
interrelationship between intestinal absorption, the renal retention of calcium, PTH 
secretion by the parathyroid gland, calcitonin secretion by the thyroid and osteoclastic 
activity (Figure1.3)  [8, 11].  Calcitonin is produced in the parafollicular or C-cells in the 
thyroid and It acts to reduce serum calcium opposing the effects of PTH [22, 23]. 
Parathyroid hormone maintains the levels of calcium in extracellular fluid by increasing the 
release of calcium from bone and osteoclast precursors are stimulated to differentiate into 
osteoclasts. Parathyroid hormone also increases the renal tubular resorption of calcium 
and promotes the synthesis of 1, 25 dihydroxyvitamin D3 in the kidney; the principle effect 
of 1, 25 dihydroxyvitamin D3 is to increase serum calcium levels by promoting intestinal 
absorption [24]. Vitamin D deficiency leads to a loss of mineralisation to the collagen 
matrix in bone, leading to rickets in children and osteomalacia in adults [25-27]. 
 
 
                                          
Figure 1.3 Calcium homeostasis. Calcium concentrations are 
maintained by a complex interrelationship between intestinal 
absorption, the renal retention of calcium, PTH secretion by 
the parathyroid gland, calcitonin secretion by the thyroid and 
osteoclastic activity. Accessed 2010 (www.renalmed.co.uk).         
                            
1.1.3 Skeletal structure and growth  
The adult skeleton is comprised of 206 bones in total, which vary in size and shape and 





    
we have approximately 275 bones that will later fuse to form the axial skeleton to which 
the appendicular skeleton is attached. The axial skeleton forms the central axis of the 
body and is responsible for maintaining the upright posture; it consists of the skull, the 
vertebral column, the ribs and the sternum. The appendicular skeleton refers to the 
remaining sections of the skeleton that are made up of long bones. Bones fall into five 
distinct classifications based on their shape: long, short, flat, irregular and sesamoid.  
Bone growth begins during early embryonic development between 6 – 7 weeks of 
gestation. During childhood and adolescence rapid skeletal growth occurs as linear and 
appositional growth [11]. Linear growth usually reaches its maximum at the latter half of 
the second decade [11]. Bone mass continues to increase by appositional growth, and 
peak bone mass is reached during the third decade of life at about the age of 35 for 
cortical bone [28] with trabecular bone mass peaking much earlier between 25 -30 years 
of age [29] (Figure1.4). Peak bone mass is defined as the amount of bony tissue present 
at the end of skeletal maturation and is a major determinant of bone mass in later life [30-
32]. With age, the density and internal architecture of bone starts to change.  Age related 
bone loss in both men and women begins at about the age of 40 and continues 
throughout life. The remodelling process becomes imbalanced resulting in a decline in 
cortical thickness and trabecular density [33]. In cortical bone the harversian canals 
become widened leading to increased intracortical porosity and trabecular bone also 
comes under strain as the trabeculae become thinner resulting in perforation and a loss of 
connectivity [11].  Women lose approximately 35% of cortical bone and 50% of trabecular 
bone during a lifetime whereas men lose approximately two-thirds of this amount in their 
lifetime [1, 34]. The changes to bone throughout the skeletal structure are not uniform  
and the most notable change is seen within the vertebrae with the loss of both horizontal 
and vertical trabeculae [11].  
                            
Figure 1.4 Lifetime changes in bone mass 
for men and women. Accessed 2010 





    
             1.2 Techniques for measuring bone mineral density (BMD) 
 
There are a variety of methods that can be utilised for the measurement of BMD, each 
with advantages and disadvantages. Each technique varies in precision and differs 
substantially in methodology, clinical and research utility and availability [35]. Methods of 
quantifying BMD include dual energy x-ray absorptiometry (DXA), spinal and peripheral 
quantitative computed tomography (QCT/pQCT), and quantitative ultrasound (QUS). 
Spinal QCT is used to measure the volumetric BMD of trabecular bone and/or cortical 
bone that forms the exterior walls of the vertebrae [36]. Trabecular bone is much more 
metabolically active compared to cortical bone and is affected by age, disease and 
therapy-related changes earlier and to a greater degree than cortical bone. The 
advantage of QCT is that it is able to detect early changes in BMD in response to 
treatment or disease [37]. Peripheral QCT (pQCT) also uses CT to measure BMD at 
peripheral body sites such as the forearm and leg, and is useful for measuring bone 
strength [38].  
 
 
1.2.1 Dual Energy X-ray Absorptiometry (DXA)  
 
DXA imaging allows the 2-dimensional visualisation and analysis of bone and the 
surrounding soft tissue. During DXA analysis, an edge detection algorithm is used to 
determine the edges of the bone. The area of the bone is derived by summing the pixels 
within the bone edges, and the BMD is calculated from the mean BMD over all pixels that 
are identified as bone. Using the surrounding soft tissue adjacent to bone is an important 
part of the overall image analysis. It serves as a reference area of comparable thickness 
and composition.  Dual energy x-ray absorptiometry uses an x-ray tube that emits x-rays 
at two different energies collimated to a narrow beam. When these pass through the 
subject, the intensity of the beam is registered by a detector situated directly opposite and 
the attenuation profiles of the two energy beams are recorded (Figure 1.5). Dual energy 
X-ray beams are produced by continuously switching the tube voltage between high and 
low values. The attenuation coefficient is dependent on the atomic number of the 
material/tissue being x-rayed and photon energy, and this allows the areal densities of 
bone mineral (hydroxyapatite) and soft tissue to be inferred [39]. Dual energy x-ray 
absorptiometry enables the measurement of BMD at clinically important sites such as the 
hip, lumbar spine and forearm. Bone mineral content (BMC) and bone area are calculated 
to provide areal BMD (g/cm2). In addition, whole body composition scans can be 
performed using DXA, providing valuable information such as fat and lean percentages as 
well as BMC and total body mass. The wealth of information provided by whole body DXA 





    
scan times, minimal scanning preparation, low radiation dose and good measurement 
precision. 
 
                                        
Figure 1.5 Image showing the mechanism of 
DXA. DXA uses an x-ray tube that emits x-rays 
at two different energies collimated to a narrow 
beam. When these pass through the subject, the 
intensity of the beam is registered by a detector 
situated directly opposite and the attenuation 
profiles of the two energy beams are recorded. 
Accessed 2012 (lsda.jsc.nasa.gov).   
 
For many years it has been widely accepted that osteoporotic fractures are associated 
with increased morbidity and mortality. Advances in the field came with the ability to 
diagnose OP before fractures occur and with the development of effective treatments and 
the measurement of BMD played an essential role in both these developments [40]. Bone 
mineral density measurements are important for the evaluation of patients at risk of OP 
and for determining the appropriate use of anti-fracture treatment [41-43]. Dual energy X-
ray  absorptiometry scans are primarily used to scan areas of the central skeleton to 
measure BMD of the lumbar spine and hip [40]. Bone mineral density at the hip is the 
most reliable measurement for predicting hip fracture risk [44-46] and the spine is an 
important skeletal site for monitoring treatment effects [47-49]. It should be noted however 







Osteoporosis is a term derived from the Greek language and directly translated means 





    
associated with OP was developed by German pathologists in the nineteenth century, 
initially to distinguish it from other conditions such as osteomalacia and osteitis fibrosa 
cystica [11]. In 1941, Albright et al defined OP pathologically ‘as a condition in which there 
is a lack of bone tissue, but that tissue which remains is fully calcified’ [51]. The current 
definition of OP originated with a Consensus Development Conference (CDC) in 1999 [52] 
and was given credibility by a World Health Organisation (WHO) Study Group in 1994 
[53]. It defines OP as:  
 ‘A progressive systemic skeletal disease characterised by low bone mass and micro-
architectural deterioration of bone tissue, with a consequent increase in bone fragility and 
susceptibility to fracture’ [42]. 
The WHO later suggested that low BMD and fracture be amalgamated and stratified into 
clear definitions (Table1.1). A T-Score is the number of standard deviations below the 
average for a young adult at peak bone density. 
Table1.1 World Health Organisation classification of osteoporosis [53]. 
Definition Criteria 
 
Normal BMD value of greater or equal value to 1 SD below the young 
adult mean value (T≥ -1.0) 
Osteopenia (low bone density) BMD value that lies between 1 and 2.5 SD below the young 
adult mean value (T -1.0  -  >2.5) 
Osteoporosis BMD value greater than or equal to 2.5 SD below the young 
adult mean value (T ≤2.5) 
Established osteoporosis BMD value greater than or equal to 2.5 SD below the young 
adult mean value (T ≤2.5) with the presence of one or more 
fragility fractures. 
 
T- Scores are calculated by taking the difference between a patient’s measured BMD and 
the mean BMD in healthy young adults, matched for gender and ethnic group, and 
expressing the difference relative to the young adult population standard deviation (SD): 
 
T-score =   Measured BMD – young adult mean BMD 
                         Young adult population SD 
                        Figure 1.6 T-score (WHO) [53]. 
 
Measurement of BMD also provides a Z-score which can be used to determine whether a 
loss of bone density is secondary to another disease or condition. The Z-score is not as 





    
individual’s risk of sustaining an osteoporotic fracture relative to their peers. Z-scores are 
similar to T-scores, however, instead of comparing the patient’s BMD with the young adult 
mean, it is compared with the mean BMD expected for a healthy normal subject matched 
for age, gender and ethnic group: 
 
Z-score =   Measured BMD – Age matched mean BMD 
                           Age matched population SD 
                                                              Figure 1.7 Z-score (WHO) [53]. 
 
The important clinical use of BMD measurements is their ability to predict fracture risk. A 
recent advance in fracture risk prediction has led to the development of a diagnostic tool 
which provides a 10-year fracture risk probability called FRAX.  FRAX integrates clinical 
risk factors (CRFs) and BMD at the femoral neck to calculate the 10-year probability of hip 
fracture and a major osteoporotic fracture (clinical spine, forearm, hip or shoulder fracture) 
[54]. An estimation of the 10-year fracture probability is calculated in men or women using 
age, body mass index (BMI), and CRFs. The CRFs assessed include a prior fragility 
fracture, parental history of hip fracture, current tobacco use, long-term use of 
glucocorticoids, rheumatoid arthritis, other causes of secondary OP and daily alcohol 
consumption. The 10-year risk of fracture can be calculated with or without femoral neck 
BMD in the model [55]. FRAX is incorporated into many national guidelines around the 
world, including those of Belgium, Canada, Japan, Netherlands, Poland, Sweden, 
Switzerland, UK (NOGG), and US (NOF).   
 
 
1.4 Risk factors for osteoporosis 
 
Osteoporosis is the most prevalent metabolic bone disease that affects an estimated 10 
million Americans and 3 million people in the UK over the age of 50 [58,59]. Various risk 
factors are associated with the development of OP and are categorised as either 
modifiable or non-modifiable risk factors. The prevalence of OP increases markedly with 
age and after menopause and by the age of 60, approximately 15% of all women will have 
OP, with the incidence increasing to over 25% by the age of 80 [56]. Osteoporosis has 
great personal and economic burden. In Europe, disability due to OP is greater than that 
caused by cancers (with the exception of lung cancer) and is comparable with or greater 
than that resulting from a variety of chronic non-communicable diseases, such as 
rheumatoid arthritis [57]. 
 
Osteoporosis is often classified as either primary or secondary OP. A diagnosis of primary 





    
with the process of normal ageing.  It is six times more common in women than men, 
occurring in women 15 to 20 years after menopause. The loss of bone is linked to 
oestrogen deficiency in women and a testosterone deficiency in men. There is a rapid loss 
of trabecular bone in primary OP resulting in the increased risk of vertebral and forearm 
fracture [58]. Secondary OP is used to define OP where there is a clearly identifiable 
cause such as disease or prolonged drug use, and it can arise at any age and affect men 
and women equally. It occurs in almost two-thirds of men, more than half of 
premenopausal and peri-menopausal women and about one-fifth of postmenopausal 




Previous twin and epidemiological studies have demonstrated that bone mass is under 
strong genetic control [60-65]. Inherited bone size, body composition and endocrine 
function may also explain genetic similarities however it is difficult to separate genetic and 
environmental roles in the determination of bone mass. One of the most important 
determinants of bone loss in women is oestrogen deficiency at menopause, and previous 
studies have indicated that age at menopause is genetically determined [66].  
 
1.4.2 Gender 
Gender plays an important part in bone mass development. It is widely accepted that men 
have a larger bone size than women and greater cortical mass [67, 68]. Puberty also 
plays an important role in determining gender differences in bone size and mass but this 
is not fully understood [69]. Before puberty, in both sexes, linear and appositional skeletal 
growth increases progressively. Boys enter puberty 2-years later than females and as a 
result can acquire greater bone length prior to puberty [70, 71]. A study by Specker et al 
showed that physical activity combined with a high calcium intake increased both bone 
circumference and cortical thickness, suggesting that gender-related differences in bone 
size are to some extent related to variation in physical activity, dietary factors or the effect 
of muscle mass on bone geometry [72]. In conclusion, males do have greater bone 
density and larger bone geometry but these differences are only partly explained by 













    
              1.4.3 Ethnicity 
It is well documented that there is great variation in both skeletal size and mass between 
racial groups [73-76]. These may be attributed to genetic factors although there are 
environmental factors such as diet and physical activity that may account for the wide 
variations. Black people have larger denser bones than whites, while the Chinese have a 
smaller skeletal mass [11]. Dietary factors may play a greater role in defining racial 
variation. For example, the correction of a low calcium diet in the Japanese population has 
led to an increase in average height [11]. 
 
1.4.4 Hormonal influences 
Women have a lower bone mass than men, and this difference increases following the 
menopause. The factors that influence skeletal development and determine gender 
differences have been assumed to be related primarily to sex steroid action. Sex steroids 
are synthesised in response to signals from the brain. It is this stimulus from the 
hypothalamus to the pituitary gland which releases hormones that target the reproductive 
organs [77]. Luteinising hormone (LH) and follicle-stimulating hormone (FSH) stimulate 
the synthesis of progesterone and oestrogens in the female ovaries and testosterone in 
the male testes [77-79]. With the onset of puberty, hormones contribute to gender 
differences and the greater bone mass in men [70]. Studies have shown that gonadal 
hormones can increase bone formation [80] particularly in cortical areas, and the absence 
of androgen action has been related to lower bone mass and smaller size [81]. 
Testosterones are known to influence weight and muscle mass and therefore also 
indirectly affect skeletal development. Oestrogens slow the rate of bone remodelling and 
help to maintain a balance between bone formation and resorption by increasing the 
release of osteoclast and osteoblast progenitor cells in the bone marrow [82-84]. 
Conversely, oestrogen deficiency causes an increase in bone remodelling where 
osteoclastic activity is increased coupled with a reduction in osteoblastic activity, resulting 
in increased resorption and reduced formation leading to bone loss [85]. 
 
1.5 Modifiable risk factors for osteoporosis 
 
1.5.1 Dietary factors 
 
The contribution of dietary calcium to bone mass has been debated but it has been shown 
that a high lifelong calcium intake is associated with a higher bone mass [86]. Calcium 





    
calcium intake, absorption and excretion. Adequate calcium intake is important throughout 
life in order to maintain bone density and if calcium intake is suboptimal peak bone mass 
may not be attained [1]. Dietary factors such as protein and vitamin K also play an 
important role in bone status along with other essential nutrients and trace elements such 
as magnesium, zinc and copper. The effects of protein on bone have been contradictory 
with studies indicating that protein increases renal excretion of calcium [87-89] while 
others have shown protein slows down age-related bone loss [90-92]. It has been 
suggested that vitamin K has a role in bone metabolism, and inadequate vitamin K intake 
has been thought to increase the risk of osteoporotic fracture [93]. Three vitamin K–
dependent proteins, osteocalcin, matrix Gla protein, and protein S, are found in bone and 
osteocalcin is the most abundant [93]. The exact role of vitamin K is unclear, however it 
has been shown to have a protective effect on bone, increasing osteoblastogenesis and 
decreasing osteoclastogenesis, thereby increasing bone formation and decreasing bone 
resorption [93].  
 
 
1.5.2 Physical inactivity 
 
The role of regulation of bone structure by physical activity has been shown to begin as 
early as 5 -7 weeks of prenatal life [94, 95]. Environmental influences during childhood 
and puberty have been shown to benefit bone mineral development. Physical activity in 
childhood stimulates the bone remodelling process and expands bone size to produce 
larger and stronger bones [96, 97]. Weight bearing exercise is believed to increase bone 
density by direct stimulation of the bone remodelling process, while a lack of weight 
bearing activity and immobilisation due to best rest, paraplegia and also during space 
flight is known to produce rapid bone loss in humans [98-100]. It has been reported that 
the initial bone loss as a result of immobilisation is approximately 1% per week and up to 
4% of bone mass can be lost per month during initial phases of bed rest [11, 101]. Bone 
remineralisation begins again following the re-introduction of weight bearing exercise 
following long periods of inactivity, however this process is much slower and often 
incomplete [102]. Studies have shown the beneficial effect of weight bearing activity on 
bone [103-106] suggesting that weight bearing exercise is an important factor in the 
regulation and maintenance of bone mass.   
1.5.3 Body mass 
Low weight, or a low BMI of <20kg/m2 is a well-documented risk factor for future fracture, 
whereas a high BMI appears to be protective [107-113]. A BMI of 20kg/m2 predicts a two-





    
1.6 Secondary causes of osteoporosis 
Hypogonadism is a well-established cause of OP in males. Conditions that may lead to 
hypogonadal OP in men are hemochromatosis and primary testicular failure [98]. Both 
cortical and trabecular bone are lost in hypogonadal osteoporosis and although the 
pathogenesis of this is unclear, the bone loss may be a result of androgen or oestrogen 
deficiency, low plasma 1,25-dihydroxyvitamin D leading to poor calcium absorption and 
reduced calcitonin levels [98]. 
 
Glucocorticoid-induced osteoporosis (GIOP) is the most common form of drug-induced 
OP [115-118] and is due to a combination of increased bone resorption and decreased 
bone formation. Many chronic rheumatological disorders are treated with glucocorticoid 
therapy including rheumatoid arthritis (RA), polymyalgia, temporal arteritis and systemic 
lupus erythematosus (SLE), however it is also used to treat asthma, chronic obstructive 
pulmonary disease (COPD), inflammatory bowel disease (IBD), and a variety of skin 
disorders [119-124]. 
 
Chronic gastrointestinal (GI) diseases leading to impaired GI absorption (malabsorption) 
are a risk factor for OP and osteomalacia [11, 125]. The most common causes of 
malabsorption are coeliac disease, blind loop syndrome as a result of intestinal 
obstruction and gastrectomy [11]. Coeliac disease is a genetically-determined chronic 
inflammatory intestinal disease caused by gluten intolerance [126] and has been found in 
approximately 3% of patients suffering from OP [127-129]. The pathogenesis of OP 
associated with coeliac disease is not well understood and it is unclear whether bone loss 
results from inadequate bone formation or from excessive bone resorption [127].  
However, the most important mechanism of BMD loss is most likely due to initial calcium 
malabsorption caused by villous atrophy and by coexisting vitamin D deficiency [130, 
131]. This leads to secondary hyperparathyroidism, increased bone resorption, and 
increased but inadequate bone formation [132-135]. 
 
Diabetes mellitus (DM) is associated with primary OP [136, 137]. The initial onset of type 
1 DM often occurs at a young age, when bone mass is still being accrued [138].  In 
individuals with poorly controlled type 1 DM, poor nutrition, excessive loss of calcium in 
the urine and ketoacidosis may all lead to bone loss and a failure to attain peak bone 
mass [136, 139].   
 
Primary hyperparathyroidism (10 HPT) is a common disease in postmenopausal women 
[140, 141].  Parathyroid hormone is secreted by the parathyroid gland and is involved in 





    
bone, absorption of calcium from the intestine, and excretion of calcium in the urine [142]. 
The overproduction of PTH in 10 HPT leads to hypocalcaemia and other metabolic 
changes and increased bone turnover, with a loss of bone more notable in cortical than 
trabecular bone [143]. Secondary hyperparathyroidism (20 HTP) often occurs in older 
people and is a physiological adaption to hypercalcaemia and is often a result of intestinal 
disease leading to malabsorption [144].  
 
Thyrotoxicosis is a metabolic syndrome associated with elevated levels of the thyroid 
hormones, thyroxin (T4) or triiodothyronine (T3). Elevated levels of thyroid hormone 
(hyperthyroidism) are associated with an increase in bone formation and resorption, 
although resorption usually exceeds formation resulting in bone loss, OP and an 
increased risk of fracture [107, 145].  
 
Chronic kidney disease (CKD) is a risk factor for secondary OP. Renal osteodystrophy or 
chronic kidney disease-mineral and bone disorder (CKD-MBD) [146] is a term applied to 
bone pathology to describe abnormalities in bone mineralisation and metabolism that 
occur in chronic kidney disease (CKD) [147], and OP is frequently associated with CKD 
stages 3-5 [148, 149]. CKD-MBD is the result of hyperparathyroidism secondary to 
hyperphosphatemia combined with hypocalcaemia, both of which are due to decreased 
excretion of phosphate by diseased or damaged kidneys. Low activated vitamin D3 levels 
are a result of the damaged kidneys inability to convert vitamin D3 into its active form, 
calcitriol, and result in further hypocalcaemia [150]. 
 
1.7 Fractures in osteoporosis 
The significant clinical outcome in OP is the increased likelihood of fracture. Fragility 
fractures at the spine, hip and forearm are the most typical sites, although fractures of the 
ribs, humerus and pelvis are not uncommon. The annual incidence of osteoporotic 
fractures (including recurrent ones) is 180,000 in England and Wales [151]. The combined 
lifetime risk for hip, forearm and vertebral fractures coming to clinical attention is around 
40%, equivalent to the risk for CV disease [152]. Fractures result in severe pain and 
disability and the cost of osteoporotic fractures to the National Health Service (NHS) each 
year is over £1.8 billion [153] and with an ageing population, it is estimated that the 
number of osteoporotic fractures over the next 50 years will double in Europe [154]. There 
is considerable morbidity after hip fracture, with 25-50% of patients becoming more 
dependent and many needing residential or nursing care [155]. Mortality rates are 
approximately 10-20% after hip fracture; with an estimated 14,000 people dying each year 





    
1.7.1 Vertebral fracture 
 
Vertebral fractures affect approximately 20% of postmenopausal women [157, 158] and 
are the most common complication of OP. Vertebral fractures are associated with 
significant pain, morbidity, excess mortality and health and social service expenditure 
resulting from long-term disability There is also an increased risk of further fractures in 
patients who have already sustained fractures [159, 160]. It is increasingly difficult to 
quantify the incidence of vertebral fracture as only a third of patients come to medical 
attention after fracture [161]. However, The European Prospective Osteoporosis Study 
(EPOS) assessed vertebral fracture incidence in 3174 men and 3614 women over a 3 
year period and reported vertebral fracture incidence increases markedly with age in both 
men and women [162]. Vertebral fractures commonly occur in the upper lumbar or lower 
thoracic vertebrae [161] and if symptomatic, typically present with the sudden onset of 
severe pain [163], and there is often an associated loss of height and thoracic kyphosis.  
One of the most important factors impairing quality of life is back pain. The EVOS study 
[159] demonstrated that patients with three or more vertebral deformities were almost 




1.7.2 Hip fracture 
 
The most severe osteoporotic fracture is that of the hip which may occur as a result from a 
fall from standing, but may also occur spontaneously [98]. Hip fractures present with 
severe pain and almost always require hospitalisation and surgical intervention [98], and 
are more common in the elderly, mostly occurring at around 80 years of age and they are 
four times more common in women [164, 165]. It is estimated that by the year 2016, there 
will be around 117,000 hip fractures a year in the UK [164]. In addition to the role of 
advancing age on the occurrence of hip fractures, both skeletal and non-skeletal risk 
factors have been identified. Low BMD is considered to be the major risk factor for hip 
fractures [107, 166], with half of all elderly women presenting with a hip fracture having 
OP [44].  
 
Hip fractures are associated with increased mortality rates [167] which may be linked to 
complications following the fracture, such as pulmonary embolism (PE), infections and 
heart failure [168-170]. In addition to high mortality rates, hip fractures also contribute to 
OP-associated disabilities such as pressure sores, bronchopneumonia and urinary tract 
infections [98]. Impaired mobility is one of the primary long-term outcomes following hip 
fracture and despite rehabilitation many patients fail to regain their pre-fracture ambulatory 





    
however, the rate of hip fracture is higher in women than in men [43] although clinical 




 1.7.3 Forearm fracture  
 
Distal forearm fractures account for approximately 15% of all fractures in adults [173]. The 
most common forearm fracture is the Colles’ fracture, and nearly always follows a fall on 
an outstretched arm. This fracture was first described by Irish surgeon and anatomist, 
Abraham Colles, in 1814 [174]. Colles’ fractures are common in women between the ages 
of 50-70 years of age and often require surgical intervention. It is characterised by a 
fracture of the distal radius in the forearm with dorsal (posterior) displacement of the wrist 
and hand. Complications following Colles’ fracture include pain and tenderness, vascular 
instability, swelling and stiffness, known collectively as algodystrophy [175].  
Approximately 95% of distal forearm fractures are the consequence of a fall [176].  Risk 
factors for wrist fracture include low BMD, a history of two or more falls in the preceding 
year, and a previous fracture after the age of 50. Poor cognitive status increases the risk 
for wrist fracture in women over the age of 75 years [177]. The incidence of Colles’ 
fractures peaks in winter, more so than that of hip fractures, and is closely related to falls 
outdoors during icy weather conditions.   
  
 
1.8 Therapy for Osteoporosis 
 
There are many treatments available that can help to maintain or increase bone density 
therefore reducing the risk of fracture. For those already affected by OP, the prompt 
diagnosis of bone loss and assessment of fracture risk are essential in order to establish 
the correct therapy available, to prevent further loss of bone and increase bone density.  
 
1.8.1 Bisphosphonates 
Bisphosphonates (BPs) are a class of drug known as anti-resorptive agents and have 
been an established treatment for bone loss, OP and hypercalcaemia in addition to 
metastatic bone disease for many years. Interest in the clinical application of BPs dates 
back to the 1960’s when they were first investigated for use in disorders of bone 
metabolism [178]. Early in-vitro laboratory studies by Fleisch et al found that blood plasma 
and urine contained a compound that inhibited calcium phosphate precipitation [179]. This 
activity was in part due to inorganic pyrophosphate, a substance not described at the time. 





    
in-vitro. However, in-vivo pyrophosphate prevented ectopic calcification but had no effect 
on normal mineralisation or bone resorption [180, 181].  It was suggested that the lack of 
activity on bone mineralisation was due to the local destruction of pyrophosphate by 
phosphatases. It was then discovered that analogs of pyrophosphate were not destroyed 
enzymatically, and from here the BP was developed [180, 181]. Bisphosphonates are 
chemically stable analogues of inorganic pyrophosphate and are compounds 
characterised by two distinct C–P bonds (Figure1.8). As a chemical structure all BPs 
share a common PCP backbone which allows a great number of possible variations, 
mostly by changing the two lateral chains on the carbon (Figure1.8) which can lead to 
extensive alterations in their physicochemical, biological, therapeutic, and toxicological 
characteristics [182].  
                                                              
Figure 1.8 The chemical structures of 
bisphosphonate and pyrophosphate. 
Accessed 2012 (en.wikipedia.org). 
 
The long R2 side-chain (Figure1.8) determines the chemical properties, the mode of action 
and the strength of the BP whereas the shorter R1 side-chain mainly influences chemical 
properties and pharmacokinetics [183]. Most of the BPs, like pyrophosphate, inhibit the 
precipitation of calcium phosphate even at very low concentrations [180] and also slow 
down the dissolution of calcium crystals [182]. The largest store of calcium in the body is 
found in bone tissue and BPs act almost exclusively on bone when administered at 
physiological doses due to their affinity to calcium [184]. Studies have shown that 1 to 2 
thirds of administered BP becomes incorporated into the skeleton and the remaining is 
excreted in the urine within the first few hours after administration [185]. Retention is 
affected in patients with high bone turnover and is also influenced by renal function [185]. 
                                 
There are two classes of BP; nitrogen containing and non-nitrogen containing and the two 





    
on bone metabolism by binding and blocking the enzyme farnesyl diphosphate synthase 
in the mevalonate pathway [187], preventing the formation of metabolites that are 
essential for connecting some proteins to the cell membrane;  a process known as 
prenylation. Inhibition of protein prenylation effects many proteins found in the osteoclast. 
These proteins can affect osteoclastogenesis, cell survival, and cytoskeletal dynamics 
[188]. The cytoskeleton is vital for maintaining the ruffled border that is required for 
contact between a resorbing osteoclast and a bone surface. Non-nitrogen containing BPs 
are metabolised in the cell to compounds that replace the terminal pyrophosphate moiety 
of adenosine triphosphate (ATP), forming a non-functional molecule that competes with 
ATP in the cell metabolism. As a result the osteoclast initiates apoptosis, leading to an 
overall decrease in the breakdown of bone [183].  
 
Bisphosphonates are widely used in the management of postmenopausal OP, due to their 
efficacy in reducing the risk of fractures [189-191]. In postmenopausal OP, BPs reduce 
bone turnover markers, increase BMD at the lumbar spine and hip, and reduce the risk of 
vertebral and non-vertebral fractures [192-194]. Bisphosphonates are also used for the 
treatment of GIOP and male OP. A variety of BP treatments are available to treat OP as 
either oral or intravenous preparations but the most commonly used are oral BPs. 
Etidronate was the first to be approved for OP [194, 195], followed by alendronate [196, 
197], risedronate [195], and ibandronate [198] and most recently Intra-venous (IV) 
zoledronate [199]. These BPs modestly increase BMD by 4% – 12% reducing fracture risk 
at the spine by 30-70% and also to varying degrees at other skeletal sites in 
postmenopausal women [195].  
 
Oral BPs are not without side effects. Nitrogen containing BP preparations can cause 
gastric upset and inflammation and erosions of the oesophagus. Intravenous BPs can 
give fever and flu-like symptoms after the first infusion, which is thought to occur because 
of their potential to activate human gamma delta (γδ) T cells [200]. When administered 
intravenously for the treatment of cancer and OP, BPs have been associated with 
osteonecrosis of the jaw (ONJ) and some rarer side effects including atrial fibrillation and 
inflammatory eye disease. Current estimates of ONJ related to oral BP therapy for 
osteoporosis are between 1 in 10,000 to 1 in 100,000 patients per year. The incidence of 
ONJ in patients with cancer, who typically receive high doses of IV BP has been 
estimated to be 1 to 10 per 100 patients [201]. Recent reports have suggested a link 
between BP use and the development of atypical fractures of the femur as this is thought 
to be due to the long term over suppression of bone turnover leading to impaired bone 





    
fragility [202, 203]. Severe joint and muscle pain has also been reported as a side effect of 




Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear 
factor kappaB ligand (RANKL), a member of the tumour necrosis factor (TNF) super 
family of ligands and receptors essential for the function of bone-resorbing osteoclasts 
[205]. RANKL interacts with a receptor (RANK) on both osteoclast precursors and 
osteoclasts. The RANKL/RANK interaction results in activation, migration, differentiation, 
and fusion of hematopoietic cells of the osteoclast lineage to begin the process of bone 
resorption [205, 206]. Denosumab acts by blocking the binding of RANKL to RANK, 
reducing the formation, function, and survival of osteoclasts, which results in decreased 
bone resorption and increased bone density [205, 206] In 2010, denosumab was 
approved for post-menopausal OP by the FDA [207] as it has been shown to improve low 
BMD in postmenopausal women [208-211].  Like BP therapy denosumab also has 
significant side effects including infections, ONJ and femoral fragility fractures. 
 
  
1.8.3 Selective Oestrogen Receptor Modulators (SERMs) 
 
Selective oestrogen receptor modulator (SERMs) is the name given to a class of 
compounds which are tissue-specific. A characteristic that distinguishes these substances 
from pure receptor agonists and antagonists is that their action is different in various 
tissues, thereby granting the possibility to selectively inhibit or stimulate oestrogen-like 
action in specific tissues [212]. SERMs block oestrogen receptors in breast tissue, but act 
as a pro-oestrogen in bone [11]. Raloxifene (Evista) is FDA approved for the prevention 
and treatment of OP in postmenopausal women. SERMs are considered good 
replacements for HRT, providing the benefits of oestrogen while avoiding the hormone's 
potential side effects such as an increased risk of breast cancer and deep vein thrombosis 
[213-215]. Raloxifene acts like oestrogen on bone, maintaining bone density and reducing 
fracture risk [216]. 
 
 
1.8.4 Hormone Replacement Therapy (HRT) 
 
Hormone replacement therapy uses oestrogens, either alone or in combination with 
progesterone for the management of menopausal symptoms, and have also been shown 
to offer good protection for bone by reducing bone turnover and therefore reducing bone 





    
heart disease, maintaining cognitive function and reducing the risk of developing 
Alzheimer’s disease [218-221].  In contrast to the beneficial effect of HRT on bone, and its 
protective role on other diseases, studies have reported health risks associated with HRT 
therapy including an increased risk of endometrial cancer in women who have not had a 
hysterectomy [213, 214] and some oestrogen-progestogen combinations may be 
associated with a small increased risk of breast cancer [222]. Due to the risks associated 
with long term HRT, it is not generally used as a first choice treatment for the long-term 
prevention OP. However, in postmenopausal women under the age of 60, who have a 
high fracture risk, HRT may be considered provided that the benefit, in terms of reducing 
fracture risk, outweighs any adverse risks for the individual. Hormone replacement 
therapy is not considered suitable for women who have risk factors for breast cancer, 




Tibolone is a synthetic steroid hormone drug, which is fairly non-selective in its binding 
profile, acting as an agonist mainly at oestrogen receptors. It is used mainly for the 
treatment of endometriosis as well as HRT in postmenopausal women and retains a 
licensed indication for the treatment of OP.  
 
1.8.6 Teriparatide and PTH 1-84 
 
Parathyroid hormone 1-34 (teriparatide, PTH-34) and PTH 1-84 belong to a class of drugs 
called anabolic agents [223]. Parathyroid hormone (PTH) is an 84-amino acid polypeptide 
secreted by the parathyroid glands in response to small changes in serum calcium [224]. 
Teriparatide is a recombinant PTH and is used to treat OP by stimulation of bone 
formation [223-225]. The mechanism of teriparatide is to stimulate new bone formation on 
inactive bone surfaces, while stimulating bone turnover by the classic remodelling cycle 
involving both osteoclastic resorption and osteoblastic reformation [224]. Teriparatide 
improves skeletal architecture; bone is gained, which is recognised as increased 
trabecular thickness and connectivity [226, 227].  
 
 
1.8.7 Calcium and vitamin D supplements  
 
Calcium and vitamin D supplements are frequently given to the elderly and patients with 
osteoporosis. However they are mainly used as an adjunct therapy for those already on 
treatments for OP. Calcium plays a vital role in the regulation of various cells in the 





    
regulation of calcium homeostasis is aimed at maintaining extracellular calcium 
concentration and balance as constant as possible in addition to protecting against 
calcium deficiency or overload [228, 229].  It should be noted however, that there is an 
increased risk or renal calculi and of cardiovascular disease with calcium and vitamin D 
supplements. Intestinal calcium absorption declines with age in both men and women, 
and calcium deficiency may play a contributory role in the development of low bone 
density [230-232] and an increased risk of fracture.  
 
Vitamin D activity is essential for the normal development of the skeleton. It is a steroid 
vitamin which encourages the absorption and metabolism of calcium and phosphorous. 
The natural form of vitamin D is cholecalciferol or vitamin D3, which is synthesised in the 
skin by the direct action of ultraviolet (UV) light on 7-dehydrocholesterol [11] The elderly 
are at high risk of vitamin D deficiency, especially the institutionalised, because of poor 
dietary intake and decreased exposure to sunlight [233, 234]. The ‘European guidance for 
the diagnosis and management of OP in postmenopausal women’ suggests that that 
where there is a high prevalence of calcium and vitamin D deficiency in the elderly, 
combined calcium and vitamin D supplements in a daily dose of 500 – 1200mg and 400-
800 IU respectively should be prescribed [235], particularly in those that are already 
receiving bone therapy.  
 
 
1.9 Cardiovascular disease 
Cardiovascular disease refers to any disease that affects the cardiovascular (CV) system, 
such as cardiac disease, vascular diseases of the brain and kidney, and peripheral arterial 
disease [236, 237]. The causes of CVD are diverse however atherosclerosis and/or 
hypertension are the most common causes. Cardiovascular disease usually affects older 
adults, and with age come a number of physiological and morphological changes that alter 
CV function and lead to an increased risk of CVD even in healthy asymptomatic 
individuals [238]. Although CVD is one of the leading causes of worldwide mortality CV 
associated mortality rates have declined in many high-income countries since the 1970s 
[239]. However,  at the same time CV deaths and disease have increased at a fast rate in 
low and middle-income countries [240]. There is increased emphasis on preventing 
atherosclerosis by modifying risk factors, such as healthy eating, exercise, and smoking 
cessation. The WHO estimates that there will be approximately 20 million CVD related 






    
1.9.1 Cardiovascular risk factors 
 
The majority of CVD is caused by risk factors that can be controlled, treated or modified, 
such as high blood pressure, cholesterol, obesity, tobacco use, physical inactivity and 




There are at least 970 million people worldwide who have hypertension, with 
approximately 330 million people in the developed world and 640 million in the developing 
world documented as having hypertension [242]. The WHO rates hypertension as one of 
the most important causes of premature death worldwide and the problem is growing.  In 
2025 it is estimated there will be 1.56 billion adults living with high blood pressure [242].  
Hypertension increases the risk for many CV diseases, including stroke, coronary artery 
disease, heart failure, and peripheral vascular disease [243]. Coronary disease in men 
and stroke in women are the principal CV events noted after hypertension onset, as 





Smoking is estimated to cause nearly 10% of CV related events, and is the second 
leading cause of CVD, after hypertension [245]. Approximately 6 million people die from 
the effects of tobacco use or as a result of passive smoking, accounting for 6 % of female 
and 12 % of male deaths worldwide, annually. By 2030 tobacco-related deaths are 
projected to increase to more than 8 million deaths a year [245]. An association between 
smoking and vascular disease has been recognised for many years [246] and is 
responsible for approximately 50% of acute myocardial infarctions (AMI) in young and 
middle-aged individuals [247] and a significant risk for coronary and peripheral artery 





The most prevalent form of diabetes mellitus (DM) is type 2, and typically occurs in later 
life. The underlying metabolic causes of type 2 DM are the combination of impairment in 
insulin-mediated glucose disposal (insulin resistance) and defective secretion of insulin by 
pancreatic b-cells [252]. Insulin resistance develops as a result of obesity and physical 
inactivity, acting on the potential for genetic susceptibility [253, 254]. Insulin resistance 
precedes the onset of type 2 DM and is commonly accompanied by other CV risk factors 





    
incidence of these risk factors is known as metabolic syndrome and many patients with 
metabolic syndrome present with impaired fasting glucose [257], even in subclinical DM 
[258]. It is the risk factors that constitute metabolic syndrome that contribute 
independently to CVD risk [252]. 
 
 
1.9.5 Physical inactivity 
 
The increasing urbanisation and mechanisation of the world has resulted in a reduction in 
the levels of physical activity. The WHO suggests that more than 60% of the global 
population is not sufficiently active [259] and approximately 3.2 million deaths each year 
are attributable to a sedentary lifestyle [260]. Research has shown that all individuals can 
benefit from regular physical activity, whether they participate in vigorous exercise or 
moderate health-enhancing exercise [261, 262]. Mobility and function can be improved 
even in the most frail and elderly adults [263]. Individuals who are physically more active 
have lower rates of all-cause mortality [264], most likely due to a decrease in chronic 
diseases, including coronary artery disease (CAD). This low rate may result from an 
improvement in CV risk factors, enhanced fibrinolysis, improved endothelial function, 
physical activity and reduced CV risk [264].  
 
 
1.9.6 Poor diet 
 
Poor diet and physical inactivity, resulting in increased weight and obesity, are the most 
common risk factors for heart disease. The role of diet and nutrition is influenced by a 
range of social, cultural, economic and physiological factors, including the availability and 
cost of food. Diet is one of the modifiable risk factors that will impact all other CV risk 
factors [265].  Hypercholesterolemia, a known precursor for CVD, is caused by saturated 
fatty acid (SFA) and trans fatty acid (TFA) found in animal products and oils that have 
been hydrogenated to turn them into semi-hard fats. In terms of nutrition, a diet high in 
SFA and TFA has been associated with CHD incidence [266]. High sodium intake is also 
a major risk factor for hypertension and subsequent CVD. During the past century, the 
evidence for the risks to human health by excess salt consumption is undeniable with 
causal associations between dietary salt intake and blood pressure being established 
through experimental, epidemiological, migration, and intervention studies [267]. It has 
been estimated that a reduction in dietary intake of sodium by approximately 1g of sodium 
a day, about 3g of salt, would lead to a 50% reduction in the number of people needing 
treatment for hypertension. The same decrease would lead to a 22% drop in the number 





    
1.9.7 Hypercholesterolemia 
 
Hypercholesterolemia is a term used to describe the presence of high levels of cholesterol 
in the blood [268]. Lipoproteins are a biochemical assembly that contains proteins and 
lipids and classified by their density; very low density lipoprotein (VLDL), intermediate 
density lipoprotein (IDL), low density lipoprotein (LDL) and high density lipoprotein (HDL) 
[269]. All the lipoproteins carry cholesterol, but elevated levels of the lipoproteins other 
than HDL (termed non-HDL cholesterol), particularly LDL-cholesterol are associated with 
an increased risk of atherosclerosis and CHD [270]. Hypercholesterolemia is attributed to 
a combination of environmental and genetic factors [271] including obesity and dietary 
choices and genetic contributions are usually due to the additive effects of multiple genes, 
though occasionally may be due to a single gene defect such as in the case of familial 
hypercholesterolemia [271]. Research has shown a strong correlation between 





Obesity is a medical condition in which excess body fat has accumulated to the extent that 
it may have a serious adverse effect on health, leading to an increase in chronic disease 
and mortality [275, 276]. The worldwide epidemic of obesity is primarily due to an 
imbalance between physical activity and dietary energy intake. A sedentary lifestyle 
coupled with an unhealthy diet resulting in obesity markedly increases the risk of CVD 
[277]. Serious complications to health as a result of obesity include type 2 diabetes [278], 
cancer and non-alcoholic fatty liver disease [278, 279]. Just as importantly, obesity leads 
to a high prevalence of CVD including ischemic heart disease (IHD) [280], angina and MI, 
congestive heart failure (CHF) [276], deep vein thrombosis (DVT) and PE [281]. Systemic 
hypertension, pulmonary hypertension (left ventricular failure, chronic hypoxia), and CHD 
all occur with disproportionately high frequency in obese individuals and may cause or 
contribute to alterations in cardiac structure and function [282, 283]. The risk of sudden 
cardiac death is also increased in obesity. The Framingham Study [283], reported that the 
annual sudden cardiac mortality rate in obese men and women was estimated to be 40 
times higher than the rate of unexplained cardiac arrest in a matched non-obese 





Atherosclerosis is the most frequent underlying cause of CHD, carotid artery disease 





    
phases of atherosclerosis [286, 287].  It is caused by a chronic inflammatory response in 
the walls of the arteries and is caused by the accumulation of macrophages and promoted 
by LDL, plasma proteins that carry cholesterol and triglycerides without adequate removal 
of fats and cholesterol from the macrophages by functional HDL [288]. Atherosclerotic 
lesions are known as atheroma [289] and the atheromatous plaque has three distinct 
components (Figure 1.9):  
1. The atheroma, which is the nodular accumulation of a soft, flaky, yellowish material at 
the centre of large plaques, composed of macrophages nearest to the lumen of the artery. 
2. Underlying areas of cholesterol crystals. 
3. Calcification at the outer base of older/more advanced lesions. 
Depending upon their composition, plaques can be classified into two types [290]:  
 
1. Stable and low risk plaques. These are relatively benign and less prone to thrombotic 
complications. Clinical symptoms present when it is large enough to compromise the 
lumen of a coronary artery, resulting in myocardial ischemia. 
2. Vulnerable, unstable or high risk plaque. This is the dangerous type of plaque which 
is liable to complications, namely rupture, tear, erosion and production of coronary 
thrombosis. 
                                          
Figure 1.9 Diagram showing the 
progression and severity of atherosclerosis 
within the arterial lumen. Accessed 2011 
(anatomyandphysiologyi.com). 
     
 
 
1.10.1 Pathophysiology of atherosclerosis 
 
Atherogenesis is a term to describe the formation of atheromatous lesions in arterial walls 
[291], and is characterised by a remodelling of arteries involving the sub-endothelial 
accumulation of atheromatous plaques. Early atherogenesis is characterised by the 
adherence of blood circulating monocytes to the endothelium of the artery, followed by 





    
macrophages [292]. This process is caused by oxidized LDL particles from plasma 
invading the endothelium. A complex set of biochemical reactions regulate the oxidation of 
LDL, involving enzymes such as lysophosphatidic acid LpA-LpA2 and free radicals in the 
endothelium [292]. Lysophosphatidic acid is a bioactive phospholipid produced by 
activated platelets and formed during the oxidation of LDL. Accumulating evidence 
suggests that this lipid mediator may serve as an important risk factor for development of 
atherosclerosis and thrombosis [293-298]. Initial damage to the endothelium results in an 
inflammatory response where monocytes enter the artery wall from the bloodstream, with 
platelets adhering to the target area. This may be promoted by redox signalling (the 
concept that free radicals and reactive oxygen species act as biological messengers) 
[299]. Redox signalling induction factors such as macrophage colony-stimulating factor 
(M-CSF) are required for the differentiation of monocytes to macrophages. Macrophages 
ingest oxidized LDL, and slowly turn into large foam cells that eventually die and 
propagate the inflammatory process [300]. There is also smooth muscle proliferation and 
migration from the tunica media into the intima responding to cytokines secreted by 
damaged endothelial cells (Figure 1.10). This causes the formation of a fibrous capsule 
covering the fatty streak (atheroma).  
                                                
Figure 1.10 The anatomy of the arterial wall showing the 
layers of cells within the intimal and medial layers of the 
arterial lumen. Accessed 2011 (www.boundless.com).  
 
 
1.11 Vascular calcification  
 
Vascular calcification is associated with congestive heart failure, hypertension, myocardial 
ischemia, and coronary insufficiency [301]. The process of VC is varied, occurring in 
different parts of the vessel and causing damage in different ways. For example, 
calcification in the vessel wall occurs in two sites: the intima and the media. Intimal 





    
plaques. Beneath the endothelium there is a fibrous cap covering the atheromatous core 
of the plaque and the presence of these plaques is generally associated with 
atherosclerotic burden, endothelial dysfunction and rupture leading to the formation of the 
thrombus [302]. Medial calcifications on the other hand are frequently found in the elastic 
interna of the aorta and coronary arteries, and appear to be independent of 
atherosclerosis, but may coexist with it. This type of calcification is also known as 
“Mönckeberg sclerosis”, after Johann Georg Mönckeberg who first described it in 1903 
[303]. Medial calcifications occur frequently in patients with CKD and DM, but also occur 
frequently within the ageing population [302-304].  
 
1.11.1 Pathophysiology of vascular calcification 
 
The mechanism by which the process of VC occurs is complex. It does not consist of a 
simple precipitation of calcium and phosphate but is instead an active and modifiable 
process in which the vascular smooth cells (VSMC’s) undergo cell death (apoptosis) and 
vesicle formation changes the phenotype of smooth vascular cells into osteoblast-like 
cells. This induces matrix formation and also attracts cells that are involved in the 
mineralisation process [302]. Vascular calcification is often triggered by active processes 
involving inflammatory cytokines such as TNF-α, C-reactive protein (CRP) and proteins 
CD40 - CD154 [305, 306] and may also be induced by disorders with calcium and 
phosphate (Ca/P) metabolism [305, 306], initiating VSMC damage and subsequent 
phenotypic switch with activation of bone forming programs [303]. Four types of 
calcification can be distinguished on the basis of location, association with plaque, and 
mode of formation [307]: Dystrophic or passive calcification - a minor form of widespread 
non-specific organ and soft tissue calcification as a result of abnormal Ca/P product, and 
three morphologic types of actively regulated calcification (in the absence of raised Ca/P 
levels),  i) calcification of cardiac valves, ii) calcification in arterial intimal layers in 
association with macrophages, lipids, and VSMC as in classical atherosclerosis, iii) 
calcification in arterial medial layers as a result of elastin fibre mineralisation, VSMC 
degeneration, and upregulation of osteogenic programs as in CKD or diabetes. The bone 
regulating proteins including OPN, OPG, MGP, Fetuin-A and receptor activator of NF-κB 
[308-310] and RANKL have been identified as playing major roles in the calcification 
developmental process [307]. 
 
 
1.12 Techniques used for measuring vascular calcification  
 
A number of non-invasive imaging techniques are now available to detect and quantify 





    
calcifications of the aorta and peripheral arteries [311-313]. Techniques such as 
echocardiography and 2-dimensional ultrasound are reliable and widely utilised methods 
for the assessment of valvular calcification [314, 315], and calcification of the carotid 
arteries, femoral arteries and aorta [316]. Computed tomography is considered to be the 
‘gold-standard’ for qualitative and quantitative assessment of coronary and aortic 
calcification (AC), and is a useful method of monitoring the progression and effects of 
therapeutic strategies aimed at modifying the progression of calcification [317, 318]. 
Although these imaging techniques are able to detect and quantify VC it is important to 
highlight a substantial limitation - that none of the techniques described are able to 
accurately differentiate between medial (arteriosclerotic) and intimal (atherosclerotic) 
calcification. For example, medial calcification is associated with arteriosclerosis which is 
characterised by the thickening, hardening and loss of elasticity of the arterial wall, 
whereas intimal calcification is associated with atherosclerosis and is characterised by the 
development of fatty plaques that subsequently obstruct the arterial lumen; It is likely that 
the quantification of VC using the imaging methods described will result with the 
measurement of either intimal or medial calcification or in some instances both types 





Ultrasound (US) based imaging methodologies have been wildly adopted to study VC in 
dialysis patients to assess superficial vessels, such as the femoral and carotid arteries 
[319].  Ultrasound involves the transmission of high frequency sound waves (2 to 10 MHz) 
through an anatomic site of interest followed by conversion of echoes into electrical 
impulses, producing 2-dimensional images [320]. Ultrasound studies rely on the 
availability of the tool, the inexpensive nature of the measurements and the ease of 
identification of superficial vessels such as the carotid and femoral arteries. Ultrasound-
based methods, however, only provide qualitative and semi-quantitative assessment of 
VC [321, 322]. The distinction between intimal and medial calcification is difficult and 
results are, for the most part, based on subjective interpretation [323].  However, the 
results generated with this methodology appear to be a reliable means for VC screening 
and outcome prediction. The advantages of US are that it is a safe method with no 
radiation exposure, and is relatively low cost, moreover,  it permits assessment of 
calcification of superficial vessels such as carotid and femoral arteries [324]. It is however 








    
1.12.2 Aortic Pulse Wave Velocity  
 
Arterial walls stiffen with age and the primary structural change with ageing is medial 
degeneration, which leads to progressive stiffening of the large elastic arteries [325]. The 
media of large arteries is composed of VSMC’s and elastic and collagen fibres, 
comprising functional musculoelastic sheets [326].  Arterial pulsation has a direct effect on 
collagen and elastin in the arterial wall, disrupting muscular attachments and causing 
elastin fibres to fatigue and fracture [325]. Another major change in the arterial wall is that 
of calcium deposition; the calcium content of the arterial wall increases with age, 
particularly after the fifth decade, which also contributes to arterial stiffness [327]. A well-
validated method for the assessment of arterial stiffness is pulse wave velocity (PWV) 
[328, 329]. Increased PWV is related in part to the extent of calcium within the artery and 
is a simple, non-invasive, radiation free method for estimating VC. Pulse wave velocity 
can be measured in any arterial segment between two regions with carotid-femoral PWV 
is the most widely used method for assessing central arterial or aortic stiffness [330] which 
is shown to be an independent predictor of CV mortality and morbidity in the elderly [331, 
332], as well as in the general population [333, 334]. The assessment of aortic PWV 
involves the measurement of two quantities: the transit time of the arterial pulse along an 
arterial segment and the distance between both recording sites (Figure 1.11).  
 
                                                   
Figure 1.11 Carotid-femoral pulse wave velocity 
(PWV). Image shows the transit time of the arterial 
pulse along an arterial segment (the aorta) and the 
distance between the carotid and femoral pulse 
recording sites. Accessed 2012 (www.neurology.org).  
 
Pulse wave velocity is calculated as the distance travelled by the pulse wave divided by 
the time taken to travel the distance [335] and increased arterial stiffness results in an 





    
is safe to use and offers good reproducible results with a coefficient of variation (CV %) 





Plain radiographs of the chest, abdomen and extremities are routinely collected in clinical 
practice and represent a valuable and inexpensive tool for detection of VC in both the 
general population [339] and in patients with chronic kidney disease (CKD) [340]. Lateral 
lumbar radiographs can also accurately detect AC and careful examination may even 
distinguish between intimal and medial calcification [313]. Medial calcification is usually 
characterised on plain radiographs as linear lesions visible along the course of an artery 
(Figure 1.12), whereas intimal calcification is more characteristically identified by patchy 
and irregular radio-opaque lesion [341].  
 
                                           
Figure 1.13 Lateral lumbar 
radiograph showing linear 
calcifications (arrows in black) 
along the wall of the abdominal 
aorta in front of lumbar 
vertebrae 1–4. 
                                          
Although plain radiographs are mostly qualitative, several semi-quantitative methods have 
been developed to assess VC. The best known of these methods is that by Kauppila et al 
[342], whereby AC visualised on a lateral radiograph of the lumbar spine is given a score 
of 0–24 based on the number and extent of calcified deposits in the aortic segments 
extending in front of lumbar vertebrae 1–4 (Figure 1.13). The advantages of plain 
radiographs are that they are low cost, and it may be possible to determine intimal from 
medial calcification based on characterisation of the plaques by the reader [341]. The 
Figure 1.12 Plain radiograph 
showing medial calcification of 







    
disadvantage is that they only provide a qualitative or semi-quantitative assessment of 
VC, and the scoring method used is reader dependent [341]. 
 
 
1.12.4 Magnetic resonance Imaging  
 
Magnetic resonance imaging (MRI) is a radiation free, non-invasive method of measuring 
VC and is capable of distinguishing various components of atherosclerotic plaques such 
as fibrous tissue, lipids, calcification, and thrombus [343-345]. MRI employs the use of 
nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body. NMR is a 
physical phenomenon in which nuclei in a magnetic field absorb and re-emit 
electromagnetic radiation.  Magnetic resonance imaging can create more detailed images 
of the human body than possible with X-rays. The quantitation of plaque dimensions and 
components is calculated using a 3-dimensional image reconstruction [346]. 
 
 
1.12.5 Computed Tomography  
 
Computed tomography is an imaging technique that utilises computer-processed X-rays to 
produce tomographic images or 'slices' of specific areas of the body. Digital geometry 
processing is used to generate a three-dimensional image of the inside of an object from a 
large series of two-dimensional X-ray images taken around a single axis of rotation [347]. 
Computed tomography produces a volume of data that can be manipulated, through a 
process known as windowing, in order to demonstrate various bodily structures based on 
their ability to attenuate the X-ray beam. This information is interpreted as Hounsfield 
Units (HU). Although historically the images generated were in the axial or transverse 
plane, perpendicular to the long axis of the body, modern scanners allow this volume of 
data to be reformatted in various planes or as volumetric (3D) representations of 
structures. 
 
Electron beam computed tomography (EBCT) and multi detector computed tomography 
(MDCT) are well-validated, non-invasive imaging methods which do not require the 
administration of radio-opaque contrast dyes [348]. The methods are considered to be the 
gold-standard for assessing the extent of VC and its progression in the coronary arteries, 
the aorta and the cardiac valves [349, 350]. Both CT technologies are considered 
equivalent in accuracy and reproducibility even though they operate on different imaging 
platforms [351-353]. Electron beam computed tomography employs a rotating fan of 
X‑rays produced by the impact of a beam of electrons against a tungsten ring. Image 
acquisition is rapid, limiting patient exposure to radiation [348]. Multi detector computed 





    
around the patient who lies on a movable bed that advances through the beam of X‑rays 
[348]. Although MDCT is slower than EBCT and provides a higher radiation dose, it has a 
higher spatial resolution (better image quality) than EBCT [354]. Despite the advantages 
of CT imaging techniques for the quantification of calcification, there are also substantial 
limitations. The method is unable to distinguish intimal from medial calcification and CT 
methods are expensive and provide increased exposure to ionized radiation. The lack of 
accessibility of scanners can present a major obstacle to its routine application and more 
importantly the method requires a clinician or highly trained and experienced reader to 
interpret the results.  
 
1.13 Cardiovascular disease and osteoporosis. 
 
It is now widely accepted that both OP and CVD are common conditions and are a major 
cause of morbidity and mortality within the ageing population. Traditionally they have been 
viewed as two separate conditions that increase with age and are therefore frequently 
seen in the same individual [355-363]. The suggestion of a relationship between OP and 
CVD was reported in 1990 [364], and furthermore a study of 115 postmenopausal women 
who had CT and DXA measurements showed reduced BMD in those with AC [365]. 
Recent evidence suggests that there are direct associations between BMD and VC, 
atherosclerotic burden and CV related events and mortality [356-363, 366, 367], 
independent of age and traditional CV risk factors.  
 
 
1.13.1 Cardiovascular disease and bone loss 
 
Subclinical or preclinical atherosclerosis refers to the early stage of the process of 
atherosclerosis where within the vascular walls pathological changes are taking place. 
Increasing evidence suggests that subclinical atherosclerosis confers an increased risk of 
CVD [368]. Studies have evaluated the association between subclinical atherosclerosis 
and OP and both men and women with progressive AC have significantly higher bone loss 
in the lumbar spine compared with subjects without AC progression [369]. These findings 
correlate with other studies where AC progression is associated with higher rates of bone 
loss in the proximal femur and metacarpal bones [370, 371]. Furthermore, several 
prospective studies showed that subjects with calcifications in the aorta, coronary arteries, 
carotid or femoral arteries have significantly lower BMD compared with subjects without 
VC [356, 360, 372-377]. Conversely, a few studies failed to find an association [378-381].  
Intima-media thickness (IMT) is used to detect the presence of atherosclerosis and may 
be used to track the regression, arrest or progression of atherosclerosis [382] and studies 





    
increased IMT and low BMD [383-390]. Altogether, study data strongly suggest that 




1.13.2 Cardiovascular disease, bone mineral density and fracture risk 
 
Several studies have examined the relationship between CVD and fracture risk [369, 370, 
391, 392]. An increased risk of incident fracture was observed in five studies [370, 391-
394]. The largest of the studies included more than 30,000 twins with a follow-up duration 
of 20 years [393]; an increased hip fracture risk was reported after all diagnoses of CVD in 
both men and women. Furthermore, the study showed that CHD and cerebral vascular 
disease was associated with an increased risk of fracture [393]. Studies have also 
evaluated the association between peripheral artery disease (PAD) and fracture risk, and 
reported PAD to be associated with an increased risk of non-vertebral fractures [391] and 
hip fractures [393]. Another large study of over 2000 healthy postmenopausal women by 
Bagger et al showed that AC was a strong predictor for fragility fractures; AC predicted a 
2.3-fold increased risk for hip fracture [370]. It has also been reported that not only 
women, but also men with advanced AC have a two- to three-fold increased fracture risk 
[394]. In 2005 Tankó reported data on fracture risk from a large study cohort of 2500 
postmenopausal women and concluded that not only did women with OP at the spine 
have a four-fold increase in the risk of a CV event occurring compared to those with 
osteopenia, but also it demonstrated that women with at least one vertebral fracture had a 
three-fold increase in the risk of a CV event as the severity of OP increased [361].  A 
study by Schulz et al examined the link between AC and the risk of osteoporotic fractures 
and concluded that AC is a strong predictor for low BMD and fragility fractures [359]. 
  
 
1.13.3 Low bone mineral density and cardiovascular morbidity 
 
Numerous studies have investigated the association between BMD and CV morbidity 
[361, 395-397]. A cross-sectional analysis from the Health, Ageing, and Body Composition 
(ABC) Study showed volumetric BMD (vBMD) measurements of the spine were 
significantly and inversely associated with prevalent CVD in men and women [398].  Other 
studies have reported significant associations between OP and CVD in women [399]. For 
example,  in a retrospective analysis of a predominantly female population referred for 
angiography and BMD assessment, OP was reported to be associated with 
angiographically-determined CAD [397]. A report from the 30 year follow-up of the 





    
from CVD at baseline, with a significant trend of decreasing CHD risk with an increase in 
MCA [392]. 
 
1.13.4 Low bone mineral density and cardiovascular mortality 
 
Low BMD and bone loss appear to be risk factors for CV mortality in both men and 
women and several prospective studies have reported low BMD to be inversely related 
with CV mortality [358, 366, 395, 400-402]. Postmenopausal women with low BMD had a 
1.2- to 2.3-fold increased risk of dying from CV events, independent of traditional CV risk 
factors [366, 384, 403]. The Study of Osteoporotic Fractures (SOF) showed that an 
increase in loss of BMD at the hip was associated with a 1.3-fold increase in CHD 
mortality among Caucasian women of 65 years and older [404]. Furthermore, in a study 
by Kado et al in 2000 calcaneal bone loss was related to increased risk of death due to 
atherosclerosis and CHD [358].  A prospective study by Triveldi et al in 2006 reported low 
BMD at the hip to be a significant predictor of CV mortality in a cohort of British men aged 





1.14 Common pathogenesis linking osteoporosis and cardiovascular disease 
 
Evidence from experimental research studies indicates a shared pathogenesis between 
OP and CVD [405].  Many of the factors that influence bone metabolism are involved in 
the development of vascular disease, namely atherosclerosis and VC, and several bone-
related proteins are involved in the calcification process resulting in mineral deposition 
[406]. Vascular calcification is considered to be an active process, and like osteogenesis, 
involves a complex interaction between various cells that produce matrix vesicles and 
mineralisation [355]. Vascular smooth muscle cells are able to re-differentiate into 
osteoblast-like cells,  and a subpopulation of cell known as calcifying vascular cells 
(CVCs), were shown to form nodules and mineralisation spontaneously [407]. In vitro, 
these osteoblastic cells produce hydroxyapatite, a mineral important in bone formation 
[408]. Paracrine regulators of bone metabolism such as MGP, OCN, BMP, OPN, ON, 
OPG, receptor-activated nuclear factor-kappa B ligand, and inflammatory cytokines are 
also present in atherosclerotic arteries [409]. In addition, osteoclast-like cells have been 
demonstrated in calcified arteries [410]. Thus, the vascular microenvironment possesses 
mechanisms to maintain the pathological development of mineralised deposits similar to 






    
Oestrogen deficiency is a major risk factor for OP and CVD. After the menopause, 
oestrogen levels decrease dramatically resulting in osteoclast formation and an increase 
in bone turnover with subsequent rapid bone loss. In addition, the decline in production of 
oestrogen causes the secretion of pro-inflammatory cytokines such as IL-6, IL-1, and 
TNF-alpha [411, 412].  
 
Bone morphogenetic proteins are members of the transforming growth factor (TGF-β) 
super family, and are important factors in the regulation of osteoblast differentiation [405]. 
Bone morphogenetic protein acts through up-regulation of transcription factors important 
in bone metabolism [405]. In animal models BMPs have been shown to inhibit the 
expression of collagenase-3 by osteoblasts, resulting in reduced collagen degradation and 
maintenance of bone mass [413]. Bone morphogenetic protein also appears to be an 
important mediator in VC as increased expression of BMP2 and BMP4 has been found in 
atherosclerotic lesions in endothelial cells, foam cells and VSMCs [408, 409]. In-vitro 
studies have shown factors known to induce CV disease, such as oxidative stress, 
oxidized low-density lipoprotein (ox-LDL) and TNF-α, are able to upregulate BMP 
expression in endothelial cells [414, 415]. 
 
Matrix Gla protein is a calcium-binding protein that requires vitamin K to fully function, and 
is found to be expressed in areas with VC [355]. Matrix Gla protein may be an important 
calcification inhibitor as animal studies have shown that MGP knockout mice develop 
extensive CAC [416].  Recently the mechanism by which MGP inhibits calcification has 
become clear; in vitro, MGP inhibits calcification by binding to BMP2, blocking the 
induction of osteoblasts [417]. However, the inhibitory effect of MGP on BMP-2 depends 
on the extent of MGP γ-carboxylation rather than the amount of MGP and It is likely that 
the lack of function from insufficient γ-carboxylation increases the risk of VC [418]. 
 
Osteopontin is a multifunctional glycoprotein that is expressed and secreted by various 
cell types including macrophages, endothelial cells, smooth muscle cells and epithelial 
cells. Osteopontin is also highly expressed in bone by pre-osteoblasts and osteoclasts 
[409] and accumulates in the extracellular matrix of bone tissue where it binds to 
hydroxyapatite and calcium [405]. Osteopontin is also found to be highly expressed in 
atherosclerotic arteries especially in association with macrophages and foam cells, 
suggesting that OPN plays an important role in the development and progression of 
atherosclerosis [409, 419]. It is not entirely clear whether OPN promotes or inhibits 
calcification in the arterial wall [420], however an experimental animal study by Speer et al 
suggests that OPN is an important negative regulator of calcification [421]. It has been 





    
hydroxyapatite in VSMCs in much the same way as it binds to hydroxyapatite and calcium 
in bone [421]. In animal studies conducted under calcification-inducing culture conditions, 
VSMCs isolated from OPN-knockout mice demonstrated significantly higher calcification, 
suggesting that OPN in VSMCs is an important inhibitor of calcification [422]. In contrast, it 
is suggested that elevated OPN serum levels are associated with VC [423] and 
experimental studies have shown that vitamin D3 increases OPN and calcification in 
bovine VSMCs [424]. 
 
Alkaline phosphatise is an enzyme found on the surface of osteoblasts and is used as a 
marker for bone turnover. The Hydrolysis of pyrophosphate, which is an inhibitor of 
hydroxyapatite formation, is needed to assist normal mineralisation [425]. Atherosclerotic 
calcification may be regulated by the induction of ALP in VSMCs in response to 
inflammatory mediators produced by macrophages and T cells present in plaque lesions 
[426].  In vitro studies on VSMCs showed that the ALP expression is increased in 
response to inflammatory markers, LDL and oxidative stress, and the increased 
expression was associated with increased mineralisation within the vascular wall [427, 
428]. Upregulation of ALP expression has been demonstrated in the aorta of uremic rats 
made by feeding adenine [429]. However, factors responsible for the upregulation of ALP 
in uraemia remain to be clarified [430].  
 
One important biochemical factor involved in bone resorption is OPG. Although not used 
as a bone marker in clinical practice, OPG may play an important role in the possible link 
between osteoporosis and VC. Osteoprotegerin production by osteoblasts is regulated by 
a number of factors, including BMP-2, inflammation, oestrogen, vitamin D and oxidative 
stress [427].  Osteoprotegerin is expressed in various tissues, including the skeleton and 
vascular wall and serves as a soluble decoy for RANKL [431]. Receptor activator of 
nuclear factor κappa-B ligand, its signalling receptor RANK, and its natural decoy receptor 
OPG are members of the tumour necrosis factor (TNF) and TNF receptor superfamily and 






    
                                               
Figure 1.14 showing RANKL/RANK/OPG interactions. When 
RANKL from osteoblasts binds to its receptor, RANK, on the 
surface of preosteoclastic cells, it induces osteoclastic 
differentiation. OPG, also from osteoblasts, acts as a soluble 
decoy receptor for RANKL and, thus, blocks osteoclastic 
differentiation. Accessed 2012 (circres.ahajournals.org). 
 
OPG knock-out mice show early-onset OP and increased VC [410]. In-vitro studies have 
shown that OPG may be important for endothelial cell survival [433] and may inhibit active 
calcification [434]. Experimental studies have shown that OPG might protect against VC, 
however, OPG levels appear to be elevated in patients with CV disease. Several studies 
have reported a correlation with high serum OPG levels and more severe CV disease 
[383, 404, 435-438]. While OPG appears to play a role in the pathogenesis of 
atherosclerosis, the exact mechanism remains to be explained [439]. 
 
Another important mechanism linking CV disease and OP is Wnt signalling [440]. Wnt 
signalling is crucial for osteoblast differentiation and bone formation and the Wnt–β-
catenin pathway plays a vital role in bone metabolism [440]. Recent studies have 
implicated the Wnt signalling pathway in the pathogenesis of VC [440-445]. Animal 
models have demonstrated the important role of Wnt signalling in bone formation through 
lipoprotein receptor-related protein 5 (LRP5), lipoprotein receptor-related protein 6 (LRP6) 
and β-catenin [446]. Tumour necrosis factor-alpha is a cytokine involved in systemic 
inflammation, and like oxidative stress and vitamin D, it is shown to promote VC through 
the Wnt signalling pathway [447-449]. Wnt-signalling inhibitors, Dickkopf-1 (Dkk1) and 
sclerostin (SCLE) have important roles in bone turnover. Dikkopf-1 modulates bone 
formation via the Wnt pathway preventing an excessive formation of bone [450], and 
SCLE has a role in the reduction of bone formation via the Wnt pathway [451]. 
Furthermore, both Dkk1 and SCLE have been shown to be up-regulated in areas of VC 





    
signalling is an interesting new molecular mechanism that influences both bone and 
vascular metabolism [440]. 
 
 
1.15 The relationship between lipids, BMD and vascular calcification 
Evidence suggests that CVD and OP share an etiologic factor – that hyperlipidemia 
contributes not only to atherosclerotic plaque formation, but also plays a role in OP, 
following a similar biologic mechanism involving lipid oxidation [454, 455] There have 
been numerous studies reporting the relationship between lipids and low BMD [454-461]. 
The artery wall contains cells capable of differentiation into osteoblasts following the same 
stages of differentiation that occur in bone-derived osteoblasts and ultimately producing 
bone mineral [454]. It is known that oxidative stress alone promotes vascular-cell 
calcification [428] and may account for the pro-calcific effects of oxidized lipids [462]. 
Oxidative stress markers are also significantly associated with BMD [463]. The oxidant 
stressor, H202, promotes osteochondrocytic differentiation of VSMCs by upregulating 
runx2, a key transcription factor associated with osteoblast differentiation [464]. In bone, 
high lipid levels inhibit osteoblastic activity resulting in reduced bone formation [454, 455, 
458]. Experimental research has shown that products of lipid oxidation, such as minimally-
modified LDL and oxidized phospholipids, induce osteogenic and apoptosis-mediated 
calcification of vascular cells [454, 465, 466].  
Growing evidence suggests a negative effect of an atherogenic lipid profile on bone 
formation. In a cohort of postmenopausal women, plasma levels of LDL- cholesterol and 
HDL-cholesterol were negatively and positively related to BMD respectively [467]. 
Furthermore, studies have shown that patients with low BMD not only have high lipid 
levels but also a more severe coronary atherosclerosis independent of age, and as a 
consequence, a greater risk of a CV event including stroke [468]. Animal studies have 
demonstrated that lipids have been shown to accumulate in bones of mice [455] and mice 
fed an atherogenic high-fat diet were found to have reduced bone formation [469]. Once 
outside the plasma, these lipid products are subjected to oxidative modification, thus 
becoming biologically active molecules capable of affecting a variety of cellular processes 
that ultimately result in atherogenesis and bone loss [469].  In view of the accumulating 
evidence for a cross-link between the role of lipids in bone metabolism and VC what is 
known from data from clinical studies is that patients with lower bone density and OP also 
have higher lipid levels, more severe coronary atherosclerosis, and have a greater risk of 






    
             1.16   Aortic calcification, arterial stiffness and BMD 
 
Calcification of the AA has been documented since the 1930’s. A study by Kiel et al 
reported that the presence of calcified lesions in the AA has been shown to predict CV 
events [472]. Wilson et al reported the impact of AAC on the prediction of CVD and 
concluded that AAC deposits, detected by lateral lumbar radiographs, are a marker of 
subclinical atherosclerotic disease and an independent predictor of subsequent CV 
morbidity and mortality [339]. A recent large meta-analysis by Gonҫalves et al in 2012 
investigated the incremental value of AAC in predicting long term CV outcome [473] and 
concluded that the presence of AAC is a relevant and independent predictor of future CV 
events [473]. Arterial stiffening and has long been associated with the ageing and elderly 
and is known to be accelerated by CV risk factors including hypertension, diabetes, and 
hypercholesterolemia and more importantly end stage renal failure in CKD [329, 357, 474-
479]. Furthermore, increased arterial stiffness is associated with OP and systemic 
inflammation [329, 357, 383, 478, 480]. Increasing arterial stiffness leads to an increase in 
systolic blood pressure (BP) and pulse pressure and a decrease of diastolic BP, resulting 
in increased left ventricular (LV) after-load and altered coronary perfusion [481] and the 
principal outcomes of these changes are left ventricular hypertrophy (LVH), coronary 
ischaemia, and an increase in fatigue in the structures of the arterial wall [481-483].  
 
Pulse wave velocity is an important measure of arterial stiffness. Pulse wave velocity 
measures the velocity of travel of the pulse along a length of artery, usually between the 
carotid and femoral arteries to provide a measure of aortic stiffness - VC causes an 
increase in the rigidity of the vascular wall resulting in a deceleration of the progression of 
a pulse wave along the vascular wall. Numerous studies have shown that PWV is an 
important predictor of risk of CV events [455, 475, 476] so much so that it is a highly 
recommended screening tool for predicting CV risk particularly in ESRD [484-488].  
Calcification is a common complication of CKD and ESRD [316, 489, 490]. In the general 
population and patients with ESRD, the extent of VC is associated with aortic stiffening 
and has shown to be predictive of subsequent CVD and mortality beyond established 
conventional risk factors [318, 321, 339, 491]. Disturbances in calcium (Ca) and 
phosphate (PO4) metabolism are associated with uremic bone disease in CKD and ESRD 
patients, and the results of several studies indicated that Ca overload is associated with 
the presence and progression of AC [318, 492]. The evidence strongly suggests complex 
interplay among bone activity, Ca load, and AC development, but whether the bone 








    
1.17 Bisphosphonates and aortic calcification: recent animal and clinical studies. 
 
Bisphosphonates have been an established treatment for bone loss, OP and 
hypercalcaemia for many years. Based on experimental data, BPs appear to be promising 
agents for reducing the progression of human VC. The concept of the common underlying 
pathogenesis of OP and VC reinforces the idea that pharmacological agents that inhibit 
bone loss could potentially provide additional benefits by slowing down the progression of 
atherosclerosis [493]. In this context, BPs may be a possible therapeutic option for VC 
resulting from atherosclerotic disease [494, 495].  
 
Bisphosphonates have been shown to be effective in treating and preventing OP by acting 
on the body’s main source of hydroxyapatite, the skeleton [496]. Furthermore, BPs are 
also effective treatments for diseases associated with osteoclast-mediated bone 
resorption such as Paget’s disease, multiple myeloma, and osteolytic tumour metastasis 
[493]. Following the deposition of new bone matrix, BPs are ingested by osteoclasts 
where they induce apoptosis, leading to decreased bone resorption [497]. 
Pharmacologically, BPs have a short half-life and are not metabolised in the body. Up to 
60% of the absorbed amount rapidly enters bone or becomes excreted through the 
kidneys. Small quantities of BP may be incorporated into the spleen and liver [497] and 
also into arterial walls [498]; BPs have been located in calcified matrix outside the bone 
and have been identified in calcified atherosclerotic plaques in both animals and humans 
[497-501]. The accumulation of BP in atherosclerotic arteries is likely due to their affinity 
for calcium and hydroxyapatite which has been identified in calcified atheromatous lesions 
[493]. However, BPs have been found in high concentrations within the aorta without 
atherosclerotic lesions in mice and in healthy human mammary arteries [498] suggesting 
an alternative mechanism of action.  
 
Great interest developed as a result of experimental findings that BPs inhibited extra 
osseous and soft tissue calcification in animal models [502, 503]. It has been reported that 
some BPs not only inhibit AC but also reduce lipid accumulation and fibrosis in 
atherosclerotic lesions in animal models [504], suggesting the potential for atherosclerotic 
disease regression. In addition, studies suggest that BPs may have an anti-atherosclerotic 
action which is independent of the lowering of cholesterol or calcium levels in circulation. 
From four of the main animal studies [503, 505-507] it has become clear that BPs have a 
protective role on the arterial wall, not only reducing calcifications but also the amount of 
lipid containing plaques regardless of diet. The mechanisms for this are unknown, 
however, what is known is that BPs accumulate in vascular tissue [508] and macrophages 





    
internalise BPs that may induce apoptosis. It is also recognised that nitrogen-containing 
BPs inhibit an enzyme involved in the cholesterol biosynthesis pathway [504].  
 
Although limited in number, clinical studies have investigated the effects of BPs on 
atherosclerosis and VC in humans, reporting favourable or neutral results [509-517]. 
Although BP therapy has shown to be effective on VC in animal models, there is still 
debate over its efficacy on VC in humans, with results differing between the different types 
of BP [516]. In studies on patients with ESRD undergoing dialysis, etidronate has been 
found to limit the progression of VC [510]. However alendronate and ibandronate have 
shown mixed results at limiting the progression of VC, with animal studies suggesting that 
they slow progression, while randomised controlled trials show no effect in humans [515].  
 
Carotid artery intima-media thickening (CIMT) has been evaluated in 4 studies using 
alendronate, etidronate and risedronate [509, 518-520].  Two studies [509, 510] reported 
a significant reduction in CIMT following the use of etidronate and alendronate after 1 
year. However, in contrast, Delibasi et al reported no significant change in CIMT after 1 
year in postmenopausal women on 70mg of weekly alendronate [520]. Kanazawa et al 
reported a halt in the progression of CAC, identified by plaque scores, with the use of 
risedronate [509]. Coronary artery calcification measured in haemodialysis patients taking 
etidronate was reported to be reduced following 1-years treatment [510]. In contrast,  a 
study by Ariyoshi et al, reported no significant difference in CAC scores in haemodialysis 
patients receiving etidronate [511]. Three studies have reported the positive effects of 
etidronate on AC measured by calcification scores [511-513] following 1-years treatment. 
A large study by Tanko et al, studied the effects of IV ibandronate in women with 
postmenopausal OP over a 3-year period. The study reported that ibandronate did not 
have any influence on the progression of AC over the 3-year follow up [514]. It is clear 
from the research that BPs have an inhibitory effect on the atherosclerotic process, 
however, there is still a need for large placebo-controlled studies to confirm this. Many of 
the studies with the exception of the study by Tanko [514], have been small in sample size 
with a short duration follow up. In addition, only a few studies have been placebo-
controlled. Furthermore, most of the study subjects were elderly with independent CV risk 
factors such as DM and CKD [515].  
 
Many of the underlying mechanisms for the association between VC and bone 
metabolism are still remain unclear. Previous clinical studies investigating the effects of 
BPs on VC have been limited to measurements of CIMT and calcification in the coronary 
arteries.  However, laboratory studies have identified a cell population called endothelial 





    
521], bone marrow [522], and foetal cord blood [523]. EPCs reside in bone marrow and 
may be a potential candidate for the link between bone metabolism and the vascular 
system due to their mobilisation and response to vascular injury and their contribution to 
vascular repair [524, 525], and more notably, their role in VC. The concept of osteogenic 
vs non-osteogenic EPCs may explain previous conflicting results in experimental studies 
in which treatment with EPCs or bone marrow mononuclear cells may accelerate vascular 
plaque formation instead of improving vascular function [526, 527]. Laboratory evidence 
suggests that EPCs express a number of endothelial-specific cell-surface markers and 
exhibit numerous endothelial properties [528, 529]. To further investigate the potential 
mechanisms by which BPs regulate VC, studies have examined the effects of BP on 
EPCs using flow cytometry to evaluate changes in co-expressed osteoblastic surface 
markers [530]. A recent study by Peris et al reported that EPCs co-expressing an 
osteogenic phenotype are significantly increased in patients with severe CAD or 
endothelial dysfunction, and in vitro these cells have been shown to mineralise [530]. 
Furthermore, BPs lower the expression of osteoblastic cell surface markers by circulating 
EPCs. Although more research is required in this area, results to date raise the likelihood 
that BPs may modulate the endothelial to mesenchymal transition, whereby endothelial 
cells differentiate into bone type cells [529, 531]. Studies have also investigated the 
effects of BPs on the proliferation, adhesion and migration of VSMCs [532]. It is well 
established that accelerated proliferation and migration of VSMCs from the media to the 
intimal are processes that are fundamental in the development of both intimal hyperplasia 
and atherosclerosis (Figure1.15) [533-536].  
                                                              
Figure 1.15 the migration and proliferation of 
vascular smooth muscle cells in an 







    
The inhibition of VSMC proliferation, adhesion and migration therefore represents a 
promising therapeutic strategy for the treatment of diseases such as atherosclerosis and 
intimal hyperplasia [532]. In an experimental study by Wu et al, zoledronate was found to 
have minor effects on VSMCs proliferation at relatively low concentrations. However, 
higher concentrations of zoledronate significantly reduced cell numbers [532], inferring the 
beneficial effects of therapeutic doses of BP on VSMCs.  There is good evidence to 
suggest that BPs may inhibit the progression of VC, based on animal, clinical and 
experimental studies [510, 537-540]. What is also clear is that the action of the BP 
depends on the mechanism of development of VC, although exact mechanisms of BP on 
the different underlying mechanisms of VC still remain to be established. 




    
   Chapter 2 
   Methodology 
 
 
2.1 Study overview 
 
This chapter will outline the study design, objectives and hypothesis, and methodologies 
used. The research was conducted on site at Guy’s Hospital, London in the Osteoporosis 
Unit and the Department of Nuclear Medicine.  Ethical approval was obtained from St 
Thomas’ Hospital Ethics committees for this study. 
 
2.2 Study objectives 
The primary study objective was to examine the relationship between BMD and AC in 
postmenopausal women. 
Secondary objectives:  
1. To evaluate two simple non-invasive techniques including pulse wave velocity (PWV), a 
measure of arterial stiffness and lateral DXA-VFA scans for quantifying AC by comparing 
to the ‘gold-standard’ of CT. 
2. To investigate the associations between AC, BMD and regulators of bone remodelling 
including sclerostin (SCLE),  Dickkopf-1 (Dkk1), vitamin D and bone resorption and 
formation biochemical markers including Serum type 1 pro-collagen N-terminal (PINP) 
and serum collagen type 1 cross-linked C-telopeptide (CTX), in addition to serum lipids.  
3. To determine if AC is significantly reduced in postmenopausal women on 
bisphosphonates by comparing with treatment naïve women. 
4. To examine the effects of the bisphosphonate alendronate on AC in women with OP or 
severe osteopenia.  
 
2.3 Study hypotheses 
1. Lateral VFA scans of the lumbar spine and PWV, a measurement of aortic stiffness, 
offer simple non-invasive methods for identifying subjects at risk of AC and subsequent 
CVD, which could be implemented into the clinical management of patients with OP.  




    
2. Low BMD is associated with a greater degree of AC in postmenopausal women. 
3. Bisphosphonate users have less AC compared to non-bisphosphonate users. 
4. Bisphosphonates decrease AC as well as increase BMD offering an effective treatment 
for both OP and VC. 
In order to meet the research objectives as detailed in Section 2.2 the study was 
presented as five individual study chapters to test the study hypotheses as detailed in 
Section 2.3: 
Chapter 3 - Intra- and inter-rater agreement of CT and lateral VFA images for the 
quantification of AC  
This chapter evaluated lateral VFA imaging – primarily used for the assessment of 
vertebral deformity - to determine whether the method may offer a quick and reproducible 
method for quantifying AAC. Furthermore, this study evaluated the use of moderate dose, 
non-diagnostic, non-contrast CT as a reproducible alternative to higher dose diagnostic 
CT methods used in clinical practice to quantify VC, and also evaluated three calcium 
scoring methods to establish which would provide the most expedient and operator 
friendly method of scoring calcification using non-diagnostic CT.  
 
Chapter 4 - Evaluation of lateral VFA images and pulse wave velocity for the 
assessment of AAC by comparison to the gold-standard of CT 
The main aim of this chapter was to evaluate the accuracy, sensitivity and specificity of 
lateral VFA scans for the detection of AAC as measured using the ‘gold-standard’ method 
of CT.  This study was performed in order to establish the reliability of lateral VFA imaging 
in clinical practice for quantifying AAC which could be performed concurrently with BMD 
scans, thus providing a quicker method of determining patients who may be at risk of 
future CV events. This chapter also explored the relationship between aortic stiffness 
measured using PWV ultrasound with AAC measured using lateral VFA imaging and VC 
measured using moderate dose, non-diagnostic, non-contrast CT to determine how well 
aortic stiffness correlates with AC in postmenopausal women.   
 
Chapter 5 - Associations between BMD, AC and aortic stiffness in postmenopausal 
women 
This study evaluated the associations between AC, arterial stiffness and BMD in a low risk 
population of otherwise healthy postmenopausal women, using non-invasive imaging 
methods including lateral VFA and moderate dose CT to quantify AC and VC and also 
PWV ultrasound to evaluate arterial stiffness. This study was performed in order to test 




    
the hypothesis that low BMD is associated with a greater degree of AC in postmenopausal 
women.  
 
Chapter 6 - Associations between regulators of bone remodelling, Dikkopf-1 (Dkk1) 
and sclerostin, BMD, VC and aortic stiffness in postmenopausal women 
The purpose of this study was to investigate the relationships between regulators of bone 
remodelling (Dkk1 and sclerostin) with BMD, VC (measured using DXA and moderate 
dose CT) and aortic stiffness (measured using PWV ultrasound)  to provide further 
evidence of their involvement in the pathogenesis of OP and VC – both of which are 
frequently observed in the ageing female population. 
 
Chapter 7 - The relationships between BMD, VC and aortic stiffness between 
bisphosphonate users and treatment naive postmenopausal women: A cross-
sectional and prospective study 
This was a two part chapter using both cross-section and prospective data to compare VC 
and aortic stiffness in postmenopausal women taking BP therapy for the treatment of OP 
and in treatment naive women, and also to evaluate the effects of the BP alendronate on 
AC and aortic stiffness in postmenopausal women with low BMD over 12-months in a 
randomised, controlled trial. This study was conducted to test the hypothesis that the use 
of BP therapy may confer an inhibitory effect on VC which is of great clinical importance 
since no therapies are available that can reverse or stop the progress of VC.   
 
2.4 Study population 
A total of 462 Postmenopausal women with and without fracture were recruited on to the 
study following written informed consent.  Subjects were aged between 50-81 (mean age 
62) years with a wide range of BMD values including women classified as having normal 
BMD, osteopenia and OP according to the WHO criteria for OP [53]. Subjects were 
recruited from 3 sources: 
1. Patients referred to the Osteoporosis Unit at Guy’s Hospital by their GP for routine DXA 
screening for OP. 
 
2. Patients attending the NHS Metabolic Bone Clinic at Guy’s Hospital. 
3. Volunteers from the general population who have contacted the Osteoporosis Unit at 
Guy’s Hospital to volunteer to take part in OP research studies. 
During the study consultation, each subject was required to complete a bone health and 
CV risk factor questionnaire. 




    
              2.4.1 Inclusion and exclusion criteria 
Inclusion criteria  
- Ambulatory postmenopausal* women. 
- Aged 50 and over. 
- With or without OP. 
- With or without fracture.   
 
Further inclusions for prospective study 
- Lumbar spine, femoral neck and/or total hip BMD measurement more than 2 standard 
deviations below the young adult mean for healthy women (T-score ≤ -2). 
-    Normal or clinically insignificant laboratory values 
 
* Postmenopausal status for women with an intact uterus is defined as no vaginal bleeding 
for at least 12 months or having undergone surgical menopause by removal of the uterus 
and/or ovaries. Postmenopausal status for women who have had a hysterectomy and/or 
bilateral oophorectomy will be defined biochemically using serum estradiol and FSH levels. 
 
              Exclusion criteria 
- Current or recent (within 1 year on enrolment) metabolic bone disorders other than 
postmenopausal OP including Paget’s disease, renal osteodystrophy, osteomalacia or 
any other disease known to influence bone metabolism. 
- Current uses of treatments know to effect bone turnover. 
- Current use of lipid lowering agents. 
 
Further exclusions for prospective study 
- Previous or current use of oral or IV bisphosphonates 
- Treatment with oestrogens, progestins or selective oestrogen receptor modulators 
(SERMS) for longer than 3 months in the past or any of these treatments within 3 months 
of study enrolment. 
- Current treatment with corticosteroids, calcitonins, strontium ranelate, anticonvulsants, 
vitamin D > 50,000 IU/week, teriparatide, PTH1-84 or any other treatment known to 
influence bone metabolism. 
- Abnormalities of the oesophagus and other factors which delay oesophageal emptying 
such as stricture or achalasia 
- Hypersensitivity to alendronic acid or to any of the excipients 
- Hypocalcaemia 




    
2.5 Study design 
The main aim of this project was to investigate the relationship between AC and BMD in 
postmenopausal women. The study was divided into three parts: 
1. Preliminary imaging study of 63 postmenopausal women to evaluate the novel 
application of imaging methods for the qualitative and quantitative assessment of AC and 
VC at other important vascular sites. 
2. Cross-sectional study of 444 postmenopausal women with a range of BMD levels, 
with or without fracture. 
3. Prospective study of 24 postmenopausal women to investigate the effects of 
alendronic acid on AC. 
 
 











Imaging method    
Lateral IVA  364 340 24 
PWV 386 362 24 
CT scan       137 113 24 
 
 
2.5.1 Preliminary imaging study 
 
The rationale for this part of the study was to evaluate the novel application of simple, 
non-invasive imaging techniques for quantifying AC. Two methods including PWV, an 
ultrasound method of assessing arterial stiffness, and lateral VFA scans, an imaging 
method traditionally used for the assessment of vertebral deformity, were compared to the 
‘gold-standard’ of CT. Traditionally CT has been used for the qualitative and quantitative 
assessment of calcified deposits within the coronary arteries [541-546].  The aim was to 
investigate the reproducibility and the intra- and inter-rater agreement of moderate dose 
CT for quantifying VC in the AA and other important vascular sites. The study focused on 
the image acquisition and the test-retest reproducibility of the scan results and the intra 
and inter-reader agreement, which will be influenced in part, by patient positioning and 
patient size. In addition to the scan acquisition, the Agatston, modified Agatston and 
volume scoring methods were assessed in order to establish the best method for scoring 
AC. Eight postmenopausal subjects aged 65 and over were recruited to have repeat CT 
scans and 19 postmenopausal women aged 50 and over were recruited to have repeat 




    
lateral VFA scans. This part of the study included women with a range of BMD levels 
including those with and without OP. 
 
 
2.5.2 Cross sectional study 
 
The rationale for this part of the study was to study the relationship between BMD and AC 
in 444 postmenopausal women; investigating associations between AC, BMD and 
regulators of bone remodelling that have been implicated in the pathogenesis of VC such 
as the Wnt signalling pathway.  The number of participants was based on a formal power 
calculation. Assuming a correlation of 0.27 between BMD and AC, estimated using pilot 
data collected previously, then a group of 260 subjects was considered sufficient to 
demonstrate a statistically significant correlation with a Type-1 error of p=0.05 and 90% 
power.  As the correlation between other important variable including biochemical markers 
would likely be lower, particularly in multivariate models, the study number was increased 
to 500 subjects to ensure adequate power to detect all correlations. Women aged 50 and 
over were recruited on to this study, with BMD values ranging between normal, 
osteopenic and osteoporotic according to the WHO criteria for OP [53].  Subjects that 
were taking treatments that are known to affect bone metabolism at the time of the 
assessments were excluded from the study, with the exception of BPs as one of the 
important aims of this part of the study was to compare AC and BMD in BP users with 
subjects that had never taken BPs.  
 
Preliminary imaging study assessments 
2 study visits: 
Visit 1  
- Bone density scans of the whole body, lumbar spine, hip and lateral VFA.  
- Blood tests to measure lipid levels and bone markers that reflect the rate of bone turnover. 
- PWV ultrasound scans to measure aortic stiffness. 
- A full medical history. 
 
Visit 2  
Computed tomography scan of the chest and abdomen 
 
Cross-sectional study assessments 
1 study visit  
- Bone density DXA scans of the whole body, spine, hip and lateral VFA.  
- Blood tests to measure lipid levels and bone markers that reflect the rate of bone turnover. 
- PWV ultrasound scans to measure aortic stiffness. 
- A full medical history. 




    
A sub-group of 100 subjects were selected to have CT scans to measure VC. 
 
              2.5.3 Prospective study 
 
This was a single-centre, 2-year, randomised, open-label study to determine the effects of 
alendronate on AC. This research was clinically important since there are no therapies 
available that can reverse VC.  Results will provide valuable information on whether BPs 
can be used to prevent or decrease AC in addition to improving BMD and reducing 
fracture risk. Since the effects of BPs on aortic stiffness (PWV) have not been previously 
investigated, a conservative value of 7.5% for the expected change in PWV had been 
estimated over the 2-year study period in response to treatment. Assuming a 7.5% 
standard deviation with a 7.5% change then a group of 21 subjects would be sufficient to 
detect statistically significant change with a Type-1 error of p=0.05 and 90% power.  
 
Thirty subjects were recruited on to this part of the study, although 6 subjects failed at 
screening. Study subjects were randomised and divided into two groups (Figure 2.1). 
 
Group 1  12 women to commence once weekly alendronate 70mg for 2-years and daily 
calcium and vitamin D supplementation providing 600mg/400IU of calcium and vitamin D. 
Group 2  12 controls that were only given calcium and vitamin D supplements providing 











   
Randomisation onto the two study groups took place after the first visit once suitability 
was established. Suitability for the study was assessed using BMD results measured 
using DXA and haematological and biochemical parameters from blood testing, which 
included a full blood count (FBC), erythrocyte sedimentation rate (ESR), bone, lipid and 
thyroid profiles, thyroid stimulating hormone (TSH), parathyroid hormone (PTH), Vitamin D 
70mg once weekly alendronic acid & calcium & Vitamin D  
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- Study meds  













Alendronic acid & 
calcium & vitamin D 
                 Or 
Calcium & vitamin D 
 
 
 Figure 2.1 prospective study design outlining requirements at each study visit. 




    
and protein electrophoresis. Blood test results from screening were used to check for 
secondary causes of OP and any subjects that were found to have secondary causes 
were considered not suitable. Only subjects with a bone density T-score of -2.0 or lower at 
the total hip, femoral neck or lumbar spine were included. Treatment compliance was 
assessed at all follow-up visits following baseline based on the returned medication and 
calculated as:  
Actual doses taken / expected doses x 100  
All subjects took a maintenance dose of calcium and vitamin D supplements once a day 
providing 600mg calcium and 400 IU vitamin D for the duration of the study. 
Measurements of BMD, lateral DXA scans, PWV scans and serum markers of bone 
formation and resorption were performed at 6, 12, 18 and 24 months.  Subjects also had 
an assessment of PWV and serum markers at 3-months.  All study subjects consented to 
have CT scans at baseline and 24-months, providing ‘gold-standard’ information on 
changes in AC in response to alendronic acid therapy.   
 
2.6 Trial Medication 
The investigational product in this study was alendronic acid 70 mg tablets, which is a 
prescription-only medication for the treatment of postmenopausal OP.  Alendronic acid 70 
mg tablets contain the active ingredient alendronate sodium trihydrate and were provided 
in tablet form for oral administration.  The strength of 70 mg once weekly is the standard 
dose for the treatment of postmenopausal women with OP. 
 
2.6.1 Alendronic Acid 
The brand of alendronic acid chosen had been decided by the hospital pharmacy (Guy’s 
Hospital) according to local practice and guidelines at the start of the study.  The brand 
used has marketing authorisation in the UK.  The alendronic acid was stored and 
dispensed by the hospital pharmacy in the standard manufacturing packaging (i.e. open 
label) in cartons containing 4 tablets and each label included the study title, subject ID and 
dispensing date.  Subjects commenced alendronic acid at the baseline visit (Visit 2).  








    
2.6.2 Calcium and vitamin D supplementation 
All subjects, in both the alendronic acid and control groups, were provided with a stable 
dose of calcium and vitamin D supplementation from baseline until the end of the study.  
Calcium and vitamin D supplements were provided in tablet form for oral administration.  
These supplements provided a minimum of 600 mg/day elemental calcium and 400 
IU/day vitamin D and were provided open-label.  This minimum dose was that used for 
patients diagnosed with low bone density or OP.  The brand used was not fixed and 
therefore decided by the hospital pharmacy according to local practice and guidelines at 
the start of the study.  The calcium and vitamin D supplements were stored and dispensed 
by the hospital pharmacy in the standard manufacturing packaging (i.e. open label) in 
cartons containing 100 tablets.  Each label included the study title, subject ID and 
dispensing date.  Subjects commenced calcium and vitamin D supplements at the 
baseline visit (Visit 2).  Calcium and vitamin D was also dispensed at 6-months, 12-
months and 18-months. 
 
2.7 Study methodology 
2.8 Dual Energy X-ray Absorptiometry (DXA) 
Dual energy X-ray absorptiometry is a widely accepted method for measuring BMD, 
assessing fracture risk, diagnosing OP, making clinical decisions about patient 
management and monitoring changes in BMD in response to therapy. This technique 
utilises two x-ray beams which have two different average x-ray energies that are 
projected through soft tissue and bone.  The attenuation is measured at high and low 
energies. The area density is calculated at each point by two simultaneous equations, 
which then calculate bone mineral content (BMC), bone area and average BMD.  In the 
present study all DXA scans were performed using standard local protocols for the 
measurement of bone density by a clinical scientist (SE) or experienced DXA 
radiographer. All study subjects had DXA scans of the lumbar spine (L1-L4) and hip to 
measure BMD and whole body DXA scans for the measurement of whole body BMD/BMC 
and body composition. In addition, each subject had a lateral VFA scan performed. The 
use of a C-arm meant that the lateral VFA scan could be performed supine. Scans were 
obtained using the Hologic Discovery QDR 4500 system densitometer (Hologic, Bedford 
MA) (Figure 2.2). The reproducibility for lumbar spine and proximal femur (hip) scans are 
approximately 1.0% (CV% at BMD =1g/cm2) and precision for whole body scans is CV 
0.75% [547].  




    
                                                     
Figure 2.2 the Hologic Discovery QDR 4500 densitometer at 
Guy’s Hospital, Osteoporosis Unit used to perform DXA scans 
to measure BMD and body composition and lateral DXA-VFA 
scans to evaluate aortic calcification.  
 
The DXA scanning system is comprised of two main elements; a table and a rotating C-
arm (Figure 2.2). The table with a cushioned table pad provides a comfortable area in 
which the subject is positioned for scan acquisition and has clearly marked indicators to 
aid subject alignment (Figure 2.3). The rotating C-arm contains the x-ray source, x-ray 
detectors and laser, and the x-rays are generated underneath the table and projected 
upwards while detectors at the top of the C-arm convert the X-rays into electronic data 
which is then sent to the computer where it is converted to two-dimensional scan images.  
A red laser projects a visual cross-hair indicator onto the patient during patient positioning 
indicating the correct start point of the X-ray beam, aiding correct image acquisition.   
                                                           
Figure 2.3 shows the scan table pad with alignment 
markings; 1: scan limit border, 2: centre lines used 
to centre the patient on the scan table. Modified from 
the Hologic QDR 4500 Discovery Operator Manual 
(www.hologic.com).  
 
Prior to performing the study DXA scans, subjects were required to remove all metal 
including underwear with under wires & clasps in addition to any clothing that may have 
metal fastenings or zips. All subjects had height and weight measured to the nearest 0.1m 




    
and 0.1kg respectively which was recorded on the Discovery QDR Apex image analysis 
programme on the DXA computer system. The level of radiation exposure was also 
recorded for each subject as required by the Ionising Radiations Medical Exposure 
(IRMER) Regulations. Effective dose is the preferred method of specifying patient dose 
from DXA investigations as it relates directly to the radiation risk involved. The effective 
dose for hip and spine scans performed on the QDR Discovery 4500 was 7.5 μSv using 
the express scan mode. This is the equivalent of 1 day or less of natural background 
radiation exposure. The effective dose for whole body DXA scans was 4.2 μSv.  
 
2.8.1    Measurement of BMD at the lumbar spine 
 
Each subject was positioned supine on the DXA scanning table, with legs elevated on to a 
foam block at 90o (Figure 2.4). This position reduces lumbar lordosis and keeps both 
femora aligned and flat on the table, enhancing the visibility of the lumbar vertebrae for 
accurate image analysis (Figure 2.4). To ensure that the fifth to first lumbar vertebra (L1-
L5) was visible in the field of view (FoV), the scan position was initiated at the midline at 
approximately 1 inch below the iliac crest (Figure 2.5). Each scan acquisition was 
performed on express mode; however, for subjects over 80kg this was performed on array 
mode. 
                                                    
Figure 2.4 Demonstrating correct positioning 
required for an AP lumbar spine. Modified 
from the Hologic QDR 4500 Discovery 
Operator Manual (www.hologic.com).  
 
The completed scan image was analysed using the Discovery QDR Apex image analysis 
software. A rectangular region of interest (ROI) was placed from L1- L4 and intervertebral 
lines were then placed between L1-L4, dividing each vertebra into a separate region of 
interest (Figure 2.6). The image analysis results were plotted against the reference data 
(NHANES III) [548] to determine the overall T and Z-score for the subject. 
           




    





2.8.2    Measurement of BMD at the Hip 
  
All hip scans were performed preferably using the left hip for accessibility. However, 
subjects with metal prosthesis including hip replacements on the left hand side had DXA 
scans performed using the right hip. The subject was positioned supine on the scanning 
table with legs straight. The left leg was internally rotated and abducted in order to 
separate the femoral neck from the ischium and the foot secured to a positioning aid to 
prevent outward rotation (Figure 2.7); the rotation was such that the lesser trochanter of 
the femur was not visualised on the image (Figure 2.7).  Scan acquisition started at the 
midline of the femur, approximately 1.5 inches below the greater trochanter (Figure 2.7) 
and performed on express mode. Image analysis was performed using the QDR Apex 
image analysis software. A ROI box was placed around the hip as shown in Figure 2.8. 
The midline was positioned along the axis of the femoral neck and the femoral neck box 
was positioned across the femoral neck, close to the greater trochanter (Figure 2.8).  As 
with the lumbar spine analysis, the results were plotted against the reference data 
(NHANES III) [548] to determine the total hip T and Z-scores for the subject, and T and Z-
scores for the femoral neck.  
 
Figure 2.5 demonstrating the correct 
positioning on the scanning couch for an 
AP lumbar spine scan. Modified from the 
Hologic QDR 4500 Discovery Operator 
Manual (www.hologic.com).  
 
Figure 2.6 DXA scan of the lumbar 
spine L1-L4. Accessed 2010 
(www.hologic.com).  




    
                                  
Figure 2.8 DXA scan of the proximal 
femur (left hip) showing ROI placement 
for image analysis. The femoral neck 





2.8.3   Whole body DXA 
 
Each of the study subjects had whole body DXA scans performed to measure body 
composition and whole body BMD/BMC. The scan provided information on lean and fat 
mass in grams and fat percentages. Whole body composition scans were acquired with 
the subject lying supine on the DXA scanning table with the head positioned straight and 
arms placed palm down either side. Legs were straight but slightly separated with toes 
touching as shown in Figure 2.9. The regions of interest were automatically selected by 
the Discovery QDR Apex imaging software for body composition analysis within each of 
the anatomical regions (Figure 2.9).   
Figure 2.7 demonstrating the 
correcting positioning on the scan 
couch for the hip scan, with correct 
foot positioning. Modified from the 
Hologic QDR 4500 Discovery Operator 
Manual (www.hologic.com).  
 




    
                                                    
Figure 2.9 Whole body DXA scan 
showing regions of interest automatically 
selected by the image analysis software 
in order to establish fat and muscles 





2.9 Lateral Vertebral Fracture Assessment (VFA) scans 
 
In this study Lateral VFA scans were performed for the purpose of quantifying AAC. 
Traditionally lateral VFA scans are used to assess vertebral deformities. However, the 
anatomical positioning of the AA anterior to the lumbar spine allowed for the assessment 
of calcium deposits within the abdominal aortic region. The scans in the present study 
were limited to the lumbar region only (L1-L4). Calcified deposits detected using lateral 
VFA scans have a similar x-ray attenuation to bone, and lateral VFA scans can provide a 
low radiation dose alternative method for the semi-quantitative assessment of AAC 
(Figure 2.10). All lateral VFA scans were performed using the Hologic High Definition 
Instant Vertebral Assessment (IVA-HD) which performs a single-energy scan of the 
lumbar spine (L1- L4) in 15 seconds with a radiation dose of <10µSv [547].  




    
                                                   
Figure 2.10 calcification of the anterior and 
posterior aspect of the abdominal aortic 
walls anterior to the lumbar vertebra. 
Calcification is marked by yellow arrows at 
the anterior and posterior walls. Modified 
from Hologic.com. 
 
Lateral VFA scans were acquired with the subject lying supine on the scanning table with 
legs elevated up on a foam block at 90o to reduce lordosis (Figure 2.4) following the same 
principle as for the AP lumbar spine scan. However, for successful image acquisition the 
arms were held in position above the head with a foam contour pillow to prevent them 
from obstructing the SFoV (Figure 2.11). 
 
                                              
Figure 2.11 demonstrating the correct 
positioning for the lateral VFA scan 
acquisition. Modified from the Hologic QDR 
4500 Discovery Operator Manual 
(www.hologic.com).  
 




    
All scans were reviewed using the Hologic QDR Apex software system to determine the 
presence of calcification within the AA (Figure 2.10). The 24- and 8-point AAC scores 
were used to grade the amount of calcification, as described by Schousboe [549]. 
 
              2.9.1 24-Point scoring method for quantifying AAC 
Calcification as detected using lateral VFA scan images was quantified using a previously 
validated semi-quantitative 24-point scoring method [550]. With this method, scans were 
assessed for the presence of calcification in the AA within the regions corresponding to 
the first through to fourth lumbar vertebrae. The anterior and posterior aortic walls were 
visually segmented into four sections corresponding to areas in front of L1-L4 using the 
midpoint of the inter-vertebral space (Figure 2.12). The severity of the anterior and 
posterior AC was graded individually on a 0-3 scale for each lumbar segment (Table 2.2). 
Aortic calcification was scored as 0 if there was zero calcification, as 1 if one-third or less 
of the aortic wall in a segment was calcified, as 2 if more than one-third but two-thirds or 
less of the aortic wall was calcified or as 3 if more than two-thirds of the aortic wall was 
calcified. Scores ranged from 0 to 6 for each vertebral level. The results for all 4 lumbar 
vertebra, including scores for both anterior and posterior walls, were summed to provide 









Figure 2.12 Example of a VFA scan 
showing the AA. The aorta has been 
visually segmented at regions 
corresponding to each of the lumbar 
vertebrae. L2, L3 and L4 show 
calcification at the anterior and 
posterior walls for the aorta. 









2.9.2   8-point scoring method for quantifying AAC 
The 8-point score, a simplified version of the 24-point AAC scoring method, was 
developed by Schousboe, Wilson, and Kiel [549, 550], and examines only the anterior and 
posterior aspects of the aortic wall adjacent to vertebrae L1-L4. The 8-point score is the 
sum of the total length of calcification for each of the anterior and posterior aortic walls in 
front of vertebrae L1 to L4. A score of 0 is given for zero calcification, 1 if the aggregate 
length of calcification is less than or equal to 1 vertebral height, 2 if that length is greater 
than 1 but less than or equal to 2 vertebral heights, 3 if that length is greater than 2 but 
equal to or less than 3 vertebral heights, and 4 if the aggregate length of calcification is 














2.10    Pulse Wave Velocity (PWV)  
 
Pulse wave velocity measurements were obtained using the SphygmoCor (AtCor Medical 
LTD, Australia) PWV system. The system used ECG and an ultrasound tonometer to 
measure the pressure pulse waveform sequentially in two peripheral artery sites - carotid 
& femoral. This method is non-invasive and the measurements obtained in part, rely on 
the degree of atherosclerotic burden within the aorta. During each cardiac cycle the pulse 
         Table 2.2 the 24-point calcium scoring method as described by Schousboe [549]. 
Description Score 
No calcification seen 0 
Deposit  < one- third length of aortic wall 1 
Deposits > one-third but < two-thirds the length of aortic wall  2 
Deposits > two-thirds the length of aortic wall 3 
Description Score 
No calcification seen 0 
Aggregate length of calcification = height of one vertebra 1 
Aggregate length of calcification > one but = two vertebra 2 
Aggregate length of calcification > two but = three vertebra 3 
Aggregate length of calcification > three vertebra 4 
         Table 2.3 8-point calcium scoring method as described by Schousboe et al [549, 550]. 




    
wave travels from the heart down the arterial wall in advance of blood flow. The more rigid 
the wall of the artery, the faster the wave moves (Figure 2.13). 
 
                                                              
Figure 2.13 Pulse wave velocity 
and the aortic pressure waveform. 
Accessed 2012.                         
 
 
The pulse pressure waveform was recorded simultaneously with the aid of an ECG signal, 
which provided and R-wave timing reference.  Pulse pressure recordings were performed 
consecutively at the carotid and femoral arterial sites using a pressure tonometer which 
was used to transcutaneously record the pressure pulse waveforms in the underlying 
artery. The carotid and femoral arteries were used so the PWV could be measured in the 
section of artery that included the aorta.  In the present study each subject was required to 
lie supine on an examination couch, exposing the areas required to attach the ECG 
electrodes and also the femoral region (Figure 2.14). An electronic blood pressure monitor 
(Omron) was used to determine systolic and diastolic blood pressures, which were 
entered onto the computer system. The entered values calibrated the averaged aortic 
waveform. Measurement of the PWV distance was estimated by measuring from the 
sternal notch to the femoral artery and this value (mm) was entered into the system. To 
obtain the PWV measurement, the tonometer was placed on the carotid and femoral 
arterial sites to record the pulse pressure waves (Figure 2.15). The transit time was 
determined from the time delay between the two corresponding systolic foot waves of the 
two signals. The distance travelled was estimated from the distance between the two sites 
(Figure 2.16).  To ensure an adequate reading, PWV was averaged over 10 consecutive 
cardiac cycles. The procedure was repeated 3 times in order to calculate an average 
PWV for each subject. The validation of this method and its reproducibility has been 
previously described by Asmar et al, with intra- and inter-observer repeatability 
coefficients of 0.935 m/s and 0.890m/s respectively [337]. 




    





                                                                    
                                     
Figure 2.16 Calculation of PWV - The time 
delay between two foot waves at peripheral 
artery sites. D/Δt/ (cm/s). Accessed 2012 
(www.indiana.edu).                                                                                                                                                                                 
 
 
 2.11   Computed Tomography (CT) 
 
The Philips Precedence single-photon emission computed tomography (SPECT)/CT 16-
Slice multi-detector (MDCT) system (Philips Healthcare, Best, Netherlands) was used for 
scans of the chest and abdomen (Figure 2.17). The scanner is capable of performing non-
diagnostic, unenhanced CT for the purpose of quantifying VC. The precedence 
SPECT/CT performs Spiral/helical scanning which is characterised by a continuous gantry 
rotation and continuous data acquisition while the scan couch is moving at constant 
speed. In the present study a scan field of view (SFoV) of 50cm was required to include 
both the chest and abdomen incorporating the carotid to the femoral arteries.  The camera 
has a rotation speed of 0.5s. The radiation dose for this scan was 5mSv; moderately lower 
Aortic PWV is measured as: 
Aortic PWV =      Distance m/s 







Figure 2.14 showing the correct ECG 
electrode placements for carotid-
femoral PWV measurement. Modified 
from the SphygmoCor Pulse Wave 
Velocity System Operator Manual 
(www.atcormedical.com) 
Figure 2.15 The principle of 
applanation tonometry. The artery is 
partially compressed against a hard 
structure. The small (0.5mm in 
diameter) sensor detects the force of 
the artery wall. Accessed 2012 
(qjmed.oxfordjournals.org). 




    
than a diagnostic CT scan used in routine clinical practice with radiation doses ranging 
between 10 – 15mSv.  
                                   
Figure 2.17 The Philips Precedence 16-slice MDCT SPECT/CT 
system (Philips Healthcare, Best, Netherlands), showing the 
rotating gantry (red arrow), X-ray source (blue arrows), and scan 
couch (green arrow). Modified from healthcare.philips.com.  
 
 
Computed tomography utilises computer-processed X-rays to produce tomographic 
images or 'slices' of specific areas of the body. Digital geometry processing was used to 
generate a three-dimensional image of the inside of the subject from a large series of two-
dimensional X-ray images taken around a single axis of rotation. Computed tomography 
produces a volume of data that can be manipulated, through a process known as 
windowing, in order to demonstrate various bodily structures based on their ability to block 
the X-ray beam or attenuation. Once the scan data had been acquired, it was then 
processed using a form of tomographic reconstruction, providing a series of transaxial 
images which were then reconstructed to contiguous 3mm slices. The final scan image 
was made up of pixels, which are 2-dimensional units based on the matrix size and field of 
view. When the CT slice thickness was also factored in, the unit was known as a voxel, 
which is a three-dimensional unit. The voxels in the image obtained were displayed in 
terms of relative radio density. The voxel itself was displayed according to the mean 
attenuation of the corresponding tissue on a scale from +3071 being the most attenuating 
to −1024 or the least attenuating on the Hounsfield scale.  Images were sent to the 
JETStream workspace software which was developed specifically for SPECT/CT to 
enable image reconstruction, manipulation and analysis. The image data was then sent to 
the Hermes Gold™ software for image analysis and the quantification of abdominal aortic 
and VC.  
 




    
In the present study each subject was required to remove any metal that may be in the 
SFoV and put on a hospital gown. The subject was then required to lay supine on the 
scan bed with arm raised above their head, and legs slightly elevated on a foam knee 
rest. To ensure all required vascular sites were within the FoV, a surview scan was 
performed initially from under the angle of the mandible to the proximal third of the femur. 
Instructions were provided by the technologist prior to commencing the scan, on how to 
perform a breath hold for 15 seconds during the scan image acquisition.  The breath hold 
was important; scans for coronary imaging traditionally use ECG gating to reduce motion 
artefacts on the image. As ECG gating was not used during the scan acquisition, the 
breath hold served to reduce movement thus minimising the risk of motion artefacts on the 
scan images. Subjects from the preliminary imaging study sub-set (Section 2.5.1) were 
required to get off and back on the scanner for a duplicate scan using the same scan 
protocol. X-ray slice data was generated using an X-ray source that rotated around the 
subject, allowing numerous data scans to be progressively taken as the subject was 
gradually passed through the gantry (Figure 2.17). 
                
2.11.1 CT Image analysis 
The Hermes Gold ™ image analysis software provides automatic or manual transfer from 
Digital Imaging and Communications in Medicine (DICOM) supported CT systems and 
NM Gamma Cameras such as the Philips Precedence SPECT/CT camera, for local 
storage or automatic forwarding to other systems such as the picture archiving and 
communication system (PACS).   
The scan image was first located on the Hermes Gold browser from the scan storage 
archives for Guy’s Hospital using the subject study number.  For subjects that had repeat 
scans, images were labelled as scan 1 and scan 2 to enable the reader to distinguish 
between the first and second scan. The image was opened in a ‘hybrid viewer’ mode 
enabling the viewer to scroll through each of the transaxial slices and identify anatomical 
regions of interest.  The image slice numbers were obtained and each of the anatomical 
regions was recorded on an ‘anatomical region data sheet’ that had been developed for 
this study. Each 3mm scan slice was analysed individually and calcified deposits were 
defined as any area greater that 1mm2 with an attenuation coefficient of ≥ 130 Hounsfield 
units (HU). Calcification within an ROI was automatically selected by a thresholding 
function. For this study an attenuation threshold of 130 Hounsfield Units (HU) had been 
set, in keeping with other studies. Calcified deposits were labelled to emphasise vascular 
sites using anatomical location and number; for example a calcified deposit located in the 
AA was labelled as AAORTA Dep 1.This process was repeated for each transaxial slice 




    
and provided a volume measurement of calcification for all contiguous slices.  Once image 
analysis was complete, the data file with information pertaining to the amount of 
calcification identified was then anonymised and exported for statistical analysis. 
 
2.12    Methods used to quantify calcification using CT 
 
2.12.1   The Agatston score 
 
The Agatston scoring method has been widely used [541-546, 551, 552] and is a 
validated and commonly used method for quantifying coronary calcium. The method is 
based primarily on the maximum CT number (measured in Hounsfield Units [HU]) or x-ray 
attenuation coefficient, and the area of the calcium deposit.  Score values have been 
established on the basis of measurements from electron beam computed tomography 
(EBCT) to establish clinical risk of future CV events. The score helps to determine if a 
subject has atherosclerosis or not and the extent of the disease. The calcified lesions are 
firstly identified on CT images by the rater (Figure 2.18) by applying a threshold of 130HU. 
Tissues with densities equal to or greater than 130HU are considered to correspond to 
echogenic calcium. For each artery in question a region of interest (ROI) is drawn around 
each calcified lesion. The maximum CT number of the ROI is determined and used to 
assign a weighting factor. The area of the ROI is also determined and the Agatston score 
is computed as the product of the weighting factor and the areas. This score does not 
correspond to a physical measure; the Agatston score relies on a weighting factor to 
provide the calcium score.  A calcified lesion is defined as an area of 0.5mm2 or greater 
and the weighting factor assigned is dictated by the maximum CT number for the lesion. 
The sum of all lesion scores is used to generate the total calcium score (TCS). 
 
                                                           
Figure 2.18 shows an axial scan showing the 
aorta (white arrow) and calcification within the 
wall of the aorta (yellow arrow). Accessed 2011 
(Medscape.com). 




    
Score of calcified deposit (CSi) = Area of deposit (Ai) x weighting factor (wi) 
Where:  
CSi = Ai x wi 
Weighting factors (wi)  
 
1 = 130 – 199 HU 
2 = 200 – 299 HU 
3 = 300 – 399 HU 
4 = >400 HU 
This equation is applied to each deposit found in each transaxial image.  
                                                                                                 Equation 2.1 
 
2.12.2 Modified Agatston score 
 
A modified version of the Agatston score was developed to improve sensitivity and 
specificity, using the mean attenuation coefficient or CT number rather than the maximum 
[553]. The modified Agatston score (ASm) is calculated as the product of the mean 
attenuation for all pixels in the deposit with attenuation higher than 130 HU (CTmean) and 
the volume of the calcified deposit (V):  
Where: 
ASm = CTmean · V. 
ASm   = modified Agatston score 
CTmean   = mean CT number of deposit 
V   = volume of deposit 
                                                                                                 Equation 2.2 
 
 
2.12.3    Volume score 
 
The volume score was first described by Callister et al in 1998 [554]. It was initially 
designed to resolve the issue of slice thickness and spacing by computing a volume 
above threshold. The calcium volume can be simply calculated by multiplying the number 
of voxels (Vn) with the voxel volume (Vv) in a deposit: 
          V  =  Vn  x  Vv  
Where:  
V = Voxel 
Vn= Number of voxels 
Vv = Volume of one voxel                
                                                                                                  Equation 2.3  




    
2.13 Anthropometric measurements, blood pressure and medical history 
 
All study subjects had their height and weight measured to the nearest 0.1m and 0.1kg 
respectively.  Body mass index (BMI) was then calculated as weight (kg) divided by height 
squared (m2). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was 
measured supine using an electronic oscillometric blood pressure device (Omron, Japan) 
after the subject had rested for a minimum period of 15 minutes.  Mean arterial pressure 
was calculated as [(2 x DBP) + SBP]/3. A detailed medical history was recorded for each 
subject, obtained using questionnaires and by personal interviews. Information collected 
included history of CV events including myocardial infarction (MI), angina, trans-ischemic 
attack (TIA), peripheral arterial disease (PAD), and intermittent claudication (IC), the 
confirmed diagnosis of diabetes mellitus, hypertension, and hypercholesterolemia, 
fracture history, smoking habits, alcohol intake and physical activity levels, and family 
history of CVD and low trauma fractures. Information was collected regarding the use of 
prescribed and over-the-counter preparations including but not exclusively, BPs, 
antihypertensive medications, analgesia and anti-inflammatory drugs, diuretics and 
vitamin and mineral supplementation.  
 
2.14 Laboratory assessments 
 
At each study visit, all subjects had venous blood samples collected by a clinical scientist 
(SE) following a 10 hour overnight fast. Thirty millilitres of whole blood was collected in 
serum separation tubes (SST’s) for measurement of lipid and bone profiles. The 
prospective study group had also had routine haematology and clinical chemistry tests 
performed at screening to exclude any secondary causes of OP. These included a full 
blood count (FBC), erythrocyte sedimentation rate (ESR), protein electrophoresis, 
parathyroid hormone (PTH), vitamin D and a full lipid, bone, renal and thyroid profile. Six 
millilitres of whole blood was sent to St Thomas Hospital Department of Clinical Chemistry 
for the measurement of total cholesterol, triglycerides, HDL and LDL-cholesterol levels in 
addition to calcium, albumin corrected calcium, albumin, phosphate and sodium, 
magnesium and chloride using standard laboratory methods on the Roche Modular 
analysers (Roche Diagnostics Limited, West Sussex, UK). The remaining 24mls of whole 
blood was centrifuged and serum was separated into 10 aliquots which were then frozen 
at -70o for the analysis of systemic and local factors involved in bone remodelling and 
atherosclerosis. These included PTH, PINP, CTX, vitamin D, sclerostin and Dkk1. 
Parathyroid hormone and vitamin D was analysed by consultant chemical pathologist Dr 
Geeta Hampson in the Department of Clinical Chemistry at St Thomas’ Hospital. PINP, 
CTX, sclerostin and Dkk1 were analysed by the commercial bone marker laboratory at the 




    
University of Sheffield.  During the prospective study a further blood sample was collected 
at 6, 12 and 24-months for the measurement of circulating endothelial progenitor cells 
(EPCs). These samples were processed immediately after collection and analysed using 
flow-cytometry to enable identification and characterisation of EPCs. Analysis was 
performed by Dr Ulrike Mödder in the flow-cytometry department of the Clinical Trials Unit 
at Guy’s Hospital. 
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Chapter 3  
The intra- and inter-rater agreement of computed 
tomography and lateral VFA images for the quantification 
of aortic calcification 
 
3.1 Introduction 
Recent evidence has shown age-independent associations between OP and CVD, which 
can be explained in part by an increase in VC seen in patients with OP [316, 360, 472]. 
From the sixth decade onwards, most individuals will have evidence of progressively large 
calcium deposits within the major arteries [555] which lead to decreased arterial elasticity 
and impaired CV function, resulting in an increased risk of CV events and significant 
morbidity and mortality [491, 556, 557].  Due to its good precision and accuracy, non-
contrast CT is recognised as the gold-standard method for quantifying AC [558-561]. 
However, CT is an imaging method limited by a lack of availability, high radiation 
exposure and high cost [562, 563]. Alternatively, bone densitometry, a low radiation and 
low cost imaging method used to routinely assess BMD and vertebral deformity may 
provide a good substitute to CT for quantifying AC [316, 564]. Anatomically, the AA is 
located anterior to the lumbar spine and therefore can be visualised on lateral VFA scans 
and this technique has been shown to be a useful imaging method for the qualitative and 
semi-quantitative assessment of AC [564].  Previous studies on high risk populations with 
CKD that have a high incidence and extent of VC [558, 559, 561, 565, 566] and more 
recently, a low risk healthy population [567] have reported good sensitivity of lateral DXA 
comparable to CT for the assessment of AAC [558, 561, 567]. Abdominal aortic 
calcifications detected by conventional radiographs, which are often performed in clinical 
trials of patients with OP, have also been shown to be a significant predictor of overall CV 
disease incidence and mortality [555]. A study by Schousboe et al confirmed a close 
correlation between AAC assessed using lateral VFA and radiographic AAC [564]. The 
results from these studies demonstrate that lateral DXA imaging, used primarily for the 
identification of prevalent vertebral fracture, also allows a simultaneous assessment of 
AAC; an important CV disease risk factor commonly encountered in postmenopausal 
women referred for bone density screening [564]. There is limited information in the 
literature regarding the intra- and inter-rater agreement and test-retest reproducibility of 
non-contrast CT for quantifying VC at non-coronary sites, with data limited to high risk 
populations with impaired renal function, which may not represent results obtained in a 
study of healthy postmenopausal population [558].  Moreover, there is limited information 
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regarding the reproducibility of calcium scoring methods, including the Agatston, modified 
Agatston and volume scores for quantifying VC at non-coronary sites using CT. A study 
by Bowden et al evaluated the inter-rater agreement for measuring AAC using CT, but the 
study was limited by its small sample size and quantified calcification using only the 
volume score. Furthermore, the study did not evaluate intra-rater agreement and test-
retest reproducibility, and image analysis was restricted to only a small 4.95cm section of 
AA [568].  
Previous studies have assessed the intra- and inter-rater agreement of lateral VFA for 
quantifying AAC using both the 24-point and 8-point scoring methods but these studies 
have again been limited to high risk populations with CKD [558, 569]. The evaluation of 
both the intra- and inter-rater agreement and test-retest reproducibility of moderate dose 
CT for quantifying VC at non-coronary vascular sites and the intra- and inter-rater 
agreement and test-retest reproducibility of lateral VFA will provide valuable data on the 
reliability of both methods for future research studies and potential implementation into 
clinical practice.  A summary of the studies used to compare and correlate with the results 
























Table 3.1 Overview of previous studies evaluating the agreement of imaging methods lateral 
VFA and CT for the measurement of AC and VC and the scoring methods used to quantify 
AC/VC.  
Author (year) Study 
design 










 Follow-up 2515 GP  >60 Rad 24-Point 
Schousboe  (2006) 
[570]





































 Cohort 40 GP  >60 CT Agatston 
Volume 
PM, postmenopausal; HD, haemodialysis; GP, general population; CKD, chronic kidney disease; CT, 
computed tomography; DXA, dual-energy x-ray absorptiometry; SXA, single-energy x-ray absorptiometry; 
Rad, radiographs.  
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3.1.1 Study aims 
 
The aim of this part of the study was to evaluate the intra- and inter-rater agreement of CT 
for quantifying VC and to examine the test-retest reproducibility of three scoring methods, 
including the Agatston, modified Agatston and volume scores, for quantifying VC in 
multiple large vessels using CT. The use of moderate dose, non-contrast CT may provide 
a reliable method for quantifying VC within the AA and at other vascular sites for use in 
future research studies. Furthermore, the current study also examined the intra- and inter-
rater agreement and test-retest reproducibility of lateral VFA for quantifying AAC using the 
previously validated 24-point and 8-point scoring methods. Results from this part of the 
study provide valuable data for assessing the potential role of lateral VFA scan images as 
a quick and simple method of assessing AC in women with low BMD and OP in both 
research studies and routine clinical practice.  
 
3.2 Study population 
 
The study population consisted of 63 healthy, ambulatory postmenopausal women with a 
mean age of 61 years who had attended the Osteoporosis Unit to take part in a large 
cross-sectional study as previously described in Section 2.4, Chapter 2. All subjects had 
CT scans of the chest and abdomen to quantify calcification at multiple vascular sites and 
lateral VFA scans of the lumbar spine to quantify AAC. A sub-set of 8 subjects had 
duplicate CT scan measurements at one session to assess test-retest reproducibility 
following confirmation of AAC on lateral VFA scans. Only women aged 65 and over were 
selected for the sub-set in an attempt to avoid subjects with zero or minimal amounts of 
VC. The number of women selected for duplicate CT scans was restricted because of 
ethical issues associated with the radiation dose involved.  A sub-set of 19 women had 
duplicate lateral VFA scans at one session to assess test-retest reproducibility.  
 
                3.3 Materials and Methods 
3.3.1 CT imaging 
Thirty-three of the 63 subjects underwent non-contrast non-diagnostic, un-gated CT scans 
of the chest and abdomen. The scans were performed using the Philips Precedence 16-
slice SPECT/CT helical scanner (Philips Healthcare, Best, Netherlands) as described in 
Section 2.11, Chapter 2. The scan field of view (FoV) was approximately 50cm which 
included the iliac arteries (IA), abdominal aorta (AA), thoracic aorta (TA) and carotid 
arteries (CA). In order to measure test-retest reproducibility, the first 8 subjects had repeat 
scans which involved getting off and back on the scanner for a second scan immediately 
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following the first scan, using the same scan acquisition protocol for the first and second 
scans (Section 2.11.1, Chapter 2). Scan images were reconstructed into contiguous 3mm 
transverse slices for viewing on the image analysis workstation (Figure 3.1), and each 
scan consisted of a median of 170 slices, varying with subject height. All images were 
viewed and analysed using the semi-automated hybrid viewer function on Hermes Gold ™ 
imaging software. 
 
3.3.2 Quantitative assessment of calcification on CT 
Scans were assessed by two raters (a clinical scientist [SE] and a Consultant Radiologist 
[DD]) who were blinded to subject demographics, BMD results, lateral VFA scores and to 
each other’s readings. Scan images were identified by the subject’s study number only. 
Scans were labelled as scan 1 and scan 2 on the workstation to enable the viewer to 
distinguish the first from the second scan. Each 3mm transverse slice was analysed 
individually and calcified deposits were defined as any area greater that 1mm2, within the 
blood vessel being assessed, with an attenuation coefficient of ≥ 130 Hounsfield units 
(HU). Individual calcified deposits on each transverse CT slice were identified by the rater 
and then a ‘seeding’ tool was used to delineate each deposit using the thresholding 
method as described in Chapter 2. Calcified deposits were labelled according to 
anatomical location and deposit number; for example a calcified deposit located in the AA 
was labelled as AAORTA Dep 1 (Figure 3.2 and 3.3). The total Agatston [349], modified 
Agatston [553] and volume scores [554] were calculated by summing the scores obtained 
for all cross-sectional slices (Section 2.12, Chapter 2). Each scan was analysed twice by 
each rater with a minimum of two weeks between the first and second analysis, with each 
scan taking approximately 45 mins to analyse. 
Chapter 3  
 
94 
    
                                                                     
Figure 3.1 Transaxial CT image showing normal     
aortic anatomy with no calcified deposits in the aorta 





                                                                         
 
Figure 3.2 Transaxial CT image showing a calcified 
deposit within the abdominal aorta with a ROI around 
the calcified deposit (shown in red). Calcium scores for 
this deposit were: Agatston 20 AU, modified Agatston 
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Figure 3.3 Transaxial CT image showing a calcified 
deposit within the right iliac artery (red arrow) with a ROI 
around a calcified deposit (shown in red). Calcium 
scores for this deposit were: Agatston score 28 AU, 




3.3.3 Lateral VFA scans 
Thirty of the 63 subjects had single-energy lateral VFA (IVA-HD) scans of the lumbar 
spine using the Hologic Discovery QDR 4500 densitometer (Hologic, Bedford MA) as 
described in Section 2.9, Chapter 2. Scans were obtained using an established local 
protocol for lateral VFA scan acquisition which was modified to include the lumbar spine 
region only. Scans were acquired using a rotating C-arm which required the subject to lie 
supine with arms raised. In order to measure the test-retest reproducibility of lateral VFA 
for quantifying AAC, a sub-set of 19 subjects had repeat scans which required getting off 
and back on the scanner for a second scan immediately following the first scan, using the 
same scan acquisition protocol for the first and second scans. 
 
3.3.4 Semi-quantitative assessment of AAC  
Abdominal aortic calcification was assessed on the lateral VFA scan images by two raters 
(both clinical scientists [SE and MF]) both blinded to subject demographics, BMD results 
and to each other’s scores. Scans were identified only by subject number and each scan 
was analysed twice by each rater with a minimum of two weeks between the first and 
second image analysis. Abdominal aortic calcification was evaluated using the previously 
described semi-quantitative 24-point and 8-point scoring methods (Sections 2.9.1 and 
2.9.2, Chapter 2) in which both the location and the severity of calcification at each lumbar 
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vertebral segment (L1–L4) were evaluated [564]. Figure 3.4 illustrates the 24-point scoring 
method as described in Section 2.9.1, Chapter 2. The analysis of lateral FVA scan images 
took somewhere in the region of 7-10 minutes, with minimal difference in time taken 
between the 24- and 8-point scoring methods.   
                            
                                  
Figure 3.4 Example of a lateral VFA scan showing calcification within the anterior and 
posterior walls of the AA. The aorta is visually segmented to correspond with vertebrae L1-L4. 
The example grid on the right hand side illustrates the anterior and posterior aspects of the 
aortic wall in relation to the lumbar spine. The 24-point score, as described in Section 2.9.1, 
Chapter 2, is applied to correspond to the location and extent of calcification identified within 
the segmented aorta.  
 
3.4 Statistical analysis 
The study population characteristics are presented as the mean and standard deviation 
(SD) unless otherwise stated. The Students t-test and chi square test was used to test for 
significant differences in characteristics between the total study cohort of 63 
postmenopausal women and sub-groups. Intraclass correlation coefficients (ICC) were 
calculated to assess intra- and inter-rater agreement and test-retest reproducibility for 
each of the CT and lateral VFA scoring methods. Bland-Altman plots were used to visually 
assess intra- and inter-rater and test-retest variability and the bias, percentage difference 
and limits of agreement between readings, raters and tests calculated. Bland-Altman plots 
provide a graphical statistical tool to compare two sets of readings, and allow the degree 
of variation between each reading to be analysed objectively [572].   
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                3.5 Results  
The study population characteristics are shown in Table 3.2. All subjects were female with 
a mean age of 61 years (range 50 to 81 years) with no prior history of CV events. Thirty-
five per cent of subjects had a family history of CVD and 13 per cent were taking 
prescribed calcium and vitamin D supplementation at the time of the investigations. 
Statistical differences in characteristics were observed between the total study cohort and 
those in the sub groups (Table 3.2). The CT sub-study group subjects were significantly 
older than the total study population and had lower total hip and femoral neck T-scores. 
Subjects in both the lateral VFA and lateral VFA test-retest groups had a significantly 
higher average femoral neck T-score. 
 
Table 3.2. Study group characteristics.  
  
 
Study   
cohort 
 






VFA  study 
 
Lateral VFA  
test-retest 
sub-study 
 63 33 8 30 19 
Age (years)                                             61.2 (7.0)   62.8 (8.2)  75.7 (3.2)
c
   59.5 (5.0)    59.8 (3.5) 
BMI (kg/m
2
)                                             25.5 (4.5)   25.2 (4.7)   28.8 (5.4)   25.7 (4.2)   26.5 (4.4) 
Lumbar spine T score                            -1.4 (1.4)    -1.8 (1.6)     0.0 (2.4)    -1.0 (1.0)    -0.9 (1.1) 
Total hip T score                                    -0.8 (0.8)  -1.2 (0.7)
b
    -0.7 (0.8)    -0.5 (0.8)    -0.4 (0.9) 
Femoral neck T-score                                   -1.3 (0.9) -1.7 (0.8)
b
     0.7 (0.1)   -0.8 (0.9)
a
   -0.7 (0.9)
a
 
History of fracture (%)                             41              22                6             19            18 
Current Smoker (%)                                                 8               6                2               2              0 
Antihypertensive meds (%)            11             15              38               7              5 







< 0.001 when compared to the study cohort. 
 
 
3.5.1 The intra- and inter- rater agreement of calcium scoring using computed 
tomography 
Eighty-two percent (n=27) of subjects had evidence of VC on CT. The mean, SD and 
range observed for each scoring method for rater 1 [SE] and rater 2 [DD] are shown in 
Table 3.3. Rater 1 had consistently higher average scores than rater 2 for all 3 scoring 
methods. The range of Agatston and volume scores were similar for rater 1 and rater 2, 
but was much wider between raters 1 and 2 for the modified Agatston score due to one 
subject who was scored much higher by rater 1.  
Chapter 3  
 
98 
    
 
 
The intra-rater and inter-rater agreement and test-retest reproducibility of CT assessments 
at all vascular sites and sub-regions can be found in Table 3.4. It was not possible to 
obtain results at the carotid arteries as only one subject had one small calcified deposit at 
this vascular site. Characteristics showed this subject was at the higher end of the age 
range of the study population at 78 years, however the other study characteristics for this 
subject were otherwise unremarkable. Intra-rater ICC for total scores were 0.98-0.99 for 
both raters.  Intraclass correlations tended to be highest at the AA and IA, ranging from 
0.70 to 0.95 and 0.95 to 0.99 for the AA and iliac’s respectively. Inter-rater ICC ranged 
from 0.43 for the TA to 0.96 for the IA, with the highest ICC observed for total score rather 
than at individual vascular sites (0.89 to 0.96).  The ICC obtained tended to be higher at 
the AA and IA, with ICC scores of 0.92 for the AA and 0.81 to 0.96 for the iliac’s 
respectively. The TA had the lowest inter-rater ICC (0.43 to 0.49) which failed to reach 
statistical significance for all three CT scoring methods.  Intraclass correlations ranged 
from 0.97 to 0.98 for test-retest reproducibility obtained by performing duplicate scans. 
The TA had a slightly lower ICC than the other vascular sites (0.92 to 0.95) while the AA 
and IA had higher ICC of 0.95 to 0.98 and 0.95 to 0.98 respectively for each of the scoring 
methods. The ICCs observed were consistent for intra-rater, inter-rater and test-retest 




Table 3.3  calcium scores obtained using CT for Rater 1 and Rater 2 (n=33) 
     Scoring method                 Mean (SD)                            Range 
Rater 1   
      Agatston score (AU)
 
3300.0 (7309.1) 0 to 30763 
      Modified Agatston score (AU)
 
59918.8 (113732.5) 0 to 509995.2 
      Volume score (cm
3
) 1.5 (3.3) 0 to 14.1 
Rater 2   
      Agatston score (AU) 2488.2 (5962.4)   0 to 30670 
      Modified Agatston score (AU) 41833.4 (77835.4) 0 to 277206.3 
      Volume score (cm
3
) 1.1 (2.7) 0 to 14.1 
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 Table 3.4  Intra-rater, inter-rater and test-retest intraclass correlations (and 95% CI) for calcium scoring using CT.  
         Rater 1  Rater 2  
       Intra-rater  Intra-rater       Inter-rater   Test-retest 
Agatston Score    
Total  0.98 (0.95 - 0.99)
c 
0.98 (0.97 - 0.99)
c 




*Carotids         ------------ ------------         ------------         ------------ 
Thoracic aorta 0.83 (0.66 - 0.92)
c 






Abdominal aorta 0.86 (0.72 - 0.93)
c 
0.70 (0.39 - 0.85)
b 




Iliacs 0.98 (0.97 - 0.99)
c 
0.99 0(.99 - 0.99)
c 




Modified Agatston score    
Total  0.98 (0.95 - 0.99)
c 
0.99 (0.98 - 0.99)
c 




*Carotids         ------------ -----------        -----------         ------------ 
Thoracic aorta 0.63 (0.25 - 0.82)
b 
0.97 (0.95 - 0.98c
b 




Abdominal aorta 0.95 (0.91 - 0.97)
c 
0.92 (0.84 - 0.96)
c 




Iliacs 0.96 (0.91 - 0.98)
c 
0.99 (0.99 - 0.99)
c 




Volume score    
Total  0.98 (0.95 - 0.99)
c 
0.98 (0.97 - 0.99)
c 




*Carotids        ------------ ------------        ------------         ------------ 
 Thoracic aorta 0.84 (0.67 - 0.92)
c 






Abdominal aorta 0.86 (0.73 - 0.93)
c 
0.71 (0.41 - 0.85)
c 




Iliacs 0.98 (0.97 - 0.99)
c 
0.99 (0.99 - 0.99)
c 










 <0.001. * ICC was not calculated at the carotid arteries as only 1 subject had one small calcification 
at this vascular site. 
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Figure 3.5 shows Bland–Altman plots for intra- and inter-rater agreement and test-retest 
reproducibility for the modified Agatston scoring method. The Bland-Altman plots for each 
of the CT calcium scoring methods were broadly equivalent therefore only those for the 
volume scoring method are presented in this chapter. For intra-rater agreement a negative 
bias was observed for each scoring method indicating that rater 1 scored consistently 
higher at the first scan reading compared to the second. Figure 3.5A shows a negative 
bias of -0.320 cm3 (22%) with three scores that fell outside the limits of agreement (LoA). 
These subjects had large quantities of calcification within the AA, TA and IA. The inter-
rater agreement between raters 1 and 2 for each of the three scoring methods also 
showed a negative bias indicating that rater 1 (clinical scientist) scored consistently higher 
than rater 2 (Consultant Radiologist). Figure 3.5B shows inter-rater agreement for the 
volume score with a negative bias of -0.407 (29%) with one score that fell outside the LoA 
showing a large difference between rater 1 and rater 2. This subject had large amounts of 
calcification within both the AA and IA. Results for this subject were also found to be 
outside the LoA on the Intra-rater Bland-Altman plot. Test-retest reproducibility for scan 1 
and scan 2 showed a negative bias indicating that scan 1 was scored higher than scan 2 
with a bias of -0.290 and a percentage difference of 5% (Figure 3.5C). Only one score fell 
outside the LoA. This subject was also found to be outside the LoA on the intra- and inter- 
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Figure 3.5 Bland-Altman plots are showing (A) intra-rater agreement, (b) inter-rater agreement 
and (c) test-retest reproducibility (C) for the volume scoring method.  The bias line is shown in 














































Mean volume score (cm3) 
 












































Mean volume score (cm3) 













































Mean volume score (cm3) 




Chapter 3  
 
102 
    
                   
3.5.2 The intra- and inter rater agreement of calcium scoring using lateral VFA 
Abdominal aortic calcification was observed on lateral VFA scans in 60% (n=18) of 
subjects. The mean, SD and range obtained for rater 1 [SE] and 2 [MF] for the 8- and 24-
point scoring methods used to quantify calcium using lateral VFA are shown in Table 3.4.  
Twenty-three percent (n=7) and ten percent (n=3) of the scans were unable to be 
analysed by raters 1 and 2 respectively as a result poor image quality due primarily to 
abdominal obesity and/or image artefacts.  Figures 3.6 to 3.9 show example lateral VFA 
scan images acquired in this study.  Figure 3.6 is an example of a good-quality lateral 
VFA image with no evidence of calcification in either the anterior or posterior aortic walls 
of the AA. Figure 3.7 shows calcification within the anterior wall of the AA at the level of 
L1-L3 with a small amount of bowel gas at the anterior wall of the AA at the level of L4. 
Figure 3.8 demonstrates a poor image quality scan taken from a subject with abdominal 
obesity and Figure 3.9 is an image from a subject with a large amount of bowel gas 
precluding identification and scoring of calcification within the AA.  
 
                                                       
Figure 3.7 Example of a lateral 
VFA scan image with calcification 
of the anterior aortic wall at L1, L2 
and L3 with a 24-point score of 4 
and an 8-point score of 2.  
Figure 3.6 Example of a lateral 
VFA scan with no evidence of 
calcification within the anterior or 
posterior aortic walls. 
Chapter 3  
 
103 
    





The scores for the 24-point scoring method did not exceed 11 and 9 for rater 1 and 2 
respectively. The 8-point scores did not exceed 5 for raters 1 and 2 (Table 3.5).   
 
Table 3.5 Calcium scores obtained using lateral VFA for rater 1 and rater 2 (n=30) 
     Scoring method Mean (SD) Range     % scans excluded 
Rater 1        23% 
             24-point 2.6 (2.9) 0 to 11  
             8-point 1.6 (1.3) 0 to 5  
Rater 2        10% 
             24-point 2.3 (2.5) 0 to 9  
             8-point 1.3 (1.3) 0 to 5  
        
The Intra-rater, inter-rater agreement and test-retest reproducibility of lateral VFA using 
the 8- and 24-point scoring methods is shown in Table 3.6.  Intra-rater ICC was 0.84 and 
0.82 for Rater 1 and 0.93 and 0.93 for Rater 2 for the 24- and 8-point scores respectively.  
Inter-rater agreement was 0.49 and 0.53 for the total 24- and 8-point scores respectively 
(not statistically significant). When calcium within the anterior and posterior walls was 
assessed separately intra-rater and inter-rater agreement was lower on average for the 
anterior compared with the posterior aortic wall (Table 3.6). Test-retest ICC was 0.94 for 
the total 24-point scoring method and 0.91 for the total 8-point scoring method.
Figure 3.8 Example of a lateral 
VFA scan with poor image quality 
due to obesity. This subject had 
a BMI of 40kg/m
2
 
Figure 3.9 Example of a lateral 
VFA scan image with profuse 
bowel gas obstructing the 
abdominal aortic anatomy. 
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Table 3.6 Intra-rater, inter-rater and test-retest intraclass correlations (and 95% CI) for lateral VFA. 
 
         Rater 1          Rater 2  
       Intra-rater         Intra-rater           Inter-rater            Test-retest 
24-point score    




0.49 (-0.23-0.78) 0.94 (0.83-0.98)
c 












0.48 (-0.25-0.78) 0.93 (0.79-0.97)
c 
8-point score    












0.46 (-0.30-0.77) 0.82 (0.46-0.93)
b 








                                                            p-value 
a
 = <0.05, 
b
 = <0.01, 
c
 = <0.001 
 




    
 
Figure 3.10 shows Bland–Altman plots for the 24-point scoring method. The Bland-
Altman plots for the two lateral VFA scoring methods were broadly equivalent and 
therefore only plots for the 24-point scoring method are shown. For intra-rater agreement 
a positive bias of 0.6 (26%) was observed for the 24-point scoring method indicating that 
rater 1 scored consistently higher at the first scan reading compared to the second with 
only 1 score falling outside the LoA (Figure 3.10A).  The study subject whose score fell 
outside the LoA had bowel gas at L3 and L4 on the scan image which, on further review 
following statistical analysis, had been misinterpreted as calcification at the first scan 
read but not the second.  The inter-rater agreement between raters 1 and 2 for each of 
the scoring methods also showed a positive bias of 0.4 (16%) indicating that rater 1 
scored consistently higher than rater 2 (Figure 3.10B). Only one score fell outside the 
LoA which was found to be the same study subject whose score also fell outside the LoA 
on the intra-rater Bland-Altman plot. Test-retest reliability for scan 1 and scan 2 showed 
a positive bias of 0.5 (19%) indicating that scores for scan 1 were higher than scan 2. All 


















    
                 
                                       
              
 
            
Figure 3.10 Bland-Altman plots showing (A) intra-rater agreement, (B) inter-rater agreement and 
(C) test-retest reproducibility for the lateral VFA 24-point scoring method. The bias line is shown 
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3.6 Discussion  
The rationale for the present study was to investigate the reproducibility and the intra- 
and inter-rater agreement of lateral VFA scans and moderate dose, non-diagnostic, non-
contrast CT for the quantification of VC. There is limited information in the literature on 
the intra- and inter-rater agreement and precision of CT for quantifying VC at non-
coronary sites in low risk populations. The results of this study showed good intra-rater 
agreement for identifying AAC on lateral VFA scan images. However, results showed the 
inter-rater agreement of lateral VFA to be relatively poor but not statistically significant. 
This study showed that intra- and inter-rater agreement for identifying and scoring VC 
using CT was excellent.  Test-retest reproducibility was excellent for both lateral VFA 
and CT.    
In the present study it was difficult to compare results of the intra- and inter-rater 
agreement of CT with other studies as available data are mainly limited to 
measurements of coronary calcification. Furthermore, there is also limited information 
regarding the test-retest reproducibility of CT for quantifying VC at non-coronary sites.  
However, a small study by Bowden et al in 2009 assessed the interobserver variability 
between raters for the evaluation of AAC using non-contrast CT scans of the abdomen 
[568], which demonstrated minimal interobserver variability using the volume scoring 
method to quantify calcium within a 4.95cm section of the aorta. The present study also 
reports minimal inter-rater variability. This study included the evaluation of calcification 
over a larger vascular region, compared with the study by Bowden et al, and included 
the thoracic and abdominal aorta, as well as the iliac and carotid arteries using three 
established scoring methods, the Agatston, modified Agatston and volume scores, 
traditionally used to quantify coronary calcification. 
In the present study test-retest reproducibility of CT was assessed to aid in determining if 
the largest source of error relates to scanner imprecision or intra- or inter-rater variability. 
The test-retest results in this study were excellent with ICC ranging from 0.92 and 0.98 
showing minimal variability between duplicate scans (Table 3.4).  In comparison the 
intra-rater results for CT were more variable with ICC ranging from 0.63 to 0.98 showing 
that the largest source error was introduced by the rater (Table 3.4). The bias and 
percentage difference as evaluated using Bland-Altman plots show only minor variation 
of 5% for test-retest reproducibility (Figure 3.5).  Individual calcified deposits on each 
transaxial CT slice had to first be identified by the rater and then a ‘seeding’ tool was 
used to delineate each deposit using the thresholding method described in the 
methodology i.e. the software did not automatically delineate individual deposits. 




    
Therefore one potential source of variability relates to the possibility that each rater may 
have overlooked smaller calcified deposit which may not have been visually obvious, or 
possibly missed due to the large number of slices per subject that had to be analysed.  
An important point to acknowledge is that it is not possible to remove rater associated 
errors during image analysis, even during the assessment of test-retest reproducibility of 
imaging methods, as these scans still require the input of a rater to evaluate the scan 
images.    
Bland-Altman plots presenting intra- and inter-rater agreement (Figures 3.10A & 3.10B) 
showed there were two subjects that had large variation between scores, between both 
read 1 and read 2 or between rater 1 and rater 2. Both subjects had a large calcium 
burden within the AA and iliac arteries. No obvious reason was established which 
explained the large variance between the scores of the two subjects, although in regions 
with greater amounts of calcification smaller deposits were often included by rater 1 and 
not rater 2. Although both raters dedicated a significant amount of time to image analysis 
in this research study, this may not be possible in a busy clinical environment and 
highlights a potential issue that could occur in clinical practice.  
 
The ICC values for CT obtained in this study were found to be excellent and in keeping 
with ICC values reported for other research studies [558, 571]. Acceptable values of ICC 
that indicate a technique can be used in clinical practice have been discussed in the 
literature [573, 574], with ICC of 0.75 or greater being considered acceptable for 
technologies used in health research and clinical practice. The intra- and inter-rater and 
test-retest ICC in this study for CT measurements at non-coronary sites exceed the 
recommended minimum showing that the methods used are adequate for this study and 
for future clinical research.   
One of the aims of this part of the study was to evaluate three calcium scoring methods 
traditionally used to quantify coronary calcification on CT to establish which method 
would be best for quantifying VC for subsequent adoption in the main clinical study. This 
study found the Agatston, modified Agatston and volume scores to be broadly equivalent 
with ICC values between 0.89 - 0.99 with the same outliers present on the Bland-Altman 
plots for each of the CT scoring methods. Intra- and inter-rater and test-retest ICC were 
improved by the addition of the IA in the analysis. The Iliacs were initially included to 
enable the identification of calcified deposits at the aortic bifurcation, often a site of 
increased deposits, and so preventing the possible exclusion of a scan slice or slices 
with increased calcification due to differences in the rater’s opinion of which transaxial 
slice includes the bifurcation.  The study by Bowden et al, described above, highlighted 
this as a potential source of error. It was not possible to remove errors associated with 




    
start and end slices entirely and any inconsistency between start points could potentially 
result in a large variation between scores e.g. due to the inclusion of calcification from 
the femoral arteries.  However, for this study a review of the start and end slice for each 
vascular site recorded by each rater confirmed consistency for the IA and all other 
vascular regions. 
In this study there was a high prevalence of calcification in the AA and the IA compared 
to the TA. It is known that VC is more prevalent within the AA compared to the TA [575, 
576], with evidence of AAC from the age of 60 and older, which is significantly 
associated with CVD mortality [555]. A large study by Honkanen et al (CORD) reported 
that AAC as detected by lumbar radiographs was present in 81% of the patients with 
CKD with the largest percentage located at L4, indicating that calcification tends to 
develop in a distal to proximal direction within the aorta [577].  More recently a study by 
Allison et al [578] demonstrated that in terms of the extent of calcification, the IA showed 
the strongest association for all-cause mortality, consistent with the well-known 
association between the severity of peripheral artery disease and both CVD and total 
mortality [578]. Furthermore the study concluded that higher levels of calcification in 
different vascular sites are associated not only with CVD mortality but also with non-CVD 
and total mortality, and that location of the arterial calcification appears to be relevant to 
the strength of the association with mortality, and CVD risk factors appear to mediate 
some of the association [578]. 
Due to the high radiation dose and cost associated with CT, along with limited scanner 
availability, there is an obvious rationale for evaluating the use of lateral VFA scans for 
the detection of AAC, especially as they can be easily acquired concurrently with routine 
bone densitometry with minimal time. The intra-rater agreement of AAC scored using 
lateral VFA scans in the present study was good and found to be comparable with other 
studies [549, 558, 569]. However, inter-rater agreement was poorer, non-significant, and 
not consistent with the findings in other studies [549, 558] The study by Schousboe et al 
[549] reported intra-rater and inter-rater ICC values of 0.81 and 0.89 respectively for 
quantifying AAC on lateral VFA using the 24-point score which were moderately higher 
than the inter-rater results obtained in the present study. However, the study by 
Schousboe did have a larger study population than the present study [549]. A study by 
Toussaint et al [558] evaluated the intra- and inter-rater agreement of lateral DXA-VFA 
for evaluating AAC in a high risk group of patients with CKD and reported intra- and 
inter-rater results closely comparable to the results in the present study with ICC values 
between 0.89 to 0.91 and 0.84 to 0.90 and 0.53 to 0.68 and 0.60 to 0.70 for the 24- and 
8-point scores respectively [558]. A further study by Toussaint et al [569] evaluated the 




    
test-retest reproducibility of lateral DXA-VFA scans for quantifying AAC and reported 
ICC values ranging from 0.91 to 0.93 and 0.82 to 0.87 for the 24- and 8-point scores 
respectively. Although the present study focused on a lower risk population, the test-
retest results in the present study were found to be comparable to those seen in renal 
dialysis patients, who had greater amounts of VC on average than the healthy 
postmenopausal women included here [569].   
Another study aim was to evaluate the previously validated semi-quantitative 24- and 8-
point scores for quantifying AAC on lateral VFA scan images [339, 564] to establish 
which method would be best for quantifying AAC for subsequent adoption in the main 
clinical study. This study found the 24- and 8-point scores to be broadly equivalent with 
intra-rater ICC values of 0.84 and 0.82 for the total 24-and 8-point scores respectively, 
and inter-rater ICC values of 0.49 and 0.53 for the total 24- and 8-point scores 
respectively, with the same outliers present on the Bland-Altman plots for both of the 
lateral VFA scoring methods.  Although the adoption of the simplified 8-point scoring 
method for use in clinical practice would be considered a sensible approach, results for 
the 24-point scoring method are presented in subsequent chapters, primarily due to the 
fact that it has been widely applied to evaluate lateral radiographs acquired in 
osteoporosis trials and has been validated as an independent predictor of vascular 
morbidity and mortality [339]. 
Both the intra- and inter-rater ICC were much lower with lateral VFA compared to CT. 
Lateral VFA scan images are two-dimensional and identification and quantification of 
AAC can only be achieved by assessing calcification on lateral scans as described by 
Schousboe et al [564]. Furthermore image resolution can be influenced by patient size 
[569], and the identification and scoring of calcification is affected by image quality and 
the presence of image artefacts such as profuse or focal bowel gas overlying the AA on 
lateral scans. Advantages of single-energy imaging are that the images can be obtained 
faster. However, single-energy images - used in the present study - are disadvantaged in 
that the shadows created by soft tissues can obscure visualisation of the vertebrae, 
especially in areas where the contrast between adjacent soft tissues is considerable. 
Dual-energy x-ray IVA imaging using the Hologic scanner on the other hand has better 
resolution than single-energy but the effective radiation dose is higher with a longer scan 
acquisition time. Furthermore, DXA-VFA images can be degraded to a greater extent by 
increasing obesity. Computed tomography scan images enable the reader to identify and 
score calcification through three-dimensional transaxial slices that allow calcified 
deposits to be identified around the entire circumference of the arterial lumen [579], 




    
without artefacts caused by overlying soft tissue or bone as for two-dimensional imaging 
methods, such as lateral VFA [564]. 
The test-retest reproducibility results for lateral VFA in this study were good with ICC 
ranging from 0.82 and 0.94 showing that scanner imprecision is minimal (Table 3.6). The 
intra-rater results were more wide-ranging with ICC ranging between 0.71 to 0.84 and 
0.67 to 0.93 for raters 1 and 2 respectively (Table 3.6), showing that the largest source 
of error was introduced by the rater, consistent with results using CT. The scoring of 
AAC on lateral VFA scan images is subjective and in some cases scans are unable to be 
assessed.  Poor image quality and image artefacts such as profuse bowel gas can mask 
calcification within the aorta resulting in under or over scoring at best or at worst having 
scans that cannot be reliably analysed. Obesity, specifically abdominal obesity, 
significantly affects the quality of lateral VFA scans, therefore hindering the identification 
of AAC. In the present study 13% (n=8) of the total study cohort were classified as obese 
using the conventional method of using BMI ≥ 30.0.  
Bland-Altman plots presenting intra- and inter-rater agreement showed there was only 
one subject that had large variation between the 24- and 8- point scores obtained by 
rater 1 and rater 2 (Figure 3.10). This subject did have a moderate amount of bowel gas 
in the region of L2 and L3 which was interpreted as calcification by one of the raters. The 
percentage difference with intra-rater and inter-rater agreement as evaluated from the 
Bland-Altman plots was 26% and 16% respectively. These results may reflect the small 
sample size used in this part of the study - The percentage bias may have been smaller 
or more comparable with results reported by Schousboe et al if a larger dataset was 
included. The percentage difference with test-retest reproducibility was higher than 
expected at 18% but this is also likely to reflect the small sample size included in this 
part of the study. However, in this study the intra-rater and test-retest ICC for lateral VFA 
and CT were similar, albeit with more variable with larger 95% CI for lateral VFA 
compared to CT, indicating that scores obtained with both imaging methods were 
reproducible. The consistency between the intra-rater ICC indicate that a single rater is 
able to obtain similar scores with subsequent scan reads with both imaging methods, 
despite the semi-automated method of image analysis with CT and the subjectivity of 
scoring AAC on lateral VFA scans. This demonstrates the importance of staff training if 
these scans are to be evaluated and scored in clinical practice. Although the scoring 
methods applied are simple, it would be vital that appropriately-qualified staff spend time 
with an experienced practitioner, for example a Consultant Radiologist as used in this 
study, to acquire the skills necessary to accurately evaluate and score calcification in the 
AA.   




    
In the present study a total of seven of the thirty lateral VFA scans were excluded by 
rater 1 and 3 by rater 2. Scans were excluded if they were unable to be analysed due to 
profuse bowel gas and/or image artefacts e.g. surgical clips or metal clothing fastenings. 
This study did not have the issue of the AA being positioned outside of the FoV as this 
was taken into account during the scan acquisition to include sufficient soft tissue 
anterior to the lumbar vertebrae. In contrast, a study by Schousboe et al [564] excluded 
39 of 174 lateral VFA scans from analysis due to the AA being outside the FoV. The 
importance of CVD and its link with bone biology is increasingly being researched in the 
field of osteoporosis and metabolic bone disease and new bone densitometers are being 
designed to incorporate not only the assessment of OP and fracture risk, but also the 
assessment of body composition to evaluate metabolic health and AC as a risk factor for 
CVD. Hologic have recently introduced the ‘Horizon’ densitometer that produces 
vertebral images, similar to the Hologic Discovery used in the present study, in high 
definition using Horizon’s high definition instant vertebral assessment (IVA-HD) feature. 
This feature is also optimised to visualise AAC which will be useful in future research 
studies [580].  
There were limitations in this study. The study sample size was small which may have 
contributed to the lower inter-rater ICC results with lateral DXA compared with those 
reported by others [558]. Only eight subjects underwent duplicate CT scans and 
nineteen subjects duplicate lateral VFAs to evaluate test-retest reproducibility. Different 
raters were used for the assessment of inter-rater agreement with lateral VFA and CT 
image analysis. The second rater analysing lateral VFA scan images was a clinical 
scientist whereas the second rater analysing the CT images was a Consultant 
Radiologist. It is important to consider that a clinical scientist will have a different skill set 
to that of a radiologist and the amount of time dedicated to image analysis will differ 
greatly between the two. This was reflected in the inter-rater ICC results for CT in the 
present study, particularly at vascular regions with smaller or fewer calcified deposits. 
For example, the TA had the lowest inter-rater ICC results which suggest a level of 
disagreement with the amount of calcification included in the analysis. However, intra-
rater ICC results with CT were closely comparable for a Consultant Radiologist and a 
clinical scientist. Inter-rater ICC results with lateral VFA were low and not significant in 
the present study. These results are a reflection of the subjectivity associated with 
calcium scoring using lateral VFA scan images. 
 
 




    
                 3.7 Conclusion 
The aim of this study was to investigate the test-retest reproducibility and the intra- and 
inter-rater agreement of lateral VFA scans and CT for the quantification of VC. The 
results showed good intra-rater agreement for lateral DXA for quantifying AAC and also 
good test-retest reproducibility. However, the non-significant results for inter-rater 
agreement demonstrate lateral VFA may not be suitable in clinical practice where 
multiple raters will be evaluating scan images. This study also showed excellent intra- 
and inter-rater agreement and test-retest reproducibility for quantifying VC using 
moderate dose, non-diagnostic CT. The CT results were superior to those obtained 
using lateral VFA, an anticipated finding, nevertheless it does demonstrate that 
moderate dose, non-diagnostic, CT offers an alternative to higher dose (diagnostic) CT 
used in clinical practice for the quantification of VC at multiple vascular sites.  An 
important secondary objective of this part of the study was to determine if any of the 
scoring methods applied to quantify calcification, for either technique, was superior. This 
information, along with correlation between calcium scored on lateral VFA images and 
AAC measured on CT included in Chapter 4, would determine which scoring method 
was applied in the core clinical study. In terms of the intra- and inter-rater agreement and 
test-retest reproducibility each of the scoring methods applied to either lateral VFA or CT 
scans were broadly equivalent.   
 




    
Chapter 4  
The evaluation of lateral VFA and pulse wave velocity for 
the assessment of AAC by comparison to the gold-
standard CT 
 
4.1    Introduction   
Atherosclerosis, a major cause of CVD continues to be the leading cause of mortality in 
postmenopausal women and the identification of those at risk of CVD and subsequent 
CV events has relied on the assessment of traditional clinical risk factors such as 
hypertension, obesity, smoking status, family history and diabetes mellitus [581]. 
Moreover, AAC, a marker of subclinical atherosclerosis, is a predictor of subsequent CV-
associated morbidity and mortality [339, 582-584]. The use of CT is recognised as the 
‘gold-standard’ method for the quantitative assessment of calcification with relatively 
good precision and accuracy [558-562, 585], however, much of the data available has 
been limited to measurements of coronary calcification [559, 585] and to high risk 
populations such as those with CKD [558, 559, 561]. Furthermore, the method is limited 
by high radiation exposure and cost [562, 563]. It has been demonstrated that AAC 
detected using lateral lumbar radiographs, traditionally used to assess vertebral 
deformity, is highly predictive of CV-related events and mortality independent of other 
clinical risk factors [342, 564]. Lateral vertebral fracture assessment imaging has been 
shown to be a reasonable substitute for standard radiography to detect vertebral 
deformities, and can be readily performed at the time of bone densitometry with minimal 
additional time and radiation exposure [586-588]. The AA can be visualised on lateral 
VFA scan images anterior to the lumbar spine, and the use of lateral VFA has been 
proposed as a useful imaging tool for the semi-quantitative assessment of AAC [564], 
with reasonably good sensitivity and specificity when compared to conventional 
radiographs [570].  Several studies have assessed the accuracy of lateral VFA scans for 
quantifying AAC by comparison with the gold-standard of CT. For example, Toussaint et 
al previously reported good sensitivity of lateral VFA for the assessment of AAC with 
results closely comparable to that of CT, and suggested that lateral DXA scans may 
allow concurrent assessment of AAC as well as BMD in women referred for routine 
screening for low BMD and OP [558]. Most of the studies assessing the sensitivity of 
lateral VFA for quantifying AAC have been limited to high risk populations with a high 
incidence and extent of VC [558, 561]. However, a recent study by Cecelja et al 




    
assessed the accuracy of lateral DXA-VFA compared to CT in a group of healthy 
postmenopausal women and  reported good sensitivity and specificity of DXA scan 
images for predicting AAC as detected by CT, supporting the suggestion that lateral 
DXA-VFA scan images may provide a useful alternative to CT for quantifying AAC [567].   
 
Pulse wave velocity is a simple, non-invasive method of measuring arterial stiffness 
(Section 2.10, Chapter 2.0) and has been shown to be an independent predictor of CV-
related events and mortality [321, 474, 589-593]. Pulse wave velocity is in part 
dependent on atherosclerotic burden and/or medial calcification, and is widely used in 
the fields of renal and diabetic research. The predictive importance of PWV was first 
highlighted in renal patients for whom the incidence of CV events is greatly increased 
in patients with a high PWV [321, 590]. These findings have been replicated in other 
study groups including hypertensive, diabetic and elderly subjects where PWV is a 
predictor of CV morbidity and mortality independent of other more established CV risk 
factors including hypertension [591, 592]. A large epidemiological study by Cecelja et 
al reported aortic PWV to be associated with age and hypertension but not with other 
clinical risk factors associated with atherosclerosis [329]. In addition to these findings in 
human studies, a study by Farrar et al demonstrated PWV is not associated with early 
stage atherosclerosis in primates [594]. Moreover, murine models of medial 
calcification resulted in increased aortic stiffness independently of the development of 
atherosclerosis [595]. Previous studies demonstrating an association between aortic 
stiffness and atherosclerosis and aortic stiffness and VC have not distinguished 
between calcified and non-calcified atheromatous plaques or between calcification in 
the presence or absence of atherosclerotic plaques [593, 596]. However, a recent 
Twins UK research study evaluated the association between aortic stiffness measured 
using PWV with atherosclerotic and calcified plaque, reporting a significant association 
between PWV and calcification, with PWV increasing with calcific burden, and the 
study concluded that aortic stiffening relates to AC but not to atherosclerotic plaque 
burden [571]. Therefore PWV provides another method for estimating AC, and is the 
rationale for inclusion in this study. The ability of lateral VFA scan images to detect 
AAC as determined by the ‘gold-standard’ of CT remains to be fully-established, 
particularly within lower risk populations with a larger sample size. Moreover, the 
relationship between PWV and AAC, a surrogate of subclinical atherosclerosis, 
remains to be established.  A summary of previous studies evaluating the accuracy of 
imaging methods used to measure VC/AAC which was used to compare and correlate 
with the results from the present study are presented in Table 4.1.  
 





























   
  4.1.1 Study aim 
 
The aim of this part of the study was to evaluate the accuracy, sensitivity and specificity 
of lateral VFA scans for the detection of AAC as measured using the ‘gold-standard’ of 
CT. A further aim of this study was to evaluate the relationship between aortic stiffness 




4.2 Study population 
 
The study population consisted of 444 healthy, ambulatory postmenopausal women with 
a mean age of 62 years who had attended the Osteoporosis Unit to take part in a large 
cross-sectional study as previously described in Section 2.4, Chapter 2. Subjects had 
carotid to femoral PWV ultrasound measurements to assess aortic stiffness, CT scans of 





Table 4.1 Overview of previous studies evaluating lateral VFA, CT and PWV for the quantification 
of AAC/VC and arterial stiffness. 
Author (year) Population  







































































HD, haemodialysis; CKD, chronic kidney disease; GP, general population; CT, computed tomography; 
AS, arterial stiffness; Rad, radiographs; Sens, sensitivity; Sig, significant.  




    
4.3 Materials and methods 
4.3.1 Measurement of PWV 
Three hundred-sixty two (82%) of the 444 subjects had carotid to femoral PWV 
performed using the SphygmoCor (AtCor Medical LTD, Australia) PWV system (Section 
2.10, Chapter 2).  Measurements were made by one clinical scientist (SE), and any 
readings which did not conform to the internal quality checks provided by the 
SphygmoCor software were rejected and subsequently repeated. Measurements were 
made in triplicate, with mean PWV values used for data analysis. The validation of this 
method and its reproducibility has been previously described by Asmar et al, with intra- 
and inter-observer repeatability coefficients of 0.935m/s and 0.890m/s respectively [337]. 
Measurements of PWV were not obtained for 82 (19%) of the total study cohort of 444 
subjects, primarily as a result of excessive amounts of adipose tissue at the femoral 
artery measurement site precluding an accurate recording of the pressure pulse.  
 
4.3.2 Lateral VFA scans 
Three hundred forty (77%) of the 444 subjects had lateral single-energy VFA (IVA-HD) 
scans of the lumbar spine using the Hologic Discovery QDR 4500 densitometer (Hologic, 
Bedford MA) (Section 2.9, Chapter 2). Scans were obtained using an established local 
protocol for lateral VFA scan acquisition which was modified to include the lumbar region 
only using a rotating C-arm which required the subject to lie supine with raised arms 
(Section 2.9, Chapter 2). One hundred four (31%) of the 340 lateral DXA scans were 
unevaluable due to poor image quality primarily as a result of abdominal obesity or 
overlying bowel gas obscuring the walls of the AA.  
 
4.3.3 Semi-quantitative assessment of AAC  
Abdominal aortic calcification was assessed on the lateral VFA scan images by a clinical 
scientist (SE), blinded to subject demographics and BMD results with scans identified 
only by the subjects study number. Scans were analysed using the semi-quantitative 24-
point and 8-point scoring methods as described in Section 2.9.1 and 2.9.2, Chapter 2 in 
which both the location and the extent of calcification at each lumbar vertebral segment 








    
4.3.4 CT imaging 
One hundred thirteen (25%) of the 444 subjects underwent non-contrast; non-diagnostic, 
un-gated CT scans of the chest and abdomen. The scans were performed using the 
Philips Precedence 16-slice SPECT/CT helical scanner (Philips Healthcare, Best, 
Netherlands) as described in Section 2.11, Chapter 2. The scan had a field of view (FoV) 
of approximately 50cm which included the IA, AA, TA and CA. Scan images were 
reconstructed into contiguous 3mm transverse slices for viewing on an image analysis 
workstation. Each scan consisted of 170 slices on average varying with the height of the 
subject. All scan images were viewed and analysed using the semi-automated hybrid 
viewer function on Hermes Gold ™ imaging software. 
 
4.3.5 Quantitative assessment of AAC on CT 
Abdominal aortic calcification was evaluated using CT scans for direct comparison to 
AAC as measured using lateral VFA scans. Vascular calcification was also assessed at 
the other vascular sites included during CT scan acquisition. Scans were assessed by 
one clinical scientist (SE), blinded to subject demographics, BMD results and lateral VFA 
AAC scores. Scan images were identified only by the subjects’ study number. Each 3mm 
scan slice was analysed individually and calcified deposits were defined as any area 
greater than 1mm2 within the blood vessel being assessed with a HU of ≥ 130, and 
lesions were recorded according to anatomical location and deposit number as 
described in Section 3.3.2, Chapter 3. The total Agatston [349], modified Agatston [553] 
and volume score [554] were obtained by summing the scores for each cross-sectional 
slice (Section 2.12, Chapter 2).   
 
4.4    Statistical analysis 
Study population characteristics are presented as the mean and standard deviation (SD) 
unless otherwise stated. The student’s t-test and chi-squared test were used to test for 
significant differences in characteristics between subject groups for PWV and lateral 
VFA. The Kolmogorov-Smirnov test was used to assess normality of distribution of 
measures of VC including lateral VFA AAC scores, CT VC scores and PWV. 
Spearman’s correlation coefficient was calculated to assess the correlation between the 
24-point and 8-point scores, the correlation between lateral VFA and CT AAC scores 
and the correlation between PWV and calcium scores obtained using lateral VFA and 
CT. Following univariate analysis outliers were removed from scatterplots to aid visual 
interpretation of the results. The sensitivity, specificity, positive predictive value (PPV) 




    
and negative predictive values (NPV) were calculated for the 24-point lateral VFA 
scoring method for identifying calcium detected by CT with a binary cut-off of 0 for zero 
calcium and 1 for calcium present. To allow an assessment of whether the accuracy of 
lateral VFA changes with increasing severity of AAC on CT, sensitivity, specificity, PPV 
and NPV were calculated for tertiles of CT calcium score for the AA with thresholds set 
at ≥117, ≥ 670 for the Agatston score, ≥ 2161.9, ≥ 15304.4 for the modified Agatston 
score and ≥ 0.074 and ≥ 0.335 for the volume score. Unlike coronary calcium scores 
which have established cut-points that are associated with increased CV disease 
incidence; all CT scores at the AA in this study were divided into equal tertiles as no 
established cut-off points exist for AAC. The area under the curve (AUC) was calculated 
using receiver operating characteristic (ROC) analysis. Multi-linear regression analysis 
was used to assess associations between PWV with AAC as measured by lateral VFA 
and VC measured using CT at multiple vascular sites, correcting for confounders 
associated with PWV and/or VC.  Confounding variables included age, BMI, MAP, anti-
hypertension medication and smoking status. P values <0.05 were considered 
statistically significant. 
 
4.5    Results 
Subject characteristics of the total study population are presented in Table 4.2. Subjects 
had a mean age of 62 years (range 50 to 81) with no prior history of CV events. Fifty-five 
per cent (n=244) of subjects had a family history of CV disease.  Thirteen percent (n=58) 
of subjects had confirmed hypertension with 10% (n=44) taking antihypertensive 
medication. Twenty-one per cent (n=92) of subjects reported taking prescribed calcium 


















Frequency distributions for AAC on lateral VFA scans quantified using the 24- and 8-
point scores are shown in Figure 4.1, and frequency distributions for VC evaluated on 
CT using the Agatston, modified Agatston and volume scores are shown in Figure 4.2. 
The distribution of scores for each of the quantitative measures of calcification were 
positively skewed (p=<0.001) with a large proportion of subjects having zero 
calcification, as shown on the frequency graphs, averaging 40% of the population using 
VFA and 23% using CT (Figures 4.1 & 4.2). 
Table 4.2 Study total population characteristics (n=444) 
  
          Mean (SD) 
 
Age (years)            61.7 (6.4)                   
Height (m) 1.62 (0.07) 




Total cholesterol (mmol/l) 6.0 (0.9)        
Total triglycerides (mmol/l)                                        1.0 (0.4) 
HDL-cholesterol (mmol/l)                       2.0 (0.5) 
LDL-cholesterol (mmol/l)                       3.5 (0.8) 
Mean arterial pressure (mm Hg) 93.6 (10.0) 
PWV  (m/s) 8.9 (1.7) 
Lumbar spine T-score -1.3 (1.2) 
Total hip T-score -0.8 (0.9) 
Hip neck T-score -1.2 (0.9) 
Prescribed Ca/vit D supplement user (%) 21 
Family history CVD (%) 55 
Hypertension (%) 13 
Hypertension treatment (%) 10 
History of fracture (%) 31 
Current Smoker (%) 6 




    
     
Figure 4.1 Frequency distribution histograms of the 24-point AAC score (A) and the simplified 8-
point AAC score (B) from lateral VFA scan images (n=340). 
                        
                   
 
Figure 4.2 Frequency distribution histograms of the total Agatston score (A), total modified 
Agatston score (B) and total volume score (C) from CT scan images which includes 
measurements of VC from the IA, CA, AA and TA (n=113). To aid visual interpretation of the 
distribution of CT scores outliers were removed from each of the histograms. 
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                4.5.1 Relationship between lateral VFA and CT 
 
Calcification was present in 78% of subjects who had CT scans, and 60% of subjects 
who had lateral VFA scans. Ninety-seven of the 104 unevaluable scans were excluded 
due to overlying bowel gas and 7 were unevaluable due to obesity affecting the image 
quality. Statistical differences between subjects with lateral VFA images that could be 
evaluated and subjects with unevaluable lateral VFA images are presented in Table 4.3. 
Subjects with unevaluable lateral VFA scan images had a lower body weight and BMI, 
lower total-cholesterol, triglycerides and LDL-cholesterol, PWV and hip BMD T-scores 
















The mean total Agatston, total modified Agatston and total volume scores for VC 
measured using CT were 2442.6 ±10129.9 arbitrary units (AU), 39787.4 ±115565.8 AUs 
and 1.15 ±4.57cm3 respectively (Table 4.4). The mean total 24- and total 8-point scores 
for AAC as measured using lateral VFA images were 2.12 ±2.42 and 1.19 ± 1.16 
respectively (Table 4.4). Mean VC scores were calculated for each vascular site using 
CT. The AA and IA had the highest extent of calcification while the lowest incidence and 
extent of calcification was observed in the CA (Table 4.4). 
Table 4.3 Study characteristics for subjects with lateral VFA scans that were evaluable 
versus subjects with scans that were unevaluable.  
 Evaluable 
VFA images   
 (n=340) 
Unevaluable 
VFA images         
 (n=105) 
 
 Mean (SD)                          Mean (SD)         
Age (years) 61.6 (6.3) 61.9 (6.6) 
Height (m) 1.62 (0.7) 1.63 (0.0) 





25.6 (4.3) 22.6 (4.2)
c
 
Total cholesterol (mmol/l) 6.0 (0.9) 5.9 (0.9) 
Total triglycerides (mmol/l)                                        1.0 (0.5) 0.9 (0.3)
a
 
HDL-cholesterol (mmol/l)                       2.0 (0.5) 2.2 (0.5)
c
 
LDL-cholesterol (mmol/l)                       3.6 (0.8) 3.3 (0.8)
c
 
Mean arterial pressure (mm Hg) 93.8 (10.1) 93.0 (9.8) 
PWV  (m/s) 9.0 (1.8) 8.4 (1.5)
b
 
Lumbar spine T-score -1.3 (1.2) -1.4 (1.2) 
Total hip T-score -0.7 (0.9) -1.0 (0.9)
b
 








<0.001 when compared to subjects with lateral VFA scans 
that could be evaluated. 
 




    
Table 4.4 Calcium scores for individual vascular sites and total scores obtained using CT 
and lateral VFA. 
 
Scoring method 
           
                Mean (SD)  
              





Total  2442.6 (10129.9) 0-98782 
Carotid arteries 18.3 (108.0) 0-1026 
Thoracic aorta 202.19 (952.2) 0-9355 
Abdominal aorta 1294.9 (5548.6) 0-55618 
Iliac arteries 927.2 (3910.2) 0-33733 
CT Modified Agatston (AU)
 
  
Total  39787.4 (115565.8) 0 - 1019091.2 
Carotid arteries 447.1 (3000.0) 0 - 29291.9 
Thoracic aorta 3047.9 (11346.7) 0 - 99876.5 
Abdominal aorta 20727.2 (62411.7) 0 - 551780.7 
Iliac arteries 15565.1 (50491.4) 0 - 366927.8 
CT Volume score (cm
3
)   
Total  1.151 (4.573) 0 - 44.323 
Carotid arteries 0.220 (0.990) 0 - 0.490  
Thoracic aorta 0.776 (1.895) 0 - 4.260 
Abdominal aorta 1.752 (3.397) 0 - 24.860 
Iliac arteries 1.736 (2.930) 0 - 15.155 
VFA 24-point score    
Total  2.12  (2.42) 0 - 11 
VFA 8-point score   
Total  1.19 (1.16)                          0 - 6 
 
Univariate analysis revealed significant positive correlations between each of the 
scoring methods used to quantify VC on CT.  A significant positive correlation was also 
observed between the semi-quantitative 24-point score and the simplified 8-point 
scoring method r = 0.95, p = <0.001. A scatterplot showing the correlation between the 
24-point and 8-point AAC scores is presented in Figure 4.3.  




    
                                          
Figure 4.3 Scatterplot of the semi-quantitative 24-point 




Univariate analysis revealed significant positive associations between measures of AAC 
on lateral VFA scans with measures of AAC on CT scans (Table 4.5). The strength of 
association was broadly equivalent between measures of AAC assessed on lateral VFA 
with AAC assessed on CT scans with r-values averaging 0.28. 
        
Table 4.5 Correlations between lateral VFA and CT VFA-matched* AAC scores.  
 r p 
 
24-point score   
 












  8-point score   
 








      Volume  
 
        0.27 0.010
 
*AAC was measured within the AA adjacent to L1-L4 on CT images as with VFA scans.  
Table 4.6 shows the sensitivity, specificity, PPV, NPV and AUC of lateral VFA for 
detecting AAC measured using CT as the gold-standard. The presence of AAC was 
correctly identified in 33 (36%) subjects, with false negatives in 27 (30%) subjects who 
did have AAC (sensitivity 55%). Fifteen subjects were correctly identified as having no 
r = 0.95 
p = <0.001 
R
2
 = 0.814 
 
Lateral VFA 24-point score  




    
AAC with false positives identified in 16 subjects who did not have AAC (specificity 
48%). The probability of subjects identified as having AAC as detected by lateral VFA 
scans that had AAC as measured by CT (PPV) was 67%, and the probability of subjects 
identified as having no AAC that were negative for AAC on CT (NPV) was 36%. The 
area under curve was 0.52 for AAC.  
To investigate if the accuracy of lateral VFA changes with different degrees of AAC as 
detected by CT, the sensitivity, specificity, PPV, NPV and AUC were calculated for 
tertiles of calcification as measured using CT (Table 4.6). Thresholds were set at each 
tertile of the variable for the CT AAC scores resulting in the same values for sensitivity, 
specificity, PPV, NPV and AUC for each of the CT scores.  Most of the measures with 
lateral VFA improved with increasing severity of AAC with moderately-good sensitivity 
(64%, 83%), specificity (55%, 56%) and area under the curve (60% and 69%). Positive 
predictive values decreased from 67% to 39% while NPV increased from 36% to 90% 
with increasing severity of AAC. 
 
Table 4.6. Sensitivity, specificity, NPV, PPV and AUC associated with lateral VFA 
predicting AAC as detected by CT. 
 





















































*Abdominal aortic calcification as measured using CT was categorised as a binary cut-off point 
of 0 for no calcium and 1 for calcium present, tertile 1 was categorised as scores ≥117AU for 
Agatston, ≥2161.9AU for modified Agatston and ≥0.074cm
3
 for volume scores respectively and 
tertile 2 as scores ≥670 AU for Agatston, ≥15304.4AU for modified Agatston and ≥0.335cm
3 
for 
volume scores respectively. 
 
Figure 4.4 shows receiver operating characteristic (ROC) curves for lateral VFA 
detecting AAC as measured by CT for the lowest to highest tertiles of AAC. The 
sensitivity and AUC increase with each tertile of AAC as presented in Table 4.6. The 
AUC at tertile 2 was found to be statistically significant from AUC at tertile 1 and the 
binary cut-off (p=0.001). 




    
                            
Figure 4.4 ROC curves for lateral VFA detecting the presence of AAC as measured 
using CT scans with the red, green and blue lines corresponding to tertiles 
increasing with increased severity of AAC. The red line shows the increase in 
sensitivity and AUC for AAC set at a threshold of >0 (p=0.945), the green line at a 
threshold of ≥117 (AU), ≥2161.9 (AU), 0.074 (cm3), (p=0.105); and the blue line at a 
threshold of ≥670 (AU), ≥15304.4 (AU), ≥0.335 (cm3) (p=0.001) for the Agatston, 
modified Agatston and volume CT scores respectively. 
 
4.5.2 Relationship between vascular stiffness (PWV) and vascular calcification 
Three hundred sixty two (82%) of the total 444 subjects had carotid to femoral PWV 
performed with a mean PWV result of 8.8 ± 1.7. The frequency distributions for PWV 
scores obtained from 362 subjects are shown in Figure 4.5. The distribution of scores 
was positively skewed (p=<0.001) with a large proportion of subjects with a low PWV 








    
                                             
Figure 4.5 Frequency distribution histogram for PWV 
(n=362).   
 
                                  
Statistical differences were observed between subjects that had PWV performed 
compared with subjects that did not (Table 4.7). Subjects who did not have PWV 
readings weighed significantly more and had a higher BMI than those that had 
successful PWV measurements, and subjects without PWV readings had a higher MAP 
and a lower total-cholesterol than those with PWV readings.  
 
 













Table 4.7 Study population characteristics for subjects with and without successful PWV 
measurements. 
     Subjects with PWV 
              (n=362) 
  Subjects without PWV 
 (n=82) 
                  Mean (SD)                Mean (SD) 
Age (years) 61.8 (6.4) 61.3 (6.5) 
Height (m) 1.62 (0.07) 1.62 (0.08) 





24.4 (3.5) 27.1 (6.7)
b
 
Total cholesterol (mmol/l) 6.1 (0.9) 5.8 (0.8)
b
 
Total triglycerides (mmol/l)                                        1.0 (0.5) 1.0 (0.4) 
HDL-cholesterol (mmol/l)                       2.0 (0.5) 1.9 (0.4) 
LDL-cholesterol (mmol/l)                       3.6 (0.8) 3.3 (0.8) 
Mean arterial pressure (mm Hg) 93.0 (9.3) 96.4 (12.8)
a
 
Lumbar spine T-score -1.4 (1.2) -1.2 (1.3) 
Total hip T-score -0.8 (0.9) -0.6 (1.1) 





<0.01 when compared to subjects who had PWV performed. 




    
There were no significant correlations observed between PWV and AAC measured using 
lateral VFA in univariate analysis (Table 4.8).  
  
Table 4.8 Correlation between PWV and AAC measured using lateral VFA 
 
VFA AAC scoring method 
 
              r 
 
                 p 
   
24-point  0.03 0.570 
 
8-point  0.02 0.687 
 
In contrast, significant positive correlations were obtained when PWV was compared to 
VC measured using CT (Table 4.9). Figure 4.6 shows scatterplots of the correlations 
between PWV and the total Agatston, total modified Agatston and total volume VC 
scores following the removal of outliers. Two outliers were excluded from the Agatston 
scores, and one outlier from the modified Agatston and volume scores. There was 
minimal difference in the associations between PWV and VC with results changing from 
r = 0.34, p = 0.001; r = 0.39, p = <0.000 and r = 0.39, p = <0.000 for the Agatston, 
modified Agatston and volume scores respectively.  
 
Table 4.9 Correlation between PWV and VC measured using CT.  
                   




          p 
 
Total Agatston  0.39 <0.001
 
 







                   




    
            
 
                                                    
 
Figure 4.6 Scatterplots showing correlations between PWV and VC quantified using the CT 
total Agatston (A), total modified Agatston (B) and volume scores (C) following the 
exclusion of outliers from the scatterplots to aid interpretation of the results. 
 
 
There were no independent associations between PWV and VC measured using the CT 
Agatston, modified Agatston and volume scores following adjustment for confounders 
associated with both arterial stiffness and VC including age, BMI, MAP and hypertension 
medication and smoking status (Table 4.10). Spearman’s correlation showed the three 
CT calcium scores to be highly correlated, and were therefore included separately into 
the regression model to avoid collinearity. Age, BMI, MAP and the use of hypertension 
medication were all found to be significantly positively correlated with PWV, with age 
being the largest contributor to the regression model.   
 r = 0.34 




 r = 0.39 




 r = 0.39 












    
Table 4.10 Multi-linear regression analysis of arterial stiffness measured by PWV as 
the dependent variable and the total Agatston, total modified Agatston and total 
volume VC scores as an independent variables.  
 
Variables 
     
R
2 
      
β-coefficients 
      
        p-value 
Agatston VC score (AU) 0.40 0.051 0.537 
Age (years)  0.386 <0.001 
BMI (kg/m
2
)  0.195 0.024 
MAP (mmHg)  0.203 0.019 
Hypertension medication  0.170 0.043 
Modified Agatston VC score (AU) 0.39 -0.001 0.982 
Age (years)  0.404 <0.001 
BMI (kg/m
2
)  0.199 0.023 
MAP (mmHg)  0.203 0.019 
Hypertension medication  0.171 0.044 
Volume VC score (cm
3
) 0.40 0.053 0.528 
Age (years)  0.386 <0.001 
BMI (kg/m
2
)  0.195 0.024 
MAP (mmHg)  0.203 0.019 
Hypertension medication  0.170 0.043 
Variables included in the model: Age, BMI, MAP, hypertension medication and 
smoking status.  
 
4.6    Discussion 
The rationale for the present study was to investigate the accuracy of lateral VFA for 
detecting AAC as measured using the ‘gold-standard’ of CT and to determine if lateral 
VFA scans can be utilised as a surrogate marker of calcification, a risk factor for CV 
morbidity and mortality, in postmenopausal women referred for OP screening. Computed 
tomography is associated with radiation exposure and cost, however lateral VFA scans 
have been proposed as a reasonable substitute for detecting AAC which can be 
performed in minimal time with low radiation exposure and cost. Furthermore, the 
present study examined the associations between PWV - a measure of aortic stiffness - 
and VC measured using lateral VFA and CT scans to establish how measures of VC 
correlate with aortic stiffness, which itself has been shown to be a strong independent 
predictor of CV mortality. The results of this study show moderately-good sensitivity of 
lateral VFA for predicting AAC as measured by CT, furthermore, the present study 
reports a significant positive association between PWV and VC as measured using CT.  




    
Vascular calcification is an increasingly important clinical concern, particularly in 
populations with CKD, type 2 diabetes mellitus and atherosclerosis. The pathophysiology 
of VC is characterised by the deposition of calcium in the intima and/or media of the 
arterial wall, resulting in increased vascular stiffness.  Most individuals aged 60 and over 
have calcification to some extent in their major arteries [578] leading to the reduction of 
arterial elasticity which impairs CV haemodynamics, resulting in morbidity and mortality 
[491, 556, 557] in the form of hypertension, aortic stenosis, ventricular hypertrophy, 
myocardial and lower-limb ischaemia, congestive heart failure, and compromised 
structural integrity [599-601].  Various diagnostic methods are currently used to assess 
VC, however there is an increased preference for simple, reliable, low radiation dose 
methods that can be readily implemented into routine clinical practice, such as lateral 
VFA scans for the semi-quantitative assessment of AAC, which can be performed 
concurrently with routine bone density screening. The presence of AAC is a marker of 
both subclinical atherosclerotic disease and arteriosclerosis, and is also an independent 
predictor of CV morbidity and mortality [339, 602]. The use of lateral VFA for the 
assessment of AAC during screening for OP may be beneficial as a tool to identify 
asymptomatic patients at low to intermediate risk of a CV event, particularly the elderly, 
who may benefit from risk factor modification and further CV screening. 
Although subjects included in the present study were healthy postmenopausal women 
from a lower risk population, a large proportion of the cohort had VC, with 78% of 
subjects having VC detected by CT imaging and 60% having AAC as detected using 
lateral VFA imaging. These findings are consistent with those previously reported [567, 
597]. A recent study by Figueiredo et al reported radiograph-detected AAC was present 
in over 60% of a low risk community-dwelling population [597]. It is now accepted that 
from the sixth decade onwards, most individuals will have evidence of calcification within 
the major arteries [578, 603]. The population in the present study had a mean age of 62 
years which is similar to those reported in other studies of low risk populations [567]; 
supporting the suggestion that AC is prevalent in later life independent of known CV risk 
factors [558]. Subjects in the present study had a high extent of calcification within the 
AA and IA which is consistent with the findings reported in Chapter 3. A recent study by 
Allison et al [578] also reported a high prevalence of calcification within the AA and IA in 
a study cohort of over 4500 subjects with a mean age of 56 years. The same study also 
confirmed that IA calcification showed the strongest association for all-cause mortality, 
consistent with the well-known association between the severity of peripheral artery 
disease and both CVD and total mortality [578].  




    
The present study assessed the association between the semi-quantitative 24- and 8-
point scoring methods for quantifying AAC on lateral VFA scan images. The 
Framingham study [560] previously reported the 24-point score to be a significant 
predictor of CV events and mortality independent of other known clinical risk factors. 
However, a more simplified 8-point score has been proposed as a quick method of 
assessing AAC on lateral VFA scans, which may be more suitable for use in clinical 
practice. Ultimately, a quick and simple scoring method for quantifying AAC for the 
assessment of future CV risk may be adopted into clinical practice for women referred 
for routine OP screening, which may be useful for identifying patients that can benefit 
from further treatments such as lipid lowering or anti-hypertensive therapy to reduce the 
risk of future CV related events. Results of the present study found the 24-and 8-point 
scores to be highly correlated (r=0.96 p=<0.001), a finding consistent with other studies 
[18,20], [558, 561, 570]. The strong correlation between the two lateral VFA scoring 
methods suggests the simplified 8-point score offers a quick tool for the assessment of 
AAC as an alternative to the widely used and validated 24-point scoring method.   
The present study found moderate agreement between AAC measured using lateral 
VFA scans and VFA L1-L4 matched AAC scores using CT (Table 4.5). Although 
statistically significant, the correlations were weak accounting for less than 10% of the 
variance. The strength of association was broadly equivalent between the 24- and 8-
point scores and each of the CT VFA-matched AAC scores. The correlations observed in 
the present study were lower than those of other studies, for example Cecelja et al 
reported a correlation of r = 0.58 between the DXA 24-point score and CT volume score 
[567]. The correlation between lateral VFA and CT is expected to be higher in subjects 
with greater amounts of calcification due to a larger range of values observed. For 
example, Cecelja et al measured AC over a larger vascular area, between the aortic 
arch and aortic bifurcation on CT [567], compared with the present study which 
measured AAC between L1-L4 on CT. The semi-quantification of AAC on lateral VFA 
images is highly subjective. With single-energy VFA, overlying bowel gas and greater 
quantities of soft tissue as a result of obesity can greatly affect image quality, precluding 
adequate image analysis which may result in inaccuracies during scoring of AAC on 
lateral VFA scan images, which would adversely influence the association between AAC 
measured using VFA and VC measured using CT. Finally, it is impossible to state 
whether the moderate correlation seen between AAC measured using VFA and AAC 
measured using CT in the present study represents atherosclerotic burden or 
arteriosclerosis. Intimal or atherosclerotic calcification is characteristically patchy 
whereas arteriosclerotic or medial calcification is characteristically more diffuse in 




    
appearance but since the medial and intimal layers of the arterial lumen are in close 
proximity, it is impossible to distinguish between the two on either lateral VFA or CT 
images.  
There is limited information in the literature reporting the accuracy of lateral VFA for the 
prediction of VC using CT in low risk populations. The information available reports data 
on high risk populations with renal disease that tend to have a greater incidence and 
extent of VC [558, 569]. For example, Toussaint et al evaluated the use of lateral DXA-
VFA scans for determining AAC as measured by CT in a cohort of 40 CKD-5 patients 
and reported that lateral DXA imaging can accurately detect AAC with good sensitivity 
and specificity [569]. However, recent research from the Twins UK study group 
evaluated the accuracy of lateral DXA-VFA in a group of postmenopausal women 
reporting reasonably good accuracy which improved with increasing calcium burden 
[567].  
The present study reported moderately-good sensitivity with the lateral VFA 24-point 
score for predicting AAC as detected by the ‘gold-standard’ of CT, which is consistent 
with results reported by others [567]. Moreover, the accuracy of lateral VFA imaging for 
predicting AAC on CT improved with the presence of a higher degree of AAC as 
detected on CT, which is consistent with the results from studies on high risk CKD and 
dialysis patients [567, 569]. For example, Cecelja et al reported a sensitivity of 56% for 
correctly detecting the presence of calcification (AAC>0) using lateral DXA-VFA 
compared to CT in a healthy low risk population, with an increase in sensitivity when 
analysis was limited to the upper tertiles of the CT calcium scores.  Toussaint et al 
reported a higher sensitivity of 72% which again increased with the severity of AAC 
[569]. Chronic kidney disease accelerates the development of atherosclerosis and it has 
been demonstrated that CKD causes excessive vascular inflammation and calcification 
[604] and therefore the higher sensitivity reported by Toussaint is likely to be a reflection 
of the greater extent of intimal calcification detected on lateral VFA scans in patients with 
CKD.  
In the present study, the specificity of lateral VFA was much lower than that reported by 
others [567, 569], with other studies reporting a higher specificity of 80% [567] and 75% 
[569]. Due to the subjective nature of calcium scoring on lateral VFA scan images, a 
proportion of scans were incorrectly identified as having calcification when calcium was 
not in fact present on CT (i.e. false positives). These results also reflect the subjectivity 
of calcium scoring on single-energy VFA scan images compared with dual-energy VFA 
scan images that are not disadvantaged by shadows and artefacts created by soft 




    
tissue. The AUC results from this study increased from 0.52 to 0.69 with increasing 
vascular burden on CT but only reached statistical significance at the highest tertile 
(Figure 4.4), and therefore indicate a moderate discriminatory value of lateral VFA in the 
presence of greater quantities of AAC. These ROC results are comparable to those 
reported by Toussaint et al and Cecelja et al of 0.63 to 0.76 and 0.68 to 0.67 
respectively [567, 569]. The negative and positive predictive values in the present study 
reflected the prevalence of AAC within this study population of lower risk 
postmenopausal women. Toussaint et al reported higher NPV of 76.9 and 92.3% for the 
upper tertiles of AAC respectively [569]. In the present study PPV decreased with each 
tertile of AAC with fewer subjects having high AAC scores. In contrast, the NPV 
increased which was a reflection of the ability of lateral VFA to accurately predict when 
subjects did not have AAC. Given the importance of sensitivity, specificity, PPV and 
NPV, and that they are a critical measure of the performance of lateral VFA for detecting 
AAC as measured on CT, the moderate scores obtained in the present study would not 
be adequate for detecting and quantifying low levels of AAC and demonstrate that lateral 
VFA may only provide an adequate substitute for CT for the detection of high levels of 
AAC in clinical practice, with values of 70% and higher considered acceptable. The 
sensitivity and NPV in the present study exceeded 70% only at the highest tertile where 
the greatest amounts of AAC were measured (Table 4.6). This perhaps should not be 
considered a negative finding since the use of lateral VFA to identify only those with 
more severe VC would seem a sensible approach to adopt in clinical practice due to the 
high incidence of AC with ageing.  Reporting the results for only those with the greatest 
extent of calcification would limit referrals for further investigations to only those patients 
who may be at greatest risk of a CV event, and importantly avoid unnecessary concern 
to the patient. 
Arterial stiffness as measured by PWV shows little or often no relation to conventional 
risk factors other than age and blood pressure [329]. Once considered to be largely 
dependent on atherosclerotic burden, arterial stiffness has been shown more recently to 
be related to calcified plaque and not non-calcified atheroma [329]. A study by Cecelja et 
al in 2009 examined the relationship of arterial stiffness to atherosclerosis and measures 
of VC in a cohort of 900 postmenopausal women and reported arterial stiffening to be 
correlated with calcified plaques but not with intima-medial thickness or non-calcified 
atheromas [329]. The study also reported AC as determined by CT was higher in 
subjects with a high PWV [329]. Animal models of atherosclerosis have also suggested 
that arterial stiffness is not affected by the early stages of atherosclerosis [594].  




    
The present study found no association between arterial stiffness measured using PWV 
and AAC as measured using lateral VFA scans (Table 4.8). These results were 
surprising considering the high incidence of AAC and increased arterial stiffness 
reported in this cohort of postmenopausal women, and that both PWV and VC increase 
with age with PWV primarily dependent on calcified plaque burden. In contrast, a recent 
study by Avramovski et al reported a strong association between PWV and AAC as 
measured by lateral lumbar radiographs in both normal subjects from the general 
population and in chronic haemodialysis patients (p=<0.001) [598]. The lack of 
association between PWV and AAC measured using lateral VFA in the present study 
may be explained by the subjectivity of quantifying AAC on single-energy VFA scan 
images as already highlighted. Furthermore, because VFA imaging, like most imaging 
methods, is unable to distinguish between intimal and medial calcification, AAC 
quantified on lateral VFA images may reflect calcified atherosclerotic plaque burden in 
contrast to medial calcification which is more strongly associated with arterial stiffness.  
In the present study PWV was found to be positively associated with VC as measured 
using CT with the correlations accounting for less than 16% of the variance (Table 4.9), 
but this association failed to remain significant after correcting for confounding factors 
including age, MAP and the use of anti-hypertension therapy which are widely accepted 
to be significantly associated with arterial stiffness [605, 606]. A significant positive 
association was observed between PWV and total calcified plaque as measured by CT 
in a recent twins UK study [571]. The subject demographics in the present study 
population and those of the twins UK cohort are comparable to the general population of 
women in the UK for disease and lifestyle characteristics including hypertension and the 
use of antihypertensive drugs. Toussaint et al also evaluated the associations between 
VC and arterial stiffness in a study population with CKD and reported a positive 
correlation between VC and PWV (r=0.33, p=0.03) but like the results from the present 
study, the association failed to remain statistically significant in multivariate regression 
analysis [561].  
This study did have limitations. The study was limited to lower risk, postmenopausal 
women and subjects who were known to be taking lipid lowering therapy were excluded, 
likely lowering both the incidence and extent of VC observed. The study used only 
moderate dose CT for image acquisition, unlike diagnostic CT scans used in clinical 
practice that require a higher radiation dose. In addition, it is possible that both lateral 
VFA and CT imaging differ in their sensitivity to detect intimal and medial calcification. 
The present study did not address the issue of how well lateral VFA predicts future CV 
related events and mortality and how those results compare to those using CT.  




    
4.7    Conclusion 
The results of this study report moderately-good accuracy of lateral VFA scans for 
predicting high levels of AAC detected by CT. The present study did not find any 
associations between PWV and VC. These results demonstrate that lateral VFA scans 
can provide a low radiation, low cost alternative to the ‘gold-standard’ of CT for 
evaluating AAC in a population of postmenopausal women referred for bone density 
screening for OP who are at a high risk for future CV-related events. Previous studies 
have evaluated the accuracy of lateral DXA-VFA compared to the ‘gold-standard’ of CT 
in both high and lower risk populations, however it is understood this is the first study to 
assess the validity of lateral VFA for detecting AAC compared to CT with directly 
comparable regions of interest within the aorta. Further clinical studies are required to 
determine how well AAC measured by lateral VFA imaging correlates with aortic 
stiffness as results may ultimately indicate whether PWV is a reliable measure of AC that 
can be implemented into routine clinical practice for postmenopausal women with low 
bone density given the prevalence of both observed in otherwise healthy 


















    
Chapter 5 
Associations between bone mineral density, aortic 
calcification and aortic stiffness in postmenopausal 
women  
 
5.1    Introduction 
Osteoporosis and CVD are common age-related conditions. Traditionally, the two 
conditions were considered unrelated and their coexistence was attributed to 
independent age-related processes. However, increasing biological and epidemiological 
evidence suggests that there are age-independent associations between BMD, VC 
[359], atherosclerotic burden and CV-related events, morbidity and mortality [358, 361, 
366, 396-398, 402, 404, 408, 409, 420, 470, 607-613]. Tankó et al in 2003 examined low 
BMD at the hip as a marker of VC in elderly women [360] and reported a significant 
negative association between BMD at the proximal femur with the severity of AC (r = –
0.12–17, p < 0.001).  A further study by the same group in 2005 investigated the 
relationship between CVD and OP in a large cohort of over 2500 postmenopausal 
women and reported women with OP at the spine have a four-fold increase in the risk of 
a CV event compared to those with osteopenia [361]. Studies have also assessed the 
relationship between AAC and fracture risk and fracture status, for example, a study by 
Schulz et al examined the association between AAC and the risk of osteoporotic 
fractures in over 2000 postmenopausal women and concluded that AAC is a strong 
predictor of low BMD and fragility fractures and that the rate of bone loss correlates with 
the progression of AAC [359]. More recently a large study assessed the relationship 
between AAC and vertebral fracture and reported increased levels of AAC as measured 
by lateral lumbar radiographs and lateral VFA scans are associated with prevalent 
vertebral fractures, independent of BMD, age, BMI and non-vertebral fracture history 
[614]. Several hypotheses have been proposed to explain the age-independent 
association between OP and CVD.  It has been suggested that CVD and bone 
mineralisation share common risk factors including physical activity, smoking, 
menopause and hypertension which may simultaneously promote or inhibit 
atherosclerosis and demineralisation of bone [355, 360, 402, 615], however, the 
association between OP and CVD remains even after correcting for these risk factors in 
many studies.  Further suggestions for the link between the two conditions involve the 
presence of common pathophysiological mechanisms involving hormones and 




    
inflammatory cytokines. Oestrogen deficiency is a major determinant of age-related bone 
loss and fracture risk in both men and women [84, 616] and may be involved in the 
pathogenesis of both atherogenesis and bone loss, either directly by the expression of 
oestrogen receptors on osteoblasts, osteoclasts [617] and VSMCs [618, 619], or through 
modulation of other factors including cytokines [620] and oxidized lipids [618]. The 
relationship between oestrogen deficiency and CV risk is well established [621], however 
observational studies have shown that postmenopausal women who receive HRT have a 
lower rate of CVD and cardiac death than those not receiving HRT [622, 623]. 
Conversely, prospective studies have shown that HRT may actually increase the risk of 
CV events including MI and CHD-related death in postmenopausal women [624-626]. 
Reasons for the contradictory results are unclear, although it has been suggested that 
age, pre-existing CVD and/or risk, when HRT was initiated, the type of HRT given (i.e. 
conjugated equine oestrogen with progestin), dosage, and the thromboembolic 
properties of oestrogen and progestin [620, 627-630] may influence CV outcomes. 
Proinflammatory cytokines including interleukin 6 (IL-6) and tumour necrosis factor (TNF) 
both play an important role in bone metabolism and CVD [631]. Interleukin 6 is secreted 
by osteoblasts in order to stimulate osteoclast differentiation and is also produced by 
smooth muscles cells in the tunica media of blood vessels and has been shown to 
stimulate the inflammatory processes involved in atherosclerosis [632]. Tumour necrosis 
factor has been shown to stimulate bone resorption in vitro [633], and is also a key 
cytokine in the recruitment and activation of inflammatory cells to the vessel wall [634].  It 
has also been suggested there is a causal association between OP and CVD whereby 
one condition may be contributing to the other [367, 399].  
 
Arterial stiffening has long been associated with the ageing and elderly and is known to 
be accelerated by conventional CV risk factors including hypertension, diabetes, and 
hypercholesterolemia and also end stage renal failure in CKD [478, 635], and is strongly 
predictive of future CVD-related events [636]. Animal and human studies suggest that 
VC may be an important determinant of arterial stiffness [313, 595, 596, 637]. For 
example, animal models, have shown warfarin and vitamin K [637], and vitamin D and 
nicotine [595] induced medial calcification to be associated with arterial stiffness, 
decreased elastin and increased collagen content [313, 595, 596, 637]. Human studies 
have also shown that warfarin and vitamin K are associated with increased calcification 
[638] have demonstrated PWV is higher in renal patients with medial and intimal VC 
[313] and a study by Odink et al reported a positive association between PWV and AC in 
a cohort of over 690 elderly, healthy subjects [639]. It has not yet been confirmed 
whether the association between calcification and arterial stiffness simply reflects an 




    
association between atherosclerosis and arterial stiffness. However, studies have shown 
increased arterial stiffness relates to calcified, echogenic plaques but not to lipid-rich 
non-calcified plaques [571, 640]. There is the suggestion that VC may occur 
simultaneously with bone demineralisation, with a shared relationship between OP and 
arterial stiffness explaining the epidemiological association with OP and CV-related 
events [361, 366, 395, 641].    
A number of studies have assessed the association between arterial stiffness and BMD 
in both high risk populations with CKD and lower risk, healthy populations [383, 395, 
480, 561, 571, 640, 641], but the findings have been inconsistent, with studies reporting 
a significant negative relationship between PWV and BMD [480], while others have 
found no relationship at all [383, 561, 571]. The inconsistent results reported may be 
explained by the different imaging techniques used to measure BMD. Dual-energy x-ray 
absorptiometry is still the most widely used method to determine BMD in clinical practice. 
Quantitative computed tomography is considered a superior technique for measuring 
BMD, assessing fracture risk and monitoring changes in BMD, but is not routinely utilised 
due to high radiation exposure, high cost and lack of scanner accessibility. Dual-energy 
x-ray absorptiometry provides 2-dimensional areal BMD measurements and the 
projected area analysed in DXA contains both cortical and trabecular bone however, PA 
DXA scans of the lumbar spine will also include considerable amounts of cortical bone 
from the spinal processes and articular facets and are patient size dependent [36].  
Furthermore, AAC is a well-recognised artefact when performing posteroanterior DXA 
scans of the lumbar spine [365, 642], which can attenuate or mask the relationship 
between PWV and lumbar spine BMD. Quantitative computed tomography on the other 
hand provides 3-dimensional volumetric BMD measurements that allow the integral 
measurement of bone which is not size dependent. In summary, there is strong evidence 
of a biological link between OP and CVD, but the mechanisms involved remain poorly 
understood [398]. Moreover, studies assessing the association between arterial stiffness 
and BMD have reported conflicting results. 
Table 5.1 provides a summary of previous studies evaluating relationships between 
BMD, AC/VC, fracture and arterial stiffness that were used to compare and correlate with 

































5.1.1 Study aim 
The rationale for this part of the study was to investigate the associations between AC, 
arterial stiffness and BMD in a low risk population of postmenopausal women by 
evaluating relationships between BMD at the lumbar spine and hip (i) AAC measured 
using lateral VFA scans, (ii) VC measured using CT and (iii) carotid-femoral PWV as a 
measure of aortic stiffness. 
 
Table 5.1 Overview of previous studies evaluating associations between BMD, AC/VC, 
fracture incidence and risk and arterial stiffness.  
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CKD, chronic kidney disease; GP, general population; PM, postmenopausal; AS, arterial stiffness; 
Frac, fracture. 




    
5.2    Study population 
 
The study population consisted of 428 healthy, ambulatory postmenopausal women with 
a mean age of 62 years who had attended the Osteoporosis Unit to take part in a large 
cross-sectional study as described in Section 2.4, Chapter 2. Subjects that were found to 
have liver or renal disease defined as CKD stage 3 or greater [595], endocrine or 
metabolic bone disorders (other than postmenopausal OP) and hyperparathyroidism 
were excluded from analysis. Four subjects found to have primary hyperparathyroidism 
and 12 subjects that were found to have CKD-3 were excluded from the study.  
 
5.3    Materials and methods 
5.3.1 Anthropometric measurements, blood pressure and medical history 
All subjects had height, weight, blood pressure and BMI measured, and a medical 
history was recorded for each subject, obtained using questionnaires and by personal 
interviews as described in Section 2.13, Chapter 2.  
 
5.3.2 Laboratory assessments 
All subjects had whole blood samples collected under fasting conditions for the 
measurement of lipid, bone and renal profiles (Section 2.14, Chapter 2).  
 
5.3.3 Measurement of BMD 
All subjects had bone density measured at the lumbar spine, total hip and femoral neck 
using DXA (Hologic, Bedford MA) as described in Sections 2.8.1 and 2.8.2, Chapter 2. 
Bone mineral density results were classified using the world health organisation (WHO) 
classification for BMD [640] as described in Section 1.3, Chapter 1. FRAX scores were 
also calculated using the FRAX fracture risk assessment tool (Section 1.3, Chapter 1). 
 
5.3.4 Lateral VFA scans 
Three hundred and thirty (77%) of the 428 subjects had single-energy lateral VFA (IVA-
HD) scans of the lumbar spine using the Hologic Discovery QDR 4500 densitometer 
(Hologic, Bedford MA) (Section 2.9, Chapter 2).  
 




    
5.3.5 Semi-quantitative assessment of AAC  
Abdominal aortic calcification was assessed on the lateral VFA scan images by one rater 
(a clinical scientist [SE]), blinded to subject demographics and BMD results with only the 
subject’s subject number included in the scan header file. Abdominal aortic calcification 
was evaluated using the 24-point scoring method as described in Section 2.9.1, Chapter 
2 in which both the location and the severity of calcified deposits at each lumbar 
vertebral segment were evaluated [596].  
 
5.3.6 CT imaging 
One hundred and twelve of the 428 subjects underwent non-contrast non-diagnostic, un-
gated CT scans of the chest and abdomen. The scans were performed using the Philips 
Precedence 16-slice SPECT/CT helical scanner (Philips Healthcare, Best, Netherlands) 
with a field of view (FOV) of approximately 50cm to include the IA, AA, TA and CA. Scan 
images were reconstructed into contiguous 3mm transverse slices for viewing on the 
image analysis workstation, and all images were viewed and analysed using the semi-
automated hybrid viewer function on Hermes Gold™ imaging software as described in 
Section 2.11.1, Chapter 2.  
 
5.3.7 Quantitative assessment of calcification on CT 
Scans were assessed by one rater (a clinical scientist [SE]), blinded to subject 
demographics, BMD results and lateral VFA AAC scores, with scans identified only by 
the subjects study number as described in Section 2.12, Chapter 2.  
 
5.3.8 PWV ultrasound 
Three hundred and fifty one (82%) of the 428 subjects had carotid to femoral PWV 
performed to measure arterial stiffness using the SphygmoCor (AtCor Medical LTD, 
Australia) PWV system (Section 2.10, Chapter 2).  Measurements were made by one 
clinical scientist (SE), and any readings which did not conform to the internal quality 
checks provided by the SphygmoCor software were rejected and subsequently 
repeated. Measurements were made in triplicate, with mean PWV values used for data 








    
5.4    Statistical analysis 
Study population characteristics are presented as the mean and standard deviation (SD) 
unless otherwise stated. To test variation between groups, analysis of variance (ANOVA) 
was used for continuous variables and the chi-square test used for categorical variables. 
In this study measures of calcification were treated as categorical rather than continuous 
variables due to data being highly positively skewed. VFA and CT acquired measures of 
AAC and VC respectively were categorised as no, moderate or high calcification with 
none defined as zero calcification, high as ≥ 75th percentile and moderate as > zero and 
< 75th percentile for this study population.  Results for PWV were categorised into tertiles 
for low, moderate and high PWV scores (Table 5.2).  
 
Table 5.2 Categories of scores for measures of VC and PWV. 
  Zero * 
0 
Moderate 





≥ 75th percentile 
Lateral VFA 24-point score (AU) 0 1 - 3 ≥ 4 
CT volume score (cm
3
) 0 0.001 - 0.375 ≥ 0.376 
PWV (m/s) ≤ 8.0 8.1 – 9.3 ≥ 9.4 
* defined as low for PWV scores in the lowest tertile.  
 
 
Bone mineral density results were categorised into diagnostic groups as normal, 
osteopenic or osteoporotic using T-scores according to the WHO criteria [640]. 
Multinomial regression analysis was used to assess associations between BMD and 
AAC measured using lateral VFA, BMD and VC measured using CT and BMD and 
arterial stiffness measured using PWV on the total study cohort and on subjects who did 
not use calcium and vitamin D supplements. This regression approach was chosen 
instead of ordinal logistic regression because the assumption of proportional odds was 
not met; that is the relationships between pairs of outcome groups were statistically 
different. Unadjusted, age-adjusted and risk factor-adjusted models were performed to 
assess associations between each measure of calcification and PWV with BMD. 
Variables included in the risk factor-adjusted model included age, BMI, MAP, total-
cholesterol, total triglycerides, smoking, physical activity and hypertension. Lumbar 
spine, femoral neck and total hip BMD SD scores were entered into the regressions 
models separately to avoid collinearity between these variables.  
 




    
5.5    Results 
The study population characteristics are presented in Table 5.3.  Subjects had a mean 
age of 62 years (range 50 to 81) with no prior history of CV events. Fifty five percent 
(n=235) of subjects had a family history of CV disease,  13% (n=55) of subjects had 
confirmed hypertension with 10% (n=42) taking antihypertensive medication and 25% 
(n=106) of subjects reported taking prescribed calcium and vitamin D supplements for an 
average duration of 5 years at the time of the investigations. Subjects on prescribed 
calcium and vitamin D supplementation reported taking an average dose of 1200 mg of 
calcium carbonate and 800 IU of colecalciferol daily. Twenty percent (n=86) had normal 
BMD, 58% (n=247) were classified as osteopenic and 22% (n=95) as osteoporotic 
according to the WHO criteria as described in Section 1.3, Chapter 1. Sixty percent 
(n=198) of the 330 subjects that had lateral VFA scans had evidence of AAC and 78% 
(n=87) of the 112 subjects that had CT scans had VC. Twenty three percent (n=98) of 
the 428 lateral VFA scan images were excluded due to poor image quality resulting from 
profuse bowel gas, obesity and/or image artefacts. Statistical differences were observed 
between characteristics from the total study cohort and those in the CT sub-study group. 
CT sub-study group subjects were older than the total study population with a mean age 

















    

























Table 5.3 Study population characteristics. 
         Total cohort       CT sub-study    p-value 
             (n= 428)      (n=112)  
           Mean (SD)         Mean (SD)  
Age (years) 61.7 (6.4) 63.0 (7.1)
 
0.048 
Time since menopause (years) 12.4 (7.4) 13.1 (7.3) 0.308 
Height (m) 1.62 (0.07) 1.62 (0.07) 0.885 
Weight (kg) 65.8 (12.0) 64.8 (9.6) 0.273 
BMI(kg/m
2
) 24.9 (4.4) 24.7 (3.7) 0.590 
MAP (mmHg) 93.6 (10.0) 93.9 (9.4) 0.758 
Cholesterol (total) (mmol/l) 6.0 (0.9) 6.1 (1.0) 0.171 
HDL-cholesterol (mmol/l) 2.0 (0.5) 2.1 (0.5)
 
0.040 
LDL-cholesterol (mmol/l) 3.5 (0.9) 3.6 (0.9) 0.516 
Triglycerides (mmol/l) 1.0 (0.5) 1.0 (0.4) 0.338 
eGFR (ml/min) 79.7 (14.6) 80.4 (15.3) 0.773 
Serum calcium (mmol/l) 2.4 (0.1) 2.4 (0.1) 0.859 
Lumbar spine BMD (g/cm
2
) 0.893 (0.1) 0.875 (0.1) 0.121 
Lumbar spine T-score -1.4 (1.1) -1.5 (1.0) 0.138 
Femoral neck BMD (g/cm
2
) 0.711 (0.1) 0.697 (0.09) 0.133 
Femoral neck T-score -1.2 (0.9) -1.3 (0.8) 0.053 
Total hip BMD (g/cm
2
) 0.839 (0.1) 0.828 (0.1) 0.272 
Total hip T-score -0.8 (0.8) -0.9 (0.8) 0.072 
% Osteoporosis 22  12 0.123 
FRAX Score major % 9.8 (5.7) 10.7 (6.0) 0.102 
FRAX Score hip % 1.6 (2.5) 2.1 (2.9) 0.062 
Dyslipidaemia % 25 5 0.061 
Hypertension % 13 2.3 0.528 
Family history of CVD % 55 17 0.536 
Current smoker (%) 6 1 0.357 
Former smoker (%) 28 8 0.245 




    
Frequency plots for AAC, volume score and PWV are shown in Figure 5.1.   
       
                               
                                  
                                                  
Figure 5.1 Frequency distribution histograms for AAC measured using the lateral VFA 24-
point score (A), VC measured using the CT total volume score (B) and the CT total volume 
scores with outlier removed. Frequency histogram D shows the distribution of PWV scores. 
Tests for normality showed each of the scores to be positively skewed with p-values of 
<0.001.   
 
The prevalence and extent of AAC as measured using the lateral VFA 24-point score 
and VC measured using the CT volume score according to age categories are presented 
in Figure 5.2A and B and the distribution of PWV scores according to age categories are 
presented in Figure 5.2C. Thirty three percent of subjects had moderate AAC with 
scores between 1 and 3 AU, and 27% of subjects had high AAC with scores ≥ 4 AU 
(Figure 5.2A). Thirty three percent of subjects had moderate VC with scores between 
A B 
C 
CT total volume score (cm3) 
CT total volume score (cm3) D 
Lateral VFA 24-point score  




    
0.001-0.375cm3, and 33% had high VC with scores ≥ 0.376 cm3, with the extent of VC 
increasing with age (Figure 5.2B). Thirty five percent of subjects had moderate PWV 
between 8.1 and 9.3 m/s and 31% had high PWV with scores of ≥ 9.4 m/s which also 
increased with age (Figure 5.2C). 
                                                                                     
             
Figure 5.2 Bar graphs showing the distribution on mean (A) AAC, (B) VC and (C) PWV 
scores according to categories of age. The cyan box shows mean AAC, VC and PWV scores 
with error bars indicating the 95%CI. 
 
5.5.1 Relationship between BMD with AAC as measured by lateral VFA  
The study characteristics for each category of AAC, as measured using VFA are shown 
in Table 5.4. There were statistical differences in subject characteristics between the 
three AAC score categories.  Subjects with high AAC scores were older than those with 
moderate and zero AAC, with a longer time since menopause.  In addition, subjects with 









    
no significant differences with BMD at the lumbar spine, femoral neck or total hip 
between AAC score categories.  
Table 5.4 Characteristics for categories of AAC as measured by the lateral VFA 24-point 
score.  
  No AAC 
  (Score = 0) 
    n=132 
   Moderate AAC 
  (Score = 1-3) 
n=109 
High AAC    
(Score = ≥ 4) 
   n=89 
 p-value 
    Mean (SD)      Mean (SD)           Mean (SD)  
Age (years) 60.7 (5.6) 61.2 (6.4) 63.2 (7.1) 0.011 
Time since menopause (yrs) 11.7 (6.8) 11.6 (7.4) 14.2 (7.4) 0.017 
Height (m) 1.62 (0.07) 1.62 (0.07) 1.64 (0.06) 0.101 
Weight (kg) 66.8 (9.5) 67.1 (12.2) 69.2 (13.2) 0.273 
BMI(kg/m
2
) 25.7 (4.0) 25.5 (4.4) 25.8 (4.7) 0.831 
MAP (mmHg) 94.7 (9.4) 92.1 (10.2) 94.8 (10.9) 0.083 
Cholesterol (total) (mmol/l) 6.1 (1.0) 6.0 (0.9) 6.1 (0.8) 0.818 
HDL-cholesterol (mmol/l) 2.0 (0.5) 1.9 (0.5) 2.0 (0.5) 0.450 
LDL-cholesterol (mmol/l) 3.6 (0.9) 3.6 (0.9) 3.6 (0.7) 0.918 
Triglycerides (mmol/l) 1.0 (0.5) 1.1 (0.5) 1.1 (0.4) 0.239 
eGFR (ml/min) 82.3 (15.2) 80.6 (13.3) 76.8 (13.2) 0.022 
Serum calcium (mmol/l) 2.4 (0.2) 2.4 (0.09) 2.4 (0.09) 0.773 
Lumbar spine BMD (g/cm
2
) 0.897 (0.1) 0.891 (0.1) 0.898 (0.1) 0.906 
Lumbar spine T-score -1.4 (1.1) -1.4 (0.9) -1.3 (1.3) 0.840 
Femoral neck BMD (g/cm
2
) 0.716 (0.09) 0.723 (0.1) 0.724 (0.1) 0.802 
Femoral neck T-score -1.2 (0.8) -1.1 (0.9) -1.2 (0.9) 0.837 
Total hip BMD (g/cm
2
) 0.850 (0.1) 0. 853 (0.1) 0.848 (0.1) 0.693 
Total hip T-score -0.8 (0.9) -0.7 (0.8) -0.8 (0.9) 0.707 
FRAX Score major % 8.9 (5.2) 9.7 (6.0) 10.7 (5.7) 0.087 
FRAX Score hip % 1.3 (1.8) 1.6 (3.0) 1.9 (2.9) 0.184 
History of fracture (%) 30 28 35 0.076 
Current smoker (%) 5 6 2     0.278 
 
Results of the multinomial regression analysis assessing the relationship between BMD 
and AAC in are presented in Table 5.5. There were no significant associations between 
moderate or high AAC with BMD at the lumbar spine, femoral neck or total hip in the 
unadjusted, age-corrected or risk-factor adjusted regression models (Table 5.5). 
Triglycerides, age, smoking status and physical activity were independently associated 
with an increased risk of AAC (OR=2.06 (1.07-3.97), p=0.029), (OR=1.07 (1.02-1.12), 
p=0.002), (OR=4.16 (1.03-16.7), p=0.044), (OR=3.25 (0.91-11.6), p=0.047). The 




    
relationship between BMD and AAC remained the same when analysis was limited to 
subjects who did not take prescribed calcium and vitamin D (data not shown). The use of 
calcium and vitamin D and fracture history were not found to be independent predictors 
of AAC when included in the regression models.  
 
Table 5.5 Results of multinomial logistic regression models for AAC as measured using 
the lateral VFA 24-point score (AU). Unadjusted, age-adjusted and risk factor-adjusted 










Lumbar Spine BMD    
Unadjusted 1.00 0.94 (0.73-1.22) 1.02 (0.78-1.34) 
Age-adjusted 1.00 0.96 (0.74-1.24) 1.07 (0.82-1.41) 
Risk factor-adjusted* 1.00 0.96 (0.73-1.26) 1.04 (0.78-1.39) 
Femoral neck BMD    
Unadjusted 1.00 1.05 (0.81-1.36) 1.01 (0.77-1.33) 
Age-adjusted 1.00 1.07 (0.83-1.40) 1.09 (0.83-1.44) 
Risk factor-adjusted* 1.00 1.17 (0.88-1.56) 1.17 (0.87-1.58) 
Total hip BMD    
Unadjusted 1.00 1.01 (0.78-1.32) 0.87 (0.65-1.14) 
Age-adjusted 1.00 1.03 (0.79-1.35) 0.94 (0.70-1.25) 
Risk factor-adjusted* 1.00 1.11 (0.83-1.50) 0.94 (0.61-1.29) 
*adjusted for age, BMI, MAP, total cholesterol, triglycerides, smoking status, PAS and 
hypertension.  
 
5.5.2 Relationship between BMD with VC as measured by CT (sub-study) 
Study characteristics for each category of VC measured using the CT total volume score 
are shown in Table 5.6. Subjects with high VC scores were significantly older than those 
with moderate or no VC with a mean age of 68 years, and had a longer time since 
menopause. Furthermore, subjects with high VC scores had significantly lower eGFR 
and significantly higher FRAX scores than those with zero calcification and moderate VC 
scores. Subjects with high VC scores had sustained significantly more fractures in the 
past than subjects with only moderate VC scores or zero calcification. There was no 
significant difference in lumbar spine, femoral neck or total hip BMD between VC score 
categories. 




    




     No VC 
    (0) 
    n=38 
 Moderate VC 
 (0.001-0.375) 
   n=37 
    High VC 
    (≥0.376) 
    n=37 
 
   p-value 
    Mean (SD)   Mean (SD)      Mean (SD)  
Age (years) 58.6 (5.2) 62.3 (6.0) 68.3 (7.7) <0.001
 
Time since menopause (yrs) 9.4 (5.8) 12.3 (6.9) 18.4 (6.7) <0.001 
Height (m) 1.64 (0.07) 1.62 (0.07) 1.60 (0.07) 0.080 
Weight (kg) 62.8 (8.7) 65.6 (9.4) 65.5 (10.5) 0.460 
BMI(kg/m
2
) 23.3 (3.0) 24.9 (3.5) 25.7 (4.4) 0.069 
MAP (mmHg) 93.3 (9.2) 94.1 (9.5) 94.1 (9.9) 0.933 
Cholesterol (total) (mmol/l) 6.0 (1.0) 6.2 (1.0) 6.1 (1.0) 0.524 
HDL-cholesterol (mmol/l) 2.2 (0.5) 2.1 (0.5) 2.0 (0.6) 0.616 
LDL-cholesterol (mmol/l) 3.3 (0.9) 3.6 (0.9) 3.5 (0.9) 0.427 
Triglycerides (mmol/l) 0.9 (0.4) 1.1 (0.5) 1.1 (0.3) 0.492 
eGFR (ml/min) 81.8 (10.2) 84.3 (15.9) 73.3 (15.6) 0.022
 
Serum calcium (mmol/l) 2.4 (0.1) 2.4 (0.2) 2.4 (0.1) 0.089 
Lumbar spine BMD (g/cm
2
) 0.883 (0.1) 0.864 (0.1) 0.896 (0.1) 0.530 
Lumbar spine T-score -1.5 (1.1) -1.7 (1.0) -1.4 (1.2) 0.580 
Femoral neck BMD (g/cm
2
) 0.679 (0.07) 0.710 (0.1) 0.689 (0.1) 0.358 
Femoral neck T-score -1.5 (0.6) -1.2 (0.9) -1.5 (0.9) 0.277 
Total hip BMD (g/cm
2
) 0.821 (0.09) 0.834 (0.1) 0.824 (0.1) 0.848 
Total hip T-score -1.0 (0.7) -0.9 (0.9) -1.0 (0.7) 0.733 
FRAX Score major % 8.4 (4.5) 10.4 (6.2) 13.3 (6.2) 0.012
 
FRAX Score hip % 1.2 (1.1) 1.9 (2.9) 3.3 (3.7) 0.022
 
History of fracture (%) 13 46 38 0.048 
Current smoker (%) 8 8 3  0.641 
 
Statistical differences in characteristics were also observed between calcium and vitamin 
D users compared to those that did not take supplements for score categories of VC 
(data not shown). Calcium and vitamin D users with high VC were significantly older 
(p=0.017), had higher systolic blood pressure (p=0.047), had higher lumbar spine BMD 
values (p=0.024) and lumbar spine T-scores (p=0.038), and had the highest PWV scores 
(p=0.009). Results of the multinomial logistical regression analysis assessing the 
relationship between BMD and VC are presented in Table 5.7.  There were no significant 
associations between BMD at the lumbar spine, femoral neck or total hip with moderate 
or high VC in the unadjusted, age-corrected or risk-factor adjusted regression models 
(Table 5.7). Age was independently associated with an increased risk of moderate and 




    
high VC in the fully adjusted models for LSBMD (OR=1.11 (1.00-1.22), p=0.033), 
(OR=1.26 (1.11-1.43), p=<0.001), and FNBMD (OR=1.28 (1.13-1.45), p=<0.001) 
respectively. There was no significant change in the relationship between BMD and VC 
in subjects who did not take prescribed calcium and vitamin D with logistical regression 
(data not shown). Calcium and vitamin D use and fracture history were not found to be 
independent predictors of VC. 
 
Table 5.7 Results of multinomial logistic regression models for VC as measured using 
the total volume score (cm
3
). Unadjusted, age-adjusted and risk factor-adjusted ORs 










Lumbar Spine BMD    
Unadjusted 1.00 0.84 (0.52-1.37) 1.15 (0.63-1.97) 
Age-adjusted 1.00 0.91 (0.53-1.56) 1.24 (0.64-2.40) 
Risk factor-adjusted* 1.00 0.89 (0.50-1.57) 1.30 (0.63-2.70) 
Femoral neck BMD    
Unadjusted 1.00 1.40 (0.83-2.38) 1.13 (0.61-2.07) 
Age-adjusted 1.00 1.55 (0.89-2.70) 1.41 (0.71-2.80) 
Risk factor-adjusted* 1.00 1.34 (0.77-2.35) 1.26 (0.59-2.70) 
Total hip BMD    
Unadjusted 1.00 1.13 (0.69-1.85) 1.03 (0.58-1.80) 
Age-adjusted 1.00 1.29 (0.76-2.18) 1.33 (0.69-2.54) 
Risk factor-adjusted* 1.00 1.11 (0.62-2.00) 1.23 (0.56-2.70) 
*adjusted for age, BMI, MAP, total cholesterol, triglycerides, smoking status, PAS and 
hypertension.  
 
5.5.3 Relationship between BMD and PWV   
Study characteristics for each PWV score category are shown in Table 5.8. There were 










    
Table 5.8 Characteristics for score categories of PWV 
 Low PWV 
(≤ 8.0) 
n=92 
    Moderate PWV 
   (8.1-9.3) 
    n=167 
 High PWV 











Age (years) 58.6 (5.1) 61.3 (5.8) 65.4 (6.5) <0.001 
Years since menopause 9.3 (5.8) 12.2 (7.2) 16.3 (7.8) <0.001 
Height (cm) 1.63 (0.06) 1.62 (0.07) 1.61 (0.06) 0.176 
Weight (kg) 61.8 (9.1) 64.5 (10.4) 67.2 (8.9) 0.002 
BMI(kg/m
2
) 23.4 (3.1) 24.3 (3.6) 25.8 (3.3) <0.001 
MAP (mmHg) 87.9 (8.2) 92.5 (8.0) 98.9 (9.5) <0.001 
Cholesterol (total) (mmol/l) 5.9 (0.9) 6.2 (0.9) 6.2 (0.9) 0.026 
HDL-cholesterol (mmol/l) 2.1 (0.5) 2.1 (0.5) 1.9 (0.5) 0.080 
LDL-cholesterol (mmol/l) 3.4 (0.8) 3.6 (0.9) 3.7 (0.9) 0.022 
Triglycerides (mmol/l) 0.9 (0.4) 1.1 (0.5) 1.1 (0.5) 0.164 
eGFR (ml/min) 80.6 (13.1) 81.9 (15.8) 78.0 (12.7) 0.140 
Serum calcium (mmol/l) 2.4 (0.06) 2.4 (0.1) 2.4 (0.09) 0.222 
Lumbar spine BMD (g/cm
2
) 0.899 (0.1) 0.892 (0.1) 0.881 (0.1) 0.610 
Lumbar spine T-score -1.3 (1.2) -1.4 (1.0) -1.5 (1.0) 0.725 
Femoral neck BMD (g/cm
2
) 0.718 (0.09) 0.711 (0.09) 0.702 (0.1) 0.569 
Femoral neck T-score -1.2 (0.9) -1.2 (0.9) -1.3 (0.9) 0.663 
Total hip BMD (g/cm
2
) 0.839 (0.1) 0.840 (0.1) 0.839 (0.1) 0.990 
Total hip T-score -0.8 (0.8) -0.8 (0.8) -0.9 (0.9) 0.996 
FRAX Score major (%) 8.2 (4.6) 9.8 (5.5) 11.6 (6.5) <0.001 
FRAX Score hip (%) 1.0 (0.9) 1.6 (2.2) 2.5 (3.8) <0.001 
Fracture history (%) 26 31 34 0.519 
Current smoker (%) 9 6 3 0.299 
 
Statistical differences in characteristics were also observed between calcium and vitamin 
D users compared to those that did not take supplements for PWV score categories 
(data not shown). Calcium and vitamin D users with high PWV scores were significantly 
older (p=<0.001), weighed more (p=0.010) had higher BMI (p=0.048) and had higher 
SBP (p=<0.0001) and MAP (p=0.022). Calcium and vitamin D users with high PWV 
scores also had a trend for high VC scores although this failed to reach statistical 
significance with ANOVA. Results of the multinomial regression analysis assessing the 
relationship between BMD and PWV are presented in Table 5.9. There were no 
significant associations between BMD at the lumbar spine, femoral neck or total hip with 




    
moderate or high PWV in the unadjusted, age-corrected or risk-factor adjusted 
regression models (Table 5.9). Age and MAP were independently associated with an 
increased risk of moderate and high PWV in the fully-adjusted models for LSBMD 
(OR=1.10 (1.04-1.17), p=<0.001), (OR=1.06 (1.02-1.11), p=<0.001), FNBMD (OR=1.09 
(1.03-1.15), p=<0.001), (OR=1.06 (1.02-1.10), p=<0.001) and THBMD (OR=1.09 (1.03-
1.16), p=<0.001), (OR=1.07 (1.03-1.10), p=<0.001) respectively. BMI was also found to 
be independently associated with an increased risk of high PWV. The relationships 
between BMD and PWV remained the same with subjects who did not take prescribed 
calcium and vitamin D (data not shown), and the use of calcium and vitamin D was not 
an independent predictor of increased arterial stiffness. Fracture history was not found to 
be an independent predictor of increased PWV. 
 
Table 5.9 Results of multinomial logistic regression models for PWV. Unadjusted, age-
adjusted and risk factor-adjusted ORs (95% CI) per 1 SD decrease in lumbar spine, 










Lumbar Spine BMD    
Unadjusted 1.00 0.94 (0.74-1.23) 0.86 (0.64-1.16) 
Age-adjusted 1.00 1.02 (0.78-1.34) 1.04 (0.75-1.44) 
Risk factor-adjusted* 1.00 0.94 (0.70-1.25) 0.82 (0.55-1.20) 
Femoral neck BMD    
Unadjusted 1.00 0.93 (0.72-1.20) 0.84 (0.63-1.13) 
Age-adjusted 1.00 1.00 (0.76-1.30) 1.06 (0.77-1.47) 
Risk factor-adjusted* 1.00 0.92 (0.68-1.24) 0.82 (0.55-1.22) 
Total hip BMD    
Unadjusted 1.00 1.01 (0.78-1.31) 0.99 (0.74-1.33) 
Age-adjusted 1.00 1.14 (0.86-1.51) 1.36 (0.97-1.90) 
Risk factor-adjusted* 1.00 0.99 (0.72-1.34) 0.66 (0.63-1.44) 
 *adjusted for age, BMI, MAP, total cholesterol, triglycerides, smoking status, PAS and 
hypertension.  
 
5.6    Discussion 
The rationale for the present study was to investigate the associations between BMD 
with measures of VC and aortic stiffness as evidence from cross-sectional and 
prospective studies suggest age-independent associations between BMD and VC [356, 
360, 371, 436, 472] - an established surrogate of atherosclerosis and CV risk [645, 646]. 




    
However, some studies have reported conflicting results [378, 643, 644, 647, 648]. The 
results of the present study showed no significant associations between BMD measured 
at the lumbar spine, femoral neck or total hip with AAC measured using lateral VFA scan 
images, and VC measured using CT.  
A number of studies have shown an inverse relationship between BMD and VC in low 
risk populations of postmenopausal women [360, 371, 472], and in high risk populations 
with CKD and ESRD [561]. However, populations with renal disease are predisposed to 
high incidence and extent of VC and adynamic bone disease.  Moreover, some studies 
have found no relationship between BMD and VC [378, 643, 647, 648].  A study by 
Farhat et al evaluated the relationship between BMD and AC both measured using CT, 
in a population of over 400 middle-aged women as part of the ‘Study of Women’s Health 
Across the Nation’ (SWAN) and reported volumetric BMD (vBMD) to be associated with 
high AC in both unadjusted and adjusted regression models [374]. The present study 
was of a similar design to the SWAN study with a similar sample size, and due to the 
highly skewed data, measures of AAC and VC were treated as categorical variables and 
categorised as zero, moderate and high AC scores. However, unlike the study described 
above, the results of the present study were not significant. The different radiological 
techniques used to measure VC and AC may partially explain the inconsistency with 
results reported from studies assessing relationships between BMD and VC. Computed 
tomography is considered the ‘gold-standard’ for measuring VC whereas the 
identification and quantification of AAC on lateral lumbar radiographs and lateral VFA 
scan images is subjective and may be greatly affected by poor image quality and/or 
image artefacts which could result in the misinterpretation of AAC. Furthermore, vBMD 
measured at the lumbar spine using CT is considered to be superior compared with DXA 
areal BMD measurements as the method eliminates the risk of including overlying AC 
from the AA.    
Results from the present study showed statistically significant differences in subject 
characteristics between AAC scores measured using lateral VFA and VC measured 
using CT, largely driven by the difference in mean age between groups, as confirmed by 
the significance of age in the age-adjusted and risk-factor adjusted models (Tables 5.4 & 
5.5). Subjects with higher levels of AAC and VC were older than those within the no 
AAC/VC and moderate AAC/VC categories; a finding consistent with those of other 
studies that report a prevalence of VC within the ageing population [555, 603]. Most 
individuals aged 60 years and older have calcification within the major arteries [556], 
which is significantly associated with CVD mortality [339]. A recent study by El 




    
Maghraoui et al of over 900 postmenopausal women demonstrated that the prevalence 
and severity of AAC increases with age [614].  
The present study found subjects with high VC measured using CT also had higher 
major osteoporotic (p=0.011), and hip (p=0.021) FRAX scores compared to subjects with 
moderate or no VC (Table 5.6). These findings are not surprising considering one of the 
major determinants of FRAX is age and moreover, subjects with higher quantities of VC 
are older than those without. However, the present study found no independent 
associations between fracture history with AAC and VC unlike the study by El Maghraoui 
et al discussed above that reported extensive AAC to be associated with prevalent 
vertebral fractures independent of age, BMD, BMI and non-vertebral fracture history 
[614]. Another recent study also found no association between AC and incident 
osteoporotic fracture [644]. Conversely, a prospective study by Schulz et al in 2004, 
evaluated AC and the risk of osteoporotic fractures in a population of over 2000 healthy, 
postmenopausal women using CT to measure both AC and vBMD, with data divided into 
quartiles based on the percentage change in AC, and results from the study reported 
women with the highest increase in AC are predisposed to OP and fragility fractures 
[359].  
A further aim of the present study was to investigate the associations between aortic 
stiffness and BMD but the study found no significant associations between BMD at the 
lumbar spine, femoral neck or total hip with aortic stiffness. Several studies have 
assessed the association between arterial stiffness and BMD in both high risk 
populations with renal disease and lower risk, healthy populations [383, 480, 561, 571] 
but the findings have also been inconsistent. The use of different imaging modalities for 
measuring BMD may, in part, explain the contradictory findings in studies evaluating 
relationships between BMD and aortic stiffness measured using PWV. For example, the 
study by Raggi et al used QCT to estimate BMD values and reported a significant 
inverse relationship between BMD and PWV [480], while other studies using DXA as a 
measure of BMD report no association between BMD and PWV [561, 571].  Although 
DXA is the most widely used method used for measuring BMD, QCT is considered a 
superior method as it provides a 3-dimensional volumetric measurement of trabecular 
and cortical bone density in g/cm3 compared with 2-dimensional areal BMD expressed in 
g/cm2 obtained by DXA [649, 650]. The application of QCT is limited by a higher 
radiation exposure as previously highlighted compared with DXA, nevertheless, BMD 
estimates by QCT have the advantage of not being biased by posterior elements of the 
vertebra including the laminae and spinous processes, severe degenerative changes, or 
AAC anterior to the lumbar vertebra [651-653]. Results of the present study also showed 




    
age and MAP to be the strongest determinants of PWV, which is consistent with the 
findings of other studies [571, 606, 654-656]. 
The present study showed the use of prescribed calcium and vitamin D was not 
associated with AAC, VC or PWV. Calcium and vitamin D supplements are widely used 
for the prevention and treatment of low bone density and OP in postmenopausal women 
who have low levels of these nutrients in their diets [657].  The consumption of calcium 
and vitamin D supplements has increased in recent years with data from the 2003–2006 
NHANES suggesting that predominantly middle-aged to elderly educated white women, 
in particular, use calcium supplements [658], which reflect the population demographics 
in the present study. Research has shown in addition to the benefits to bone, calcium 
and vitamin D may confer other health benefits such as a reduced risk of CVD [659, 660] 
and related CV risk factors, including hyperlipidemia [661, 662], hypertension [663, 664] 
and obesity [665, 666] type 2 diabetes [667, 668], certain cancers [669-671] and 
mortality [672, 673].  Conversely, more recently there has been much attention on the 
possible harmful effects of calcium intake on vascular outcomes and mortality in healthy 
adults [657, 674-677], and it has been suggested that calcium supplementation at doses 
used in clinical practice accelerates the calcification of vascular tissue [678, 679]. The 
mechanisms by which the use of calcium supplements increases the risk of CV events 
are open to speculation however, a number of studies have reported an acute increase 
in serum calcium following 500–1,000mg doses of supplemental calcium which may be 
contributing to the development of calcification within the vascular wall [678, 680-682]. 
Moreover, Rubin et al reported carotid plaque thickness to be greater in older subjects 
with higher serum calcium levels [683] and Bolland et al reported that for each 0.1 
mmol/L increase in serum calcium, the likelihood of AAC increases by 23% in a 
population of normal older women [684]. 
The present study had several limitations. Only a sub-group of 112 out of the 428 
subjects had CT measurements of VC. The quantification of AAC on single-energy 
lateral VFA scan images is highly subjective with image quality greatly affected by 
overlying bowel gas, patient size and/or image artefacts precluding adequate image 
analysis. Bone mineral density was measured using the widely used method of DXA, 
however the addition of BMD results measured using QCT may have strengthened the 
relationships between BMD, VC and arterial stiffness as observed by others. It should 
also be noted in the present study only 106 subjects of the total cohort were reported to 
be taking prescribed calcium and vitamin D supplements, with only 23 of those subjects 
having had CT scans to measure VC. Moreover, the use of supplementation in the 
present study was self-reported, and the study did not account for treatment compliance 




    
and the additional dietary intake of calcium and vitamin D. Finally, the present study 
cohort consisted of healthy, postmenopausal women and therefore may not represent 
the male population or other populations with chronic disease. 
 
5.7 Conclusion 
The present study did not find any significant associations between BMD and measures 
of VC or aortic stiffness as reported in other studies.  Moreover, this study did not find 
the use of prescribed calcium and vitamin D supplements to be independently 
associated with VC, AAC or aortic stiffness. Due to the highly subjective nature of 
quantifying AC using single-energy lateral VFA scans the method cannot be considered 
reliable enough to measure any associations between BMD and AAC and results may 
not be comparable to those obtained using dual-energy VFA scans. Furthermore the 
measurement of vBMD measured at the lumbar spine is considered superior compared 
with DXA that provides only areal BMD, and therefore further observational and 
prospective studies using the ‘gold-standard’ of CT to measure both vBMD and VC are 
required to fully establish the relationships between BMD, AC/VC, aortic stiffness and 
fracture risk and also to further explore the relationships between calcium and vitamin D 
supplementation with AAC, VC and aortic stiffness.  
 
 




    
Chapter 6 
Associations between regulators of bone remodelling 
dickkopf-1 (Dkk1) and sclerostin, and BMD, VC and 
arterial stiffness in postmenopausal women 
 
6.1    Introduction 
The relationship between OP, VC and subsequent CV morbidity and mortality has been 
demonstrated in numerous epidemiological studies [361, 369, 376, 685], and it is clear 
that there are causal associations between low BMD and CVD.  Prospective studies 
have shown AC to be related to bone loss and an increase in fracture risk [359, 686], 
and animal studies have shown that many important biochemical factors involved in the 
regulation of bone and mineral metabolism may also be implicated in the pathogenesis 
of VC.  For example, several murine knockout models of genes that regulate bone 
formation have led to new insights into the pathogenesis of VC [687]. However, many of 
these studies focus mainly on the osteoprotegerin/receptor activator of nuclear factor-B 
(RANK)/RANK ligand triad, the FGF-23/Klotho axis, and circulating osteogenic cells 
[688].  Mice lacking matrix Gla protein (MGP) have extensive calcification within the 
aorta and coronary arteries [416]. A study by Bucay et al demonstrated OPG-null mice 
developed medial and sub-intimal calcifications that were apparent within two weeks, 
and these mice also developed severe OP [410]. Fibroblast growth factor-23 (FGF-23) is 
a bone hormone that promotes phosphate excretion and inhibits vitamin D biosynthesis 
in the kidney. Klotho, which acts as both a membrane associated protein and a secreted 
mediator, is responsible for the kidney-specific action of FGF-23 [689]. Studies have 
demonstrated the deletion of Klotho in mice leads to accelerated ageing, osteopenia and 
extensive VC [690, 691].  An increase in the number of circulating osteoprogenitor cells 
was observed in OPG-null mice, and was found to correlate with the amount of calcium 
in the vessels [692].  Despite the significance of these findings, the clinical importance of 
the results remains inconclusive.  There is increasing interest in signalling pathways that 
are involved in both bone metabolism and the development of VC and it has been 
suggested that the examination of these pathways may provide further insight into the 
association and co-existence of bone and vascular disease. The Wnt signalling pathway 
is an essential physiological regulator involved in the embryonic development and 
maintenance of various organs and tissues in the body, and the Wnt/β-catenin signalling 
pathway plays an important role in bone formation by the regulation of osteoblast 




    
proliferation and differentiation [693]. Wnt’s and their receptors have also been identified 
as having defined roles in vascular development [442]. Although the exact role of the 
Wnt pathway in vascular development is relatively understudied, research is providing 
new and convincing data which support the role of this signalling pathway as a possible 
causal link between OP and VC. The Wnt signalling pathway is regulated by a number of 
secreted inhibitors including Dickkopf-1 (Dkk1) and Sclerostin. Dickkopf-1 has been 
shown to be expressed in atherosclerotic plaques [444], which is suggestive of a role of 
Wnt/β-catenin signalling in the development of VC [444]. However, the precise role of 
Dkk1 and both its association with VC and systemic effects on bone remain to be 
elucidated.  In-vitro studies have found sclerostin, another of the Wnt inhibitors, to be 
expressed in calcifying VSMCs [453]. Recent studies by Mӧdder et al and Mirza et al 
have demonstrated that circulating levels of sclerostin are higher in postmenopausal 
women compared to premenopausal women, and sclerostin may be a potentially 
important mediator of oestrogen effects on bone turnover [694, 695]. A recent study by 
Thambiah et al reported a positive association between circulating sclerostin, age and 
bone mass in pre-dialysis CKD patients [696] and a further study by Mӧdder et al also 
found circulating sclerostin to be positively associated with age and bone mass [697]. It 
is clear that the Wnt/β-catenin pathway has an important role in vascular pathology as 
well as in bone biology and evidence confirming the presence of Wnt inhibitors Dkk1 and 
sclerostin within blood vessels provides the rationale for investigating whether they have 
a protective role or are directly involved in the pathogenesis of VC.  
A summary of previous animal and human studies evaluating relationships and 
associations between BMD, AC/VC, arterial stiffness with Dkk1 and that have been used 




















6.1.1 Study aim 
 
The rationale for this part of the study was to investigate the relationships between 
circulating Wnt inhibitors, Dkk1 and sclerostin, with BMD, aortic stiffness and VC in 
healthy postmenopausal women. Relationships between inhibitors of the Wnt signalling 
pathway Dkk1 and sclerostin with BMD and VC may provide further evidence of their 
Table 6.1 Overview of previous animal and human studies evaluating associations between 
BMD, AC/VC and arterial stiffness with Dkk1 and sclerostin. 
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HD, haemodialysis; CKD, chronic kidney disease; GP, general population; CT, computed 
tomography; AS, arterial stiffness; PM, postmenopausal; DM-2, type 2 diabetes mellitus; pQCT, 
peripheral quantitative computed tomography; vBMD, volumetric bone mineral density; Dkk1, 
dickkopf-1; SCLE, sclerostin; NS, not stated; An, animal; TB-BMC, total body bone mineral content; 
Expres, expression; NCAP, non-calcified atherosclerotic plaque; Rad, radiographs.  




    
role in the pathogenesis of OP and VC, both of which are frequently seen in the ageing 




6.2    Study population 
 
The study population consisted of a sub-set of 106 healthy, ambulatory postmenopausal 
women with a mean age of 62 years who had attended the Osteoporosis Unit to take 
part in a large cross-sectional study as previously described in Section 2.4, Chapter 2. 
Only women who had serum sclerostin and Dkk1 levels measured were included in this 
part of the study. Subjects had BMD measurements of the lumbar spine and hip, PWV 
ultrasound measurements to assess aortic stiffness, CT scans of the chest and 
abdomen and lateral VFA scans to quantify AC. Subjects also had routine laboratory 
assessments measurements of sclerostin and Dkk1.  
 
6.3    Materials and methods 
6.3.1 Anthropometric measurements, blood pressure and medical history 
All subjects had height, weight, BMI and BP measured as described in Chapter 2. A 
detailed medical history was recorded for each subject, obtained using questionnaires 
and by personal interviews as described in Chapter 2.  
 
6.3.2 Laboratory assessments 
All subjects had whole blood samples collected under fasting conditions for the 
measurement of lipid, bone and renal profiles (Chapter 2). Serum samples were stored 
frozen at -70° and measurements of serum sclerostin and serum Dkk1 were performed 
as one batch at the end of the study. The sclerostin and Dkk1 samples were analysed at 
the Bone Biochemistry Laboratory (Sheffield Teaching Hospitals NHS Foundation Trust). 
Serum sclerostin was measured using a commercially available enzyme linked 
immunosorbent assay (ELISA) (Biomedica Gruppe, Wien, Austria). The intra-assay CV 
was 5% at a mean sclerostin concentration of 54.0 pmol/l and the minimum detection 
limit of each assay was 2.6 pmol/l. Serum Dkk1 was measured using ELISA (Biomedica 
Gruppe, Wien, Austria) according to the manufacturer's instructions. The minimum 
detection limit was 0.38 pmol/l and the intra-assay CV was 7% and 8% at Dkk1 
concentrations of 19.1 pmol/l and 10.1pmol/l respectively. One subject with primary 
hyperparathyroidism was excluded from the study (Chapter 2). 




    
6.3.3 Measurement of BMD 
All subjects had bone density measured at the lumbar spine, total hip and femoral neck 
in addition to whole body composition scans to measure total body-bone mineral content 
(TB-BMC) using DXA (Hologic, Bedford MA) as described in Sections 2.8.1 and 2.8.2, 
Chapter 2. Bone mineral density results were classified using the world health 
organisation (WHO) classification for BMD [53] as described in Section 1.3, Chapter 1. 
FRAX scores were also calculated using the FRAX fracture risk assessment tool 
(Section 1.3, Chapter 1). 
 
6.3.4 Lateral VFA scans 
All subjects had single-energy lateral VFA (IVA-HD) scans of the lumbar spine using the 
Hologic Discovery QDR 4500 densitometer (Hologic, Bedford MA) (Section 2.9, Chapter 
2). Scans were obtained using the established local protocol for the evaluation of 
vertebral deformity which was modified to include the lumbar region only as described in 
Section 2.9, Chapter 2. Eighty four (80%) of the 106 lateral VFA scans were successfully 
evaluated. Twenty two (20%) of the 106 lateral VFA scans were unevaluable due to 
overlying bowel gas and abdominal obesity affecting image quality and therefore 
precluding adequate image analysis. 
 
6.3.5 Semi-quantitative assessment of AAC 
Abdominal aortic calcification was assessed on lateral VFA scan images by one clinical 
scientist (SE), blinded to subject demographics and BMD results with scans identified 
only by the subjects study number. Scans were analysed using the semi-quantitative 24-
point scoring method [564] as described in Section 2.9.1, Chapter 2.  
 
6.3.6 CT imaging 
One hundred and six subjects underwent non-contrast non-diagnostic, un-gated CT 
scans of the chest and abdomen as described in Section 2.11.1, Chapter 2.  
 
6.3.7 Quantitative assessment of VC  
Scans were assessed by one clinical scientist (SE), identified only by the subjects study 
number. Each 3mm scan slice was analysed separately and calcified deposits were 




    
defined by the rater as any area greater that 1mm2 with a HU of ≥ 130, and calcified 
deposits were recorded according to anatomical location and deposit number as 
described in Section 3.3.2 in Chapter 3. Calcification was quantified using three 
established VC scoring methods as described in Section 2.12, Chapter 2.   
 
6.3.8 Measurement of arterial stiffness 
All 106 subjects had carotid-femoral PWV performed to measure aortic stiffness using 
the SphygmoCor (AtCor Medical LTD, Australia) PWV system (Section 2.10, Chapter 2). 
Ninety four (89%) of the 106 subjects had successful PWV measurements. Pulse wave 
velocity measurements were not possible on 12 subjects due to large amounts of 
adipose tissue precluding an adequate reading from the femoral artery. Measurements 
were made by one clinical scientist (SE), and any readings which did not conform to the 
internal quality checks provided by the SphygmoCor software were rejected and 
subsequently repeated. Measurements were made in triplicate, with mean PWV values 
used for data analysis. The reproducibility of measurements of PWV has been previously 
described in Chapter 4.  
 
6.4    Statistical analysis 
Study population characteristics are presented as the mean and standard deviation (SD) 
unless otherwise stated. Analysis of variance was used to test for differences between 
categories of BMD, VC, AAC and PWV. To allow for multiple comparisons between 
categorical groups, ANOVA was used to calculate statistical significance between 
groups with a Bonferroni correction to control for Type-1 errors. The Kolmogorov-
Smirnov test was used to assess normality of distribution for measures of VC including 
lateral VFA 24-point scores, CT volume scores and PWV. Variables that were found to 
be positively skewed were log transformed to normalise the data distribution. Results for 
AAC, VC and PWV were divided into 3 tertiles as described in Chapter 5. Abdominal 
aortic calcification measured using the lateral VFA 24-point score was categorised as; no 
calcification (zero score), moderate calcification (scores 1 to 2) and high calcification 
(scores ≥ 3). Similarly, calcification measured using the CT volume score (cm3) was 
categorised as no calcification (zero), moderate calcification (scores >0 to 0.384) and 
high calcification (≥ 0.385). Pulse wave velocity scores were also categorised as low (≤ 
8.0), moderate (8.1 to 9.4) and high (≥ 9.5).  Univariate analysis using the Pearson’s or 
Spearman’s correlation coefficient was used to explore the relationships between 
parametric and nonparametric variables respectively. Multivariate regression analysis 




    
was used to assess associations between Dkk1 and sclerostin and both BMD and 
measures of VC correcting for confounders. Further multivariate regression analysis was 
performed to assess associations between sclerostin and measures of VC correcting for 
total body-bone mineral content (TB-BMC). Sclerostin is primarily produced by 
osteocytes and increased levels of circulating sclerostin may reflect increased osteocyte 
numbers in individuals with a higher skeletal mass, providing the rationale for including 
TB-BMC in the analysis. Confounding variables included age, menopause age, BMI, 
MAP, lipid levels, fracture history, smoking status and physical activity. P values <0.05 
were considered statistically significant.  
 
 
6.5    Results 
The characteristics of subjects included in this study are presented in Table 6.2. 
Subjects had a mean age of 63 years (range 50 to 81) with no prior history of CV events. 
Seventy two per cent (n=76) of subjects had a family history of CV disease.  Nine (9%) 
of subjects had confirmed hypertension, of which 7 were currently taking 
antihypertensive medication. Eighteen per cent (n=19) of subjects reported taking 
prescribed calcium and vitamin D supplements at doses used to treat OP at the time of 
the investigations.  Of the 84 lateral VFA scans that were successfully evaluated 61% of 
subjects had AAC using lateral VFA. Seventy eight percent of subjects had evidence of 


































6.5.1 Associations between Sclerostin and Dkk1 with BMD 
Both Dkk1 and sclerostin data were normally distributed (p=0.16, p=0.118). Linear 
regression showed that sclerostin and Dkk1 were not correlated (r=0.04, p=0.664). 
Univariate analysis revealed significant positive correlations between sclerostin and 
lumbar spine (r=0.22, p=0.030), femoral neck (r=0.31, p=0.002), and total hip (r=0.27, 
p=0.006) BMD as shown in Figure 6.1 and this association remained significant in the 
adjusted models (Table 6.3). Dkk1 was not associated with BMD at any site after 
correcting for confounders.  
 
Table 6.2 Population characteristics for the total study cohort. 
    (n= 106)         Mean (SD) 
Age (years) 62.9 (6.7) 
Age at menopause (years) 49.6 (4.2) 
Height (m) 1.62 (0.07) 
Weight (kg) 65.5 (10.0) 
BMI(kg/m
2
) 24.8 (3.8) 
MAP (mmHg) 93.6 (8.9) 
Cholesterol (total) (mmol/l) 6.7 (1.0) 
HDL-cholesterol (mmol/l) 2.1 (0.5) 
LDL-cholesterol (mmol/l) 3.5 (0.9) 
Triglycerides (mmol/l) 1.0 (0.4) 
Sclerostin (pmol/l) 35.0 (12.2) 
Dkk1 (pmol/l) 25.1 (9.2) 
Lumbar spine BMD (g/cm
2
) 0.884 (0.1) 
Lumbar spine T-score -1.4 (1.1) 
Femoral neck BMD (g/cm
2
) 0.704 (0.09) 
Femoral neck T-score -1.2 (0.8) 
Total hip BMD (g/cm
2
) 0.834 (0.1) 
Total hip T-score -0.8 (0.8) 
Hypertension (%) 8 
Family history of CVD (%) 72 
History of fracture (%) 33 
Current smoker (%) 1 
Former smoker (%) 29 




    
            
 
                                             
 
Figure 6.1 Scatterplots showing the associations between sclerostin with BMD at the lumbar 
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Table 6.3 Multi-linear regression analysis of lumbar spine, femoral neck and total hip BMD as 
the dependent variables and Dkk1 and sclerostin as independent variables.  




p-value     THBMD 
β-coefficient 
 p-value 
Age (years) -0.228 0.032 -0.188 0.068 -0.215 0.034 
BMI (kg/m
2
) 0.309 0.011 0.204 0.077 0.271 0.015 
Menopause age 0.021 0.827 0.099 0.297 0.157 0.092 
Physical activity 0.402 0.001 0.054 0.640 0.005 0.965 
Smoking status 0.124 0.228 0.169 0.085 0.167 0.083 
Fracture history 0.061 0.559 -0.154 0.128 -0.206 0.037 
Sclerostin (pmol/l) 0.296 0.006 0.328 0.001 0.281 0.004 
Dkk1 (pmol/l) 0.006 0.951 -0.126 0.185 -0.115 0.216 
 
 
6.5.2 Associations between vascular calcification, Sclerostin and Dkk1 
There were no significant associations between either sclerostin or Dkk1 with AAC or VC 
following univariate analysis. Following adjustment for confounders multi-linear 
regression did not reveal any significant associations between sclerostin and Dkk1 with 
AAC, with age being the only variable positively associated with AAC (Table 6.4).  
 
Table 6.4 Multi-linear regression analysis of log AAC measured using lateral VFA and log 
VC measured using the CT volume score as the dependent variables and Dkk1 and 
sclerostin as independent variables.  
  Variables AAC 
β-coefficient 
 p-value VC 
β-coefficient 
      p-value 
Age (years) 0.387 0.035 0.640 <0.001 
BMI (kg/m
2
) 0.103 0.579 -0.035 0.766 
Menopause age 0.164 0.292 -0.044 0.677 
Physical activity 0.191 0.245 -0.052 0.649 
Smoking status 0.105 0.521 0.093 0.364 
Fracture history -0.025 0.882 -0.075 0.497 
Total cholesterol (mmol/l) 0.267 0.104 -0.180 0.110 
Total triglycerides (mmol/l) 0.063 0.725 0.039 0.734 
Sclerostin (pmol/l) 0.132 0.392 -0.006 0.957 
Dkk1 (pmol/l) 0.142 0.410 -0.153 0.156 
 
There was no significant association between sclerostin and TB-BMC following 
univariate analysis (p=0.090). The multi-linear regression model was repeated with the 
addition of total body BMC. The associations between sclerostin and Dkk1 with AAC and 




    
VC remained non-significant following adjustment for TB-BMC (Table 6.5). Analysis of 
variance revealed there were no significant variations in median sclerostin and Dkk1 
values across the three AAC/VC score categories.  
 
Table 6.5 Multi-linear regression analysis of log AAC measured using lateral VFA and log 
VC measured using the CT volume score as the dependent variables and Dkk1, sclerostin 
and TB-BMC measured using DXA as independent variables.  
  Variables AAC 
β-coefficient 
  p-value VC 
β-coefficient 
      p-value 
Age (years) 0.433 0.022 0.639 <0.001 
BMI (kg/m
2
) 0.033 0.853 -0.035 0.768 
Menopause age 0.175 0.238 -0.044 0.681 
Physical activity 0.181 0.248 -0.052 0.651 
Smoking status 0.070 0.651 0.092 0.384 
Fracture history -0.018 0.915 -0.075 0.507 
Total cholesterol (mmol/l) 0.285 0.071 -0.180 0.113 
Total triglycerides (mmol/l) 0.142 0.424 0.039 0.736 
Sclerostin (pmol/l) 0.084 0.571 -0.006 0.954 
Dkk1 (pmol/l) 0.056 0.736 -0.153 0.159 
TB-BMC (g) 0.321 0.036 0.003 0.982 
 
 
6.5.3 Associations between arterial stiffness, Sclerostin and Dkk1 
There were no significant associations between Dkk1, sclerostin and PWV in univariate 
or multi-linear regression analysis after correcting for confounders. Age, BMI and MAP 













    
Table 6.6 Multi-linear regression analysis of arterial stiffness measured by PWV 
as the dependent variable and Dkk1 and sclerostin as independent variables. 
 
Variables  β-coefficients      p-value 
Age (years) 0.406 <0.001 
BMI (kg/m
2
) 0.310 0.009 
Menopause age -0.140 0.159 
Physical activity 0.012 0.915 
Smoking status -0.130 0.201 
Fracture history -0.025 0.808 
Alcohol intake -0.044 0.654 
MAP (mmHg) 0.238 0.025 
Total cholesterol (mmol/l) -0.029 0.786 
Total triglycerides (mmol/l) -0.085 0.439 
Sclerostin (pmol/l) -0.080 0.439 
Dkk-1 (pmol/l) 0.000 0.999 
R
2
 =0.35         
           
  
Analysis of variance revealed there was a statistically significant difference in sclerostin 
values across the three PWV score categories (p=0.019). Post-hoc tests were 
conducted to evaluate pairwise differences among the three PWV score categories, 
correcting for multiple comparisons using a Bonferroni correction. Further analysis using 
ANCOVA to correct for variables significantly associated with PWV as determined in the 
regression model (i.e. age, BMI and MAP) showed no statistical difference in sclerostin 
values across the three PWV score categories  (p=0.395).  Analysis of variance revealed 
there was no significant difference in median Dkk1 values across the three PWV 
categories with or without inclusion of confounders. 
             
6.6 Discussion 
The rationale for the present study was to investigate the associations between 
circulating concentrations of the Wnt inhibitors - sclerostin and Dkk1 - with BMD, AAC, 
VC and arterial stiffness as the Wnt signalling pathway has been implicated in the 
pathogenesis of OP and may also be involved in the pathogenesis of VC.  The presence 
of Wnt inhibitors, Dkk1 and sclerostin in and around the site of VC in blood vessels 
demonstrates that further research is needed to investigate their precise role and 
function in the development of both OP and VC.  The results from the study presented 
here showed sclerostin to be positively associated with BMD at the lumbar spine, 
femoral neck and total hip as confirmed in previous studies [445, 698, 705, 706]. In 




    
contrast, Dkk1 was not associated with BMD at any site. This study did not find any 
association between either sclerostin or Dkk1 with AAC, VC or with PWV. 
 
A recent study completed by our research group using samples from a different sub-set 
of 140 postmenopausal women also showed that circulating sclerostin levels were 
positively associated with femoral neck and total hip BMD [445]. In addition, the positive 
relationship between sclerostin and BMD has also been reported in high risk populations 
with CKD [698]. The Wnt signalling pathway and its antagonists play an important role in 
the regulation of bone mass and osteoblastogenesis. When Wnt is absent in this 
pathway, β-catenin is phosphorylated and degraded, and when Wnt is present it binds to 
speciﬁc receptors (frizzled) and co receptors (LRP-5 and -6), leading to the inhibition of 
β-catenin phosphorylation and degradation. Wnt/-β-catenin signalling is not only critical 
for osteoblastogenesis but also for normal osteocyte function [707]. Sclerostin, a major 
Wnt antagonist is secreted almost exclusively by osteocytes [693, 708-710] and the 
binding of sclerostin to the canonical Wnt-β-catenin receptors inhibits the Wnt signalling 
and consequently bone formation by inhibiting the proliferation and differentiation of 
osteoblasts [711], and it has been suggested that this process may occur to prevent 
overfilling of the BMUs during the bone remodelling process, maintaining the balance 
between bone formation and resorption [710]. Sclerostin gene (SOST) knockout mice 
have increased bone formation rates and increased bone mass [712], and over 
expression of the SOST gene has been found to result in osteopenia [713]. A SOST 
gene mutation in humans, where an enhancer element (52kb) that is normally 
downstream of the SOST gene is deleted, leads to sclerosteosis [714] and van 
Buchem’s disease [715] which are associated with markedly increased bone mass [716]. 
Furthermore, treatment of postmenopausal women with a sclerostin monoclonal 
antibody increases bone formation markers and therefore BMD at the lumbar spine and 
hip [717].  
Given that sclerostin is an inhibitor of osteoblastic activity, negative associations 
between sclerostin and BMD would be expected. However, in the present study this was 
not found to be the case in agreement with other studies described above.  There are 
currently no data in the literature on the metabolism of sclerostin, and it is unclear 
whether the positive relationship between sclerostin and BMD reflects an increased 
sclerostin production due to high osteocyte numbers in subjects with a high bone mass 
or due to a reduced renal degradation and clearance. Recent research has 
demonstrated that bone marrow and circulating blood sclerostin concentrations are 
highly correlated, which suggest that circulating concentrations of sclerostin may reflect 




    
the bone marrow environment and therefore increased production is unlikely due to 
decreased clearance or breakdown [445, 718].   
A large study by Mӧdder et al in 2011, found sclerostin levels to be positively associated 
with total body bone mineral content in addition to lumbar spine and femoral neck BMD 
in a large study of over 650 subjects suggesting an increased sclerostin production by 
osteocytes in subjects with a higher bone mass [697]. However, this was not found to be 
the case in the present study as there was no significant association between sclerostin 
levels and TB-BMC.  
In contrast to the positive association observed between sclerostin and BMD, results of 
the present study showed no association between Dkk1 and BMD (Table 6.3).  Results 
from studies evaluating the relationship between Dkk1 and BMD have been inconsistent, 
with some reporting significant negative associations between Dkk1 and BMD in renal 
patients [696], and in patients with OP [699], while others have reported no relationship 
[700] consistent with the results of the present study. Unlike sclerostin that is almost 
exclusively expressed by osteocytes, Dkk1 has a wider tissue distribution and is 
expressed by tissues including endothelial cells, neural cells and platelets among others, 
with the latter being considered a major contributor to circulating Dkk1 levels in recent 
studies [719, 720]. This will mask or attenuate any significant relationship particularly as 
the skeletal expression of Dkk1 is not the only contributor to circulating Dkk1 levels.  
The present study found no significant association between sclerostin and AAC 
measured using lateral VFA or with VC measured at multiple vascular sites using CT. 
Furthermore, there were no significant differences in sclerostin levels with increasing 
levels of calcification (Table 6.4). Sclerostin is expressed in high levels by mature 
osteocytes and previous experimental studies have demonstrated an increased 
expression of sclerostin in areas of VC and in calcifying VSMC [453, 721]. For example, 
Zhu et al reported sclerostin to be up-regulated during VSMC calcification in vitro and 
also reported an increased expression of sclerostin in the calcified media of aortic tissue 
in NPP1-null mice [453] - ecto-nucleotide pyrophosphatase/phosphodiesterases-1 
(NPP1) is a major generator of extracellular pyrophosphate which is a known VC 
inhibitor [722]. Further research on NPP1-null murine models showed that these mice 
spontaneously developed calcified articular cartilage, peri-spinal calcification, and medial 
AC at a young age [701]. Interestingly, these NPP1-null mice share phenotypic features 
with a human disease, idiopathic infantile arterial calcification [723, 724].  Furthermore, 
experimental studies of CMV-Msx2 transgenic mice develop extensive VC and have also 
shown an increased expression of sclerostin at the site of VC [443]. The expression of 




    
sclerostin has also been found within the sub endothelial layer of the intima in 
pathological specimens of human aorta [725].  
There are limited data regarding the association between circulating concentrations of 
sclerostin and VC in humans and although these studies have demonstrated both a 
positive and inverse relationship between sclerostin and VC, the majority have been 
limited to higher risk populations with renal disease and DM that have a greater 
incidence and severity of VC [700, 702, 703]. For example, a recent cross-sectional 
analysis evaluating the association between sclerostin and AC in patients with CKD 
showed a positive association between AC and higher sclerostin levels, although this 
association became inverse following multivariate analysis [702].  Another similar cross-
sectional study on chronic haemodialysis patients showed a strong positive association 
between sclerostin and calcifying aortic heart valve disease and further demonstrated 
sclerostin is locally expressed in aortic valve tissue adjacent to areas of calcification 
[704]. Results from a pilot study evaluating associations between aortic valve 
calcification (AVC) and sclerostin showed increased circulating sclerostin levels to be 
associated with increased severity of AVC, compared with healthy controls that had 
lower sclerostin levels [726]. In contrast to these findings, a post-hoc analysis of data 
from 100 haemodialysis patients revealed that increased circulating levels of sclerostin 
were associated with a decrease in all-cause mortality, and authors go as far to suggest 
that high circulating sclerostin levels protect patients on dialysis from CV calcification 
[703]. It has been suggested that associations between sclerostin and VC may imply an 
increase in the phenotypic transition of VSMCs to osteocytes and an up-regulation of 
sclerostin by these transformed vascular cells during the VC process [445, 453]. 
Therefore circulating sclerostin concentrations may partly reflect the production and 
secretion by cells within the arterial wall. Thus, it can be postulated that increased 
production of sclerostin may simply be a protective mechanism preventing further 
progression of VC [445]. However, further clinical and experimental studies are required 
to clarify whether or not sclerostin protects against the progression of VC.  
The present study did not observe any associations between Dkk1 with AAC or VC at 
multiple vascular sites. The recent study by our group on a different sub-set of 
postmenopausal women than those included in the present study showed that Dkk1 
concentrations were significantly lower in those with high AAC as measured by lateral 
DXA [445]. The analysis of the Dkk1 samples was carried using two different laboratory 
locations with the present study data reported by the Bone Biochemistry Laboratory, 
Sheffield, whereas the Dkk1 data from the different subset of women was reported by 
the Department of Clinical Chemistry, St Thomas Hospital [441]. Therefore the variation 




    
between assays may account for the different results reported here. An inverse 
relationship between Dkk1 and calcified plaques in higher risk patients with type-2 DM 
has also been reported [700]. Studies have also reported an increased expression of 
Dkk1 in atherosclerotic plaques and in the circulation of patients with unstable angina 
[452] which may reflect an increased inflammatory response, or may potentially be a 
protective response against the development and progression of further calcification 
[445]. The varying effects and interactions between Dkk1, VSMCs, endothelial cells or 
vascular adventitia observed in different clinical settings may also reflect differences 
between the study populations.  
The present study found age to be positively associated with VC, which is a common 
occurrence within the ageing population [429]. Medial calcification is recognised as a 
significant contributing factor to arterial stiffness and studies have shown sclerostin to be 
associated with medial calcification [452, 453, 727], whereas Dkk1 appears to be closely 
related to intimal calcification which represents the advanced stage of atherosclerosis 
[728]. This suggests that a high expression of sclerostin in the presence of large 
quantities of medial calcification would result in increased serum sclerostin levels in 
subjects with a high PWV. However, the present study found no association between 
sclerostin and PWV even after correcting for confounders associated with arterial 
stiffness. Moreover, there was also no association between Dkk1 and PWV (Table 6.6). 
Data from the present study did show a trend for higher sclerostin levels in women with 
high PWV although this was not significant. Similarly, the study on a different sub-set of 
postmenopausal women by our group reported no significant association between 
sclerostin and PWV, but did observe a significant difference in sclerostin levels between 
high and low PWV score groups [445]. Conversely, a recent study on pre-dialysis CKD 
patients reported a negative association between sclerostin and arterial stiffness [695]. 
There are limited data in the literature regarding the associations between circulating 
sclerostin and Dkk1 levels with arterial stiffness in healthy, ambulatory populations, and 
whether arterial stiffness and its contributing factors lead to an increase in circulating 
sclerostin, or increased circulating sclerostin levels result in a reduction of arterial 
compliance and a subsequent increase in PWV remains to be determined. The present 
study found age to be positively correlated with PWV which was not an unexpected 
finding as age is considered to be a significant contributory factor responsible for the 
reduction in arterial compliance leading to increased PWV.  Results also showed MAP 
and BMI to be associated with PWV which is consistent with previous studies [729, 730].  
This study had several limitations. The cross-sectional design did not facilitate the 
assessment of causal associations between sclerostin, BMD, arterial stiffness and VC. 




    
Furthermore, the present study did not include measurements of inflammatory markers, 
although it is thought inflammation may enhance the extra-skeletal expression of 
circulating Dkk1 [696]. The study consisted of only a small sub-set of women from the 
total study cohort, and women who were known to be taking lipid lowering drugs were 
excluded. Limitations with the imaging techniques used meant it was not possible to 
distinguish between intimal and medial calcification which may have allowed the 
assessment of both, particularly as both medial and intimal calcification can be present 
in areas of VC.   
 
6.7 Conclusion 
In conclusion, the present study found Wnt inhibitor sclerostin to be positively associated 
with BMD measured at multiple sites but no association was found between BMD and 
Dkk1. Furthermore this research did not find any association between VC or arterial 
stiffness with either sclerostin or Dkk1. This is the first study to clinically evaluate not 
only associations between Dkk1 and SCLE with BMD, but also AC measured using VFA 
scans, VC at multiple vascular sites using CT and arterial stiffness using PWV. However, 
further clinical studies are required to clarify the precise role of sclerostin in the 
pathogenesis of VC to establish whether or not sclerostin promotes or indeed protects 





 Chapter 7 
Associations between bisphosphonates (BP), vascular 
calcification (VC) and aortic stiffness 
 
7.1 Introduction 
Bisphosphonates are chemically stable analogues of inorganic pyrophosphate and are 
potent inhibitors of osteoclastic activity, primarily used in the management of OP and 
also to treat metastatic bone disease to prevent osteoclast-mediated bone resorption by 
binding to hydroxyapatite [731]. The most widely used BPs in current clinical practice are 
nitrogen-containing BPs (NCBPs) including alendronate, risedronate, ibandronate and 
zoledronate. They inhibit the activity of farnesyl diphosphate synthase, a key regulatory 
enzyme in the mevalonate pathway which is the biosynthetic pathway for the production 
of cholesterol, other sterols and isoprenoid lipids, including farnesyl diphosphate [191, 
732, 733]. Consequently BPs have similar pharmacological effects as statin therapy 
[734] in terms of decreasing LDL-cholesterol and increasing HDL-cholesterol levels [735, 
736]. 
 
Vascular calcification exists in two distinct, but not mutually exclusive entities; intimal and 
medial calcification. Intimal or atherosclerotic calcifications are predominantly located in 
the coronary arteries and aorta and are the clinical manifestation of advanced 
atherosclerosis, obstructing the artery lumen increasing the risk of stroke, myocardial 
infarction and angina [645]. Medial or Mönckeberg’s calcification on the other hand 
develops in the medial layer of the artery wall, and unlike intimal calcification medial 
calcification does not cause obstruction within the arterial lumen. It does, however, lead 
to increased stiffness of the elastic layer of the arterial wall, resulting in increased pulse 
pressure which subsequently leads to left ventricular hypertrophy, vascular dysfunction 
and failure [737, 738]. Although the precise mechanisms of VC remain undefined it has 
been suggested that VC is a consequence of a process which is similar to osteogenesis 
[407, 641, 739-741]. Ordinarily, mesenchymal stem cells, found in bone marrow, 
differentiate into adipocytes, chondrocytes, osteoblasts and VSMCs. However, oxidative 
stress, inflammatory cytokines or BMPs can stimulate VSMC to undergo differentiation 
into osteoblast-like cells, and it has been suggested this process may be critical in the 





MGP, OPN and OPG inhibit VC and the inadequate function or loss of these inhibitors is 
associated with VC [416, 435, 741].  
 
In view of the common underlying pathological mechanisms between VC and bone 
formation, agents that inhibit bone loss may also inhibit VC or slow the rate of 
progression of VC and consequently lower CV-related morbidity and mortality.  
Bisphosphonates have shown a consistent effect on inhibiting VC in both experimental 
and animal studies and research has shown that BPs inhibit experimentally induced VC 
in rodents through the inhibition of osteoclast-mediated bone resorption [742-744]. For 
example, in an experimental study by Saito et al in 2007, pamidronate was reported to 
inhibit VC induced by inorganic phosphate in bovine aortic smooth muscle cells, with the 
results showing a reduction in AC by 88%. Moreover, the study found that the inhibitory 
effect of pamidronate increased with higher doses of BP [744]. Price et al in 2001 
conducted a series of animal studies to examine the effects of BPs on induced VC in rats 
and concluded that alendronate and ibandronate inhibited VC, at doses that inhibit bone 
resorption without affecting normal bone mineralisation [742]. Tamura et al in 2007 
evaluated the effect of etidronate in rats with induced AC and reported etidronate also 
significantly inhibited AC at doses that did not affect bone metabolism [743].  Although 
the precise mechanism by which BPs inhibit VC still remains to be established, these 
studies provide evidence that BPs can inhibit VC and at doses equivalent to those used 
in clinical practice. 
 
The effect of BPs on VC in humans is less clear, with clinical studies reporting conflicting 
results [509-515, 745]. To date there have been no large-scale observational studies 
evaluating the effects of BPs of VC and there is a lack of unequivocal evidence 
supporting the inhibitory effect of BPs on VC in humans.  Previous studies have reported 
the beneficial effects of BP on VC/AC [510-513, 745], while others have shown clinical 
doses of BP did not decrease or slow the progression of AC [514, 515]. The conflicting 
findings from these studies suggest that the effects of BP on VC in humans are still 
inconclusive and further research is required to confirm the effects of BPs on VC and 
arterial stiffness.  
 
A summary of previous clinical studies evaluating the use of bisphosphonate therapy 
and the effects on BMD, AC/VC, arterial stiffness and serum lipids used to compare and 

























7.1.1 Study aim 
The aim of this part of the study was to: (1) compare VC and aortic stiffness in 
postmenopausal women who have been prescribed BP therapy for the treatment of OP 
and in women who have never used BPs using cross-sectional data; (2) evaluate the 
effects of alendronate treatment on AC in postmenopausal women with low BMD over 
12-months using data acquired in a prospective, randomised, controlled trial (RCT).  
 
7.2 Study population 
 
7.2.1 Cross-sectional study 
This study consisted of a population of 418 healthy, ambulatory postmenopausal women 
with a mean age of 62 years who had attended the Osteoporosis Unit as previously 
described in Section 2.4, Chapter 2. All subjects had BMD measurements of the lumbar 
spine, total hip and femoral neck using DXA, carotid-femoral PWV ultrasound 
Table 7.1 Overview of previous studies evaluating the effects of bisphosphonate therapy on 
BMD, AC/VC and arterial stiffness and serum lipids.  













 PM (1189) 64.6 DXA P1NP 
CTX 
BMD 
Sig <P1NP & 
CTX with BP 
Adami (2000) 
[735]
 PM (87) >53 N/A HDL 
LDL 




 PD (20) 67.6 N/A HDL 
LDL 




 GP (>3600) 63.0 CT CVC BP assoc < 




 PM (>400) >55 Rad AC No change 
AC over 3yrs 
Toussaint (2010) 
[515]













 PM (38) NS PWV AS Min change in 
PWV over 1yr 
CKD, chronic kidney disease; GP, general population; AS, arterial stiffness; PM, postmenopausal; 
PD, Paget’s disease; NS, not stated; N/A, not applicable; CVC, cardiovascular calcification; IMT, 
intima-media thickness; US, ultrasound; P1NP, procollagen type 1 N-terminal propeptide; CTX,  C-





measurements to assess aortic stiffness, CT scans of the chest and abdomen to quantify 
VC, and single-energy lateral VFA scans to quantify AAC. Subjects also had blood 
samples collected for the measurement of bone, lipid and renal profiles and markers of 
bone formation and resorption. Subjects that were found to have liver or renal disease 
defined as CKD-3 or greater, endocrine or metabolic bone disorders and 
hyperparathyroidism were excluded from analysis, as described in Chapter 2. Four 
subjects that were found to have primary hyperparathyroidism and 12 subjects that were 
found to have CKD-3 were excluded from the study. Eleven subjects that had previously 
used but were not currently taking BPs were also excluded from this study.  
 
7.2.2 Prospective 
This study consisted of data for the first 14 patients recruited on an ongoing single-
centre, 2-year, randomised, controlled, open-label trial to determine the effects of 
alendronate on AC and aortic stiffness. The principle inclusion criteria for enrolment onto 
this trial was a T-score of -2.0 or less at the lumbar spine or hip and further details 
regarding the inclusion and exclusion criteria can be found in Section 2.4, Chapter 2. 
Subjects were required to attend for a baseline and 3-month visit, followed by 5 further 
visits at 6-monthly intervals up to 24-months. Only 12-month data for the first 14 patients 
enrolled are reported here as the study is ongoing.  Subjects had BMD measurements of 
the lumbar spine, total hip and femoral neck using DXA, carotid-femoral PWV ultrasound 
measurements to assess aortic stiffness, CT scans of the chest and abdomen to quantify 
VC, and lateral VFA scans to quantify AAC. Each subject had blood samples collected at 
each study visit for the measurement of bone, lipid and renal profiles and also for the 




7.3 Materials and methods 
7.3.1 Anthropometric measurements, blood pressure and medical history 
7.3.2 Cross-sectional  
All subjects had height, weight, BMI and blood pressure measured as described in 
Chapter 2. A detailed medical history was recorded for each subject, obtained using 
questionnaires and by personal interviews. Information collected included family history 
of CVD, family history of low trauma fractures, history of CV events, the presence of 
diabetes mellitus, hypertension, and hypercholesterolemia, fracture history, smoking 








A detailed medical history was recorded at the screening visit for each subject by the 
study physician, followed by a physical examination.  All subjects had anthropometric 
and blood pressure measurements at subsequent study visits as described in Chapter 2.  
 
 
7.3.4 Laboratory assessments 
7.3.5 Cross-sectional 
All subjects had whole blood samples collected following an overnight fast for the 
measurement of total cholesterol, LDL- and HDL-cholesterol and triglycerides. Subjects 
also had serum calcium, albumin corrected calcium, albumin, phosphate, alanine 
transaminase (ALT), alkaline phosphatase (ALP), bilirubin, parathyroid hormone (PTH) 
and estimated glomerular filtration rate (eGFR) measured to determine renal function 
status and exclude any subjects with liver or renal disease, endocrine or metabolic bone 
disorders and hyperparathyroidism from the analysis as described in Chapter 2 .  
7.3.6 Prospective 
Subjects had lipid and bone profiles performed at each of the study visits as described in 
Section 2.5.3, Chapter 2. Serum samples that were frozen and stored at -70°c were 
used to measure markers of bone formation and resorption at baseline, 3, 6 & 12-
months including serum type 1 procollagen N-terminal (P1NP) and C-terminal 
telopeptide (CTX). The P1NP and CTX samples were analysed at the Bone 
Biochemistry Laboratory, Sheffield Teaching Hospital NHS Trust. Serum P1NP was 
measured using a commercially available enzyme linked immunosorbent assay (ELISA) 
(Roche Diagnostics, Mannheim, USA). The intra-assay CV was 2.9% at a mean P1NP 
concentration of 29.1ng/mL and the minimum detection limit of each assay was 
<5ng/mL. Serum CTX was measured using ELISA (Roche Diagnostics, Mannheim, 
USA) according to the manufacturer's instructions. The minimum detection limit was 
0.010ng/mL and the intra-assay CV was 4.6% at CTX concentrations of 0.08 ng/mL.   
 
7.3.7 Measurement of BMD 
7.3.8 Cross-sectional 
All subjects had BMD measured at the lumbar spine, total hip and femoral neck using 






All subjects had BMD measured at the lumbar spine, total hip and femoral neck 
(Sections 2.8.1 and 2.8.2, Chapter 2), at baseline, 6 and 12-months as described in 
Section 2.5.3, Chapter 2. Bone mineral density results were classified using the WHO 
classification for BMD as described in Section 1.3, Chapter 1, and fracture risk was 
assessed using the FRAX fracture risk assessment tool (Section 1.3, Chapter 1) which 
calculates a 10-year probability of a hip and major osteoporotic fracture.  
 
7.3.10 Lateral VFA scans 
7.3.11 Cross-sectional 
All subjects had single-energy lateral VFA (IVA-HD) scans of the lumbar spine using the 
Hologic Discovery QDR 4500 densitometer (Hologic, Inc. USA) (Section 2.9, Chapter 2). 
Scans were obtained using the established local protocol which was modified to include 
the lumbar region only as described in Section 2.9, Chapter 2. Three hundred and 
twenty of the 418 lateral VFA scans were successfully evaluated. Of the remaining 98 
(23%) lateral VFA scans 7 were unable to be evaluated due to abdominal obesity and 91 
scans due to overlying bowel gas affecting image quality.  
7.3.12 Prospective 
Subjects taking part in the RCT had lateral VFA (IVA-HD) scans performed at baseline, 6 
and 12-months as described in Section 2.5.3, Chapter 2. At baseline 13 of the 14 scans 
were successfully evaluated with one scan un-evaluable due to abdominal obesity 
affecting image quality. At 6 and 12-months 9 and 8 scans respectively were adequately 
evaluated, with 5 and 6 scans respectively rejected due to overlying bowel gas 
precluding adequate image analysis.  
 
7.3.13 Semi-quantitative assessment of AAC 
Abdominal aortic calcification was assessed on lateral VFA scan images by one clinical 
scientist (SE), blinded to subject demographics and BMD results with scans identified 
only by the subjects’ study number. Scans were analysed using the semi-quantitative 24-









7.3.14 Measurement of aortic stiffness 
7.3.15 Cross-sectional 
Three hundred and forty four of the 418 study subjects had successful carotid-femoral 
PWV performed to measure aortic stiffness using the SphygmoCor (AtCor Medical LTD, 
Australia) PWV system (Section 2.10, Chapter 2). Seventy four (18%) of the 418 PWV 
measurements were unsuccessful, with large amounts of adipose tissue precluding 
adequate readings from the femoral artery. Measurements were made by one clinical 
scientist (SE), and any readings which did not conform to the internal quality checks 
provided by the SphygmoCor software were rejected and subsequently repeated by the 
operator.  Measurements were made in triplicate, with mean PWV values used for data 
analysis. The reproducibility of this method has been previously described (Chapter 2). 
7.3.16 Prospective 
Pulse wave velocity measurements were not successful for 1, 3, 3 and 5 patients at 
baseline, 3, 6 and 12-months respectively due to adipose tissue precluding adequate 
readings from the femoral artery.  
 
7.4 Statistical analysis 
7.4.1 Cross-sectional 
Study population characteristics are presented as the mean and standard deviation (SD) 
and median and interquartile range (IQR) were stated. Differences in characteristics 
between the BP and control groups were determined using the student t-test for normally 
distributed continuous variables, the Mann-Witney test for continuous variables not 
normally distributed and the chi-squared test for categorical variables. P values <0.05 
were considered statistically significant. The Kolmogorov-Smirnov test was used to 
assess normality of distribution for measures of VC including lateral VFA AAC scores 
and PWV. Positively skewed data including the lateral VFA 24-point AAC score and 
PWV score was log transformed to normalise the distribution for multivariate regression 
analysis. Multivariate regression analysis was used to evaluate the relationships 
between the severity of VC and BP use and also the duration of BP use and the severity 
of VC, correcting for confounders associated with VC and/or aortic stiffness including 
age, BMI, MAP, physical activity, smoking status, and lipid levels.  Duration of BP use 
was divided into three categories and defined as 1-3, 4-7 and 8+ years. Prevalence 
ratios were assessed using logistic regression with a modified Poisson regression 





binary data scores of 0 for zero calcium and 1 for calcium >0, for the lateral VFA 24-point 
score.  The threshold for PWV was defined as the median score of 8.7 m/s, with scores 
<8.7 assigned a binary value of 0 and scores ≥8.7 assigned a binary value of 1. 
Prevalence ratios were also calculated for AAC and PWV with thresholds above the 75th 
percentile of the variable.  
7.4.2 Prospective 
Study population characteristics are presented as the mean and standard deviation (SD) 
and median and interquartile range (IQR) were stated. Differences in characteristics 
between the BP and control group were determined using the student t-test for normally 
distributed continuous variables, the Mann-Witney test for continuous variables not 
normally distributed and the chi-squared test for categorical variables. P values <0.05 
were considered statistically significant. The percentage change for outcome variables 
including lateral VFA 24-point score, PWV, BMD, bone turnover markers and lipid levels 
were calculated. The paired t-test and Wilcoxon signed rank tests were used to test for 
significant change in variables from baseline for each of the prospective study treatment 
arms. The un-paired t-test and Mann Whitney tests were used to explore the percentage 
change in outcome variables at each time-point between the treatment and control arms. 
  
7.5 Results 
7.5.1 Association between bisphosphonate use, VC and aortic stiffness in 
postmenopausal women: a cross-sectional study.  
Subjects had a mean age of 62 years (range 50 to 81) with no prior history of CV events. 
Fifty five percent (n=230) of subjects had a known family history of CV disease. Thirteen 
percent (n=54) of subjects had confirmed hypertension, 42 (10%) of which were taking 
antihypertensive medication at the time of investigations. Seventy five percent (n=60) of 
subjects in the BP group reported the use of concomitant prescribed calcium and vitamin 
D supplements and 8% (n=27) in the control group reported taking prescribed calcium 
and vitamin D supplementation at doses used to treat osteopenia and OP. Seventy nine 
(99%) of the BP users took nitrogenous BPs (predominantly alendronate and 
residronate) with only one subject reportedly taking a non-nitrogenous BP (etidronate). 
Subjects in the BP group were significantly older with a longer time since menopause, 
weighed less and had a lower BMI. Furthermore, the BP group had higher total 
cholesterol and lower LDL-cholesterol levels compared with controls. The BP group also 
had lowers LS, FN & TH T-scores and higher FRAX and PWV scores compared with the 





Table 7.2 Study population characteristics for the BP groups and subjects who have 
never used BPs. 
   Bisphosphonate Group 
  (n=80) 
    Controls 
    (n=341) 
  p-value 
   
  Mean (SD) 
 
 Mean (SD) 
 
Age (years) 64.3 (7.0) 60.8 (6.0) <0.001 
Time since menopause (years) 15.4 (8.4) 11.6 (6.9) <0.001 
Height (m) 1.63 (0.07) 1.62 (0.07) 0.438 
Weight (kg) 60.4 (9.1) 67.0 (12.3) <0.001 
BMI(kg/m
2
) 23.0 (3.4) 25.4 (4.5) <0.001 
MAP (mmHg) 92.7 (8.7) 93.7 (10.4) 0.483 
Cholesterol (total) (mmol/l) 5.8 (0.8) 6.1 (1.0) 0.017 
HDL-cholesterol (mmol/l) 2.1 (0.5) 2.0 (0.5) 0.202 
LDL-cholesterol (mmol/l) 3.3 (0.8) 3.6 (0.9) 0.002 
Triglycerides (mmol/l) 1.0 (0.5) 1.1 (0.5) 0.357 
eGFR (ml/min) 81.0 (16.8) 80.5 (14.0) 0.986 
Serum calcium (mmol/l) 2.4 (0.1) 2.4 (0.1) 0.713 
Lumbar spine T-score -2.1 (1.1) -1.2 (1.1) <0.001 
Femoral neck T-score -1.8 (0.6) -1.1 (0.9) <0.001 
Total hip T-score -1.5 (0.7) -0.7 (0.9) <0.001 
FRAX Score major (%) 13.5 (6.6) 8.8 (5.1) <0.001 
FRAX Score hip (%) 3.1 (3.1) 1.3 (2.2) <0.001 
Current smoker (%) 2 6 0.733 
Hypertension (%) 19 12 0.075 
Hypertension medication (%) 16 6 0.030 
Family history of CVD (%) 56 55 0.837 
24-point AAC score (AU) 2.6 (2.7) 2.1 (2.4) 0.105 
PWV (m/s) 9.3 (2.1) 8.7 (1.6) 0.006 
 
Figure 7.1 shows the mean lateral VFA 24-point and PWV scores for the control versus 
the BP group.  Mean AAC and PWV scores were higher in the BP group compared to 
subjects who had never taken BPs (Figure 7.1). Further analysis with ANCOVA using 
age as a covariate showed no significant difference in PWV between the BP group and 





                              
Figure 7.1 Mean 24-point AAC score (A) and mean PWV score (B) for the BP group and 
subjects who did not take bisphosphonates. The error bar represents the 95% CI. 
 
AAC was present in 48% (n=154) of subjects in the control group and 46% (n=37) of 
subjects in the BP group.  There was no statistical significance in the prevalence of AAC 
> 0 and PWV scores ≥ the median score of 8.7 or with AAC and PWV scores above the 
75th percentile between the BP group and those that had never taken BPs.   
Of the 80 subjects in the BP group 39% (n=31) had taken BPs between 1-3 years, 28% 
(n=22) between 4-7years and 34% (n=27) for 8+ years.  When the subjects were split 
into groups according to duration of BP use no significant differences were observed in 



































    
Table 7.4 shows the prevalence ratio (PR) and 95% CI for the total AAC and PWV 
scores. Multi-logistic regression models adjusting for age, BMI, physical activity status 
(PAS), smoking status, total cholesterol and triglycerides demonstrated that variables 
associated with BP use were also significantly associated with age (Table 7.5). Two 
models were used as described in Section 7.4.1 with prevalence ratios calculated for 
AAC scores >0 and ≥75th percentile of the variable. High and low PWV scores were split 
at the median and also at the 75th percentile of the variable (Table 7.4). The results 
showed the use of BP treatment was not associated with an increased risk of AAC or 
arterial stiffness in either of the models described above. Body mass index and total 
cholesterol were also significantly associated with BP use in both the 24-point score and 
PWV models (p=0.002, p=0.001).  
Table 7.3 Subject characteristics according to duration of BP treatment In years 
  Category 1 
 (1-3yrs) 
  n=31 
 Category  2 
  (4-7yrs) 
  n=22 
Category 3 
(8+yrs) 
n=27    
p-value 
    Mean (SD)    Mean (SD)      Mean (SD)  
 
Age (years) 64.2 (7.0) 64.0 (7.0) 65.7 (7.2) 0.611 
Time since menopause (yrs) 14.7 (9.0) 14.9 (7.6) 16.7 (8.6) 0.627 
Height (m) 1.63 (0.07) 1.63 (0.07) 1.62 (0.07) 0.895 
Weight (kg) 60.9 (8.9) 61.9 (8.1) 58.8 (10.3) 0.485 
BMI(kg/m
2
) 23.0 (3.4) 23.4 (3.4) 22.3 (3.2) 0.517 
MAP (mmHg) 93.3 (8.6) 93.9 (8.1) 90.9 (8.2) 0.400 
Cholesterol (total) (mmol/l) 5.8 (0.8) 5.7 (0.8) 5.9 (0.9) 0.683 
HDL-cholesterol (mmol/l) 2.2 (0.5) 2.1 (0.5) 2.1 (0.5) 0.681 
LDL-cholesterol (mmol/l) 3.2 (0.8) 3.2 (0.7) 3.5 (0.7) 0.266 
Triglycerides (mmol/l) 1.0 (0.4) 1.1 (0.8) 0.9 (0.3) 0.636 
eGFR (ml/min) 81.2 (18.6) 72.0 (12.2) 82.5 (19.0) 0.097 
Serum calcium (mmol/l) 2.4 (0.2) 2.4 (0.06) 2.4 (0.08) 0.147 
Lumbar spine T-score -1.6 (1.2) -1.1 (1.0) -1.5 (1.0) 0.313 
Femoral neck T-score -1.3 (0.8) -1.4 (0.8) -1.3 (0.9) 0.827 
Total hip T-score --0.8 (0.8) -1.1 (0.7) -0.8 (0.8) 0.512 
FRAX Score major (%) 9.1 (4.9) 10.4 (5.1) 10.1 (7.6) 0.698 
FRAX Score hip (%) 1.2 (1.4) 2.0 (2.9) 1.3 (1.1) 0.301 
AAC 24-point score (AU) 3.2 (3.0) 2.1 (2.7) 2.5 (2.5) 0.509 





Table 7.4 Prevalence ratio (95%CI) for binary lateral VFA AAC and PWV scores. Results 
are presented as AAC >0 and median PWV. High AAC and PWV values are set at the 
75
th













Total 24-point AAC score    <0.001 
> 0  1.00 0.60-1.66 0.988  
≥ 5  0.97 0.54-1.74 0.922  
PWV (m/s)    <0.001 
≥ 8.7  1.44 0.83-2.52 0.195  
≥ 10.0  1.09 0.64-1.86 0.742  
 
Multivariate regression analysis showed no association between the use of BPs with 
AAC in the unadjusted, age-adjusted or fully-adjusted models after correcting for 
confounders associated with VC and arterial stiffness. Age and PAS were both 
significantly associated with AAC (Table 7.5). In contrast, there was a significant positive 
association between BP use and PWV in the unadjusted regression model (p=0.009) but 
this association did not remain in the age-adjusted model. After correcting for 
confounders in the fully-adjusted model, BP use was found to be significantly associated 
with PWV (Table 7.5).  
 
Table 7.5 Multivariate regression analysis of log AAC measured using lateral VFA and 
log PWV as the dependent variable and BP use (binary) as the independent variable. 





Age (years) 0.198 0.009 0.341 <0.001 
BMI (kg/m
2
) 0.040 0.625 0.130 0.012 
Physical activity 0.161 0.031 -0.073 0.113 
Smoking status 0.032 0.656 -0.029 0.521 
MAP (mmHg) 0.112 0.126 0.353 <0.001 
Total cholesterol (mmol/l) 0.129 0.102 0.034 0.495 
Triglycerides (mmol/l) -0.035 0.667 -0.017 0.735 
Bisphosphonate use 0.029 0.708 0.105 0.031 
 
Further multivariate analysis showed no association between the duration of BP use with 





7.5.2 Effects of alendronate on aortic calcification and aortic stiffness in 
postmenopausal women: A pilot RCT  
At the time of reporting only 14 subjects had completed the 12-month follow-up visit, with 
10 subjects randomised to the treatment arm and only 4 subjects randomised to the 
control arm.  
The results of the RCT are not presented here. The pilot randomised controlled study 
started only after the PhD project had commenced and was therefore limited by a small 
sample size that was not sufficiently powered to detect statistically significant change. 
Although the preliminary results of the RCT were not included they were considered a 
useful adjunct to the results of the cross-sectional study and will be published at the end 
of the 24-month study period. 
 
                7.6 Discussion 
The rationale for the present study was to evaluate the effects of BP treatment on VC 
and aortic stiffness in postmenopausal women as BPs are the first line treatment for the 
treatment of OP and prevention of OP-related fractures [747], and accumulating 
evidence from experimental, animal and clinical studies suggest that BPs also have the 
potential to slow the progression or even induce the regression of VC [510, 537-540]. 
There are currently no licensed therapies which have been shown to reduce VC – an 
independent predictor of CVD risk – therefore a concurrent therapy that can not only 
treat OP but also prevent or reduce the progression of AC may be beneficial in reducing 
mortality resulting from CVD. Results from the cross-sectional study showed the use of 
BPs and the duration of BP use to be positively associated with PWV but not AAC.  
 
Vascular calcifications can occur at two distinct sites within the vessel wall: the intima 
and the media. Intimal calcification occurs in the context of atherosclerosis and 
characterised by lipid accumulation, inflammation, fibrosis and the development of focal 
plaques. It is these atherosclerotic plaques that are predominantly found within the aorta 
[748-750].  In contrast, medial calcification, which usually occurs along the elastic 
lamina, is a common occurrence in patients with CKD whereby the dysregulation of 
calcium and phosphate metabolism is the main contribution to VC. Elevated calcium and 
phosphate levels have direct effects VSMCs and sequentially the VSMCs stimulate 
osteogenic/chondrogenic differentiation, vesicle release, apoptosis, loss of inhibitors, 
and extracellular matrix degradation to drive the development of VC. Research has 





in which BPs influence its development remains to be fully established.  It is known, 
however, that BPs have a direct effect on the arterial wall where there is a possible 
interaction with sub-endothelial lipid-phagocytic cells [504]. Bisphosphonates are 
internalised into the arterial wall by macrophage phagocytosis; a process in which 
macrophages ingest BPs and once phagocytosed, BPs have been reported to affect the 
ability of macrophages to internalise atherogenic LDL-cholesterol and the subsequent 
transformation into foam cells [498]. It has been suggested that BPs influence the 
development of VC by the reduction of serum calcium and phosphate limiting their 
deposition within the vascular wall. Furthermore, it has been suggested that BPs have a 
direct effect on calcium crystal formation by blocking hydroxyapatite nucleation and 
growth [751].  Results of the cross-sectional study found no association between the use 
of BPs and the duration of BP use and AAC measured using lateral VFA scans [Table 
7.5]. Contrary to these results a recent study evaluating NCBP use and the prevalence 
of VC in over 3700 women showed that NCBPs were associated with a decreased 
prevalence of VC in subjects aged 65 years and over [734]. Possible explanations for 
why the present study failed to find an association between the use of BPs and AAC 
may be due to the small sample size compared with the significantly larger cohort in the 
study by Elmariah et al described above.  Moreover, in the present study VC was only 
measured at the AA using 2-D lateral VFA imaging in only 54 subjects whereas the study 
by Elmariah et al evaluated coronary calcification using CT in over 3700 subjects. Both 
lateral VFA and CT imaging are methods which are limited by their inability to distinguish 
between intimal and medial calcifications and image quality can be greatly affected by 
patient size, which is particularly true with lateral VFA scan images where poor image 
quality results in a large percentage of scan images that cannot be evaluated. Moreover 
lateral VFA scan image analysis has a lower inter-rater agreement compared with that of 
CT as highlighted in preceding chapters.   
 
Cross-sectional data from this study showed that BP users had significantly higher total-
cholesterol and lower LDL- cholesterol results compared with those who had not used 
BPs. Nitrogen-containing BPs, including alendronate, inhibit farnesyl-pyrophosphate 
synthase, an enzyme in the mevalonate pathway, the site of statin action [752] and intra-
venous administered BP has been shown to decrease serum LDL-cholesterol levels by 
approximately 5% and raise HDL-cholesterol levels by 10% to 18% [735, 736]. 
Conversely, research evaluating the effects of alendronate on lipid metabolism and BMD 
in over 120 osteoporotic postmenopausal women reported no significant change in any 
components of the serum lipid profile following 12-months of treatment [753]. Although 





736] the data from the present study represent orally administered BPs.  In addition to 
the effects of BP in the mevalonate pathway, IV- administered BP has also been shown 
to reduce inflammation by inhibiting the secretion of several inflammatory cytokines, 
including IL-6 and TNF [754, 755]. Vascular inflammation to some degree is a frequent 
concomitant of most forms of VC, therefore a reduction in inflammatory markers by BPs 
may confer beneficial effects in the context of inhibiting the development and 
progression of inflammatory diseases such as atherosclerosis and subsequently the 
development of VC.  
 
Results of the cross-sectional study found a significant difference in PWV scores 
between BP users and those who had never used BPs [Figure 7.1], however this 
significant association was found to be largely driven by age. Cross-sectional data also 
showed a significant positive association between BP use and the duration of BP use 
with PWV, although this association was also confounded by age and MAP [Table 7.5] 
which are both significantly associated with arterial stiffness [605, 606]. Moreover, 
subjects taking BPs were significantly older than subjects that had never taken BPs and 
therefore would most likely have increased arterial stiffness. Toussaint et al evaluated 
changes in PWV as an outcome measure in a randomised controlled trial evaluating the 
effects of alendronate on VC, and the mean PWV was reported to have increased 
significantly throughout the 18-month study in both the alendronate and control arm 
[515]. Conversely, a recent study reported minimal change in arterial stiffness in 
osteoporotic postmenopausal women following 12-months treatment with oral 
alendronate [746]. Arterial stiffness is in part dependent on atherosclerotic burden and/or 
medial calcification, and a reduction in PWV would be expected in subjects taking 
alendronate due to the inhibitory effects of BP on the development of atherosclerosis 
and VC [321, 605].  
The present study did have several limitations. Subjects who were known to be taking 
lipid lowering therapy were excluded, likely lowering both the incidence and extent of VC 
within the study population. Only a limited number of BP users were recruited to the 
cross-sectional study and therefore results may not represent the true effects of BP use 
on VC in the wider population. Bisphosphonate use and the duration of BP use was self-
reported and precluded information on treatment compliance, both of which create 
significant limitations, and therefore there may have been over or underestimation of 
duration of use. The use of lateral VFA imaging to quantify AC was limited by the inability 
of the technique to distinguish between intimal and medial AC, and it is possible that 
intimal and/or medial calcification was being measured. Most of the subjects that were 





was not possible to separate the effects of BPs on VC from the effects of calcium and 
vitamin D on VC. The pilot randomised controlled study started only after the PhD project 
had commenced and was therefore limited by a small sample size that was not 
sufficiently powered to detect statistically significant change. Although the preliminary 
results of the RCT were not included they were considered a useful adjunct to the results 
of the cross-sectional study and will be published at the end of the 24-month study 
period.  
 
                7.7 Conclusion 
Results of the cross-sectional study presented here did not show any significant 
association between BP use with AAC or arterial stiffness. Large-scale RCTs are 
required to evaluate the vascular effect of BPs to establish whether they can provide a 
concurrent therapy that not only treats OP and reduces fracture risk, but may also 
prevent the progression or decrease VC in subjects that have an increased risk of CV 








Conclusion and further work 
 
8.1 Summary 
The principle objective of this research project was to investigate the relationship 
between osteoporosis and aortic calcification in postmenopausal women, during which 
the study has provided an extensive evaluation of not only the associations between VC 
within the aorta and at other vascular sites with aortic stiffness, BMD and regulators of 
bone remodelling, but also the imaging techniques that can be used to quantify vascular 
and aortic calcification not only in clinical practice but also for research purposes.  
 
8.1.1 The role of Lateral VFA and CT for quantifying VC 
The specifically designed preliminary imaging study as detailed in Chapter 3 was aimed 
to test the hypotheses that lateral VFA imaging – primarily used for the assessment of 
vertebral deformity – may offer a quick and reproducible method for quantifying AAC 
which could be implemented into routine clinical practice and performed concurrently 
with bone density scans in women referred for OP screening. Furthermore, that 
moderate dose, non-diagnostic, non-contrast CT may also provide a reproducible 
alternative to higher dose diagnostic CT methods that are routinely used in clinical 
practice for quantifying coronary VC. Research has shown that most individuals in later 
life – from the sixth decade onwards – will have evidence of calcium deposition within 
the major arteries leading to an increased risk of CV events and subsequent significant 
morbidity and mortality, and moreover VC is frequently observed in patients with OP. 
This research study demonstrated that lateral VFA imaging may indeed offer a 
reproducible imaging method to quantify AAC however, for the use of lateral VFA scan 
images to be expedient in clinical practice, it is important that the process be quick and 
reliable. The lateral VFA inter-rater agreement data reported in Chapter 3 highlighted the 
importance of training required to adequately interpret and evaluate the scan images to 
ensure results are reported accurately and consistently between multiple raters and limit 
delay and the possibility of the misinterpretation of image artefacts. The preliminary 
imaging study CT reproducibility data demonstrated that the modified scanning protocol 
developed specifically for this research study does provide highly reproducible results 





evaluating coronary calcification in clinical practice. Additionally, the modified CT scan 
protocol was suitable for quantifying VC at multiple vascular sites and results 
demonstrated that scan images can be interpreted and evaluated by an appropriately 
trained clinical scientist and/or experienced radiographer, and therefore remove the 
burden of extra scan reporting time imposed on a radiologist.  The cross-sectional study 
results as presented in Chapter 4 further tested the reliability of lateral VFA scan images 
for quantifying calcification, evaluating its sensitivity and specificity by comparing to the 
gold-standard of CT. This was an important aspect of the study as there is very limited 
information published on the accuracy of lateral VFA for the prediction of VC in lower risk 
populations as the available data are limited to higher risk study populations with renal 
disease that will have a greater incidence and extent of VC. Results from this study 
showed that lateral VFA scan images were only able to predict high levels of AAC as 
detected by CT with moderately-good accuracy and may therefore be limited in any 
potential clinical application. However, this was not necessarily considered a negative 
finding. Due to cost, risks associated with radiation exposure and the potential burden on 
the health service it would be considered prudent in clinical practice to limit the use of 
imaging techniques used to quantify VC to patients who are at a higher risk for future CV 
events and who would benefit from further clinical intervention and management.  
 
8.1.2 Relationship between BMD, regulators of bone remodelling and AC/VC 
It is now well established that OP and CVD are common age-related conditions and 
although traditionally, the two conditions were considered unrelated and their 
coexistence attributed to independent age-related processes, increasing biological and 
epidemiological evidence suggests that there are age-independent associations 
between BMD, VC, atherosclerotic burden and CV-related events, morbidity and 
mortality. The cross-section data from this research was used to investigate the 
relationship between BMD and AC by evaluating associations between BMD measured 
at the lumbar spine, femoral neck and total hip with AC measured using lateral VFA scan 
images and VC at multiple sites using the gold-standard CT. Notwithstanding significant 
results reported by others, the results of this study failed to find any significant 
associations between BMD and measures of VC. These results were surprising, 
particularly in view of the size of the study population data set which included over 400 
postmenopausal women. Indeed limitations of imaging methods likely provide the 
explanation as to why this study found no significant relationship between BMD and 
AC/VC. As highlighted in Chapter 5 and preceding chapters, quantitative analysis of 





image artefacts and furthermore, the quantification of AAC on lateral VFA scan images 
can be highly subjective and relies on the skill and interpretation of the reader. Another 
important consideration is that CT imaging methods (like most imaging methods) are 
currently unable to distinguish between the different types of VC including intimal and 
medial calcification, so there was no way of determining which type of calcification was 
being identified, and whether the method used was more sensitive to one type of 
calcification over another. 
Prospective studies have shown AC to be related to bone loss and an increase in 
fracture risk, and animal studies have shown that many important biochemical factors 
involved in the regulation of bone and mineral metabolism may also be implicated in the 
pathogenesis of VC, which provided the rational to investigate the associations between 
regulators of bone remodelling with VC and BMD in the present study. Chapter 6 reports 
results of the association between circulating Wnt inhibitors sclerostin and Dkk1 with AC, 
VC and BMD which are of particular interest as relationships with Dkk1 and sclerostin 
may provide further evidence of their role in the pathogenesis of OP and VC, both of 
which are frequently seen in the ageing female population. Furthermore, there are 
limited data in the literature regarding the associations between sclerostin and VC in 
humans and although these studies have demonstrated both a positive and inverse 
relationship between sclerostin and VC, the majority have been limited to higher risk 
populations with renal disease and DM that have a greater incidence and severity of VC. 
Data from this research study demonstrated that serum Dkk1 was not associated with 
BMD or AC/VC but sclerostin on the other hand was significantly associated with BMD 
but like Dkk1 was not associated with AC or VC. Only a limited number of subjects were 
included in this particular study as described in Chapter 6 which may account for the 
lack of significant results, and as previously reported there are also limitations 
associated with the imaging methods used to quantify AC/VC. Further large-scale 
observational and prospective epidemiological studies are required to fully establish the 
relationships between BMD and VC.  
 
8.1.3 Relationships between PWV, BMD, regulators of bone remodelling and VC.  
Pulse wave velocity is a simple, non-invasive method of measuring arterial stiffness and 
has been shown to be an independent predictor of CV-related events and mortality. It is 
in part dependent on atherosclerotic burden and/or medial calcification however the 
relationship between PWV and BMD is less apparent. This study evaluated the 
relationships between arterial stiffness with BMD, AV/VC and regulators of bone 





significant associations between PWV with BMD measured at multiple sites. 
Furthermore, there was no association between arterial stiffness and Dkk1 or sclerostin 
– regulators of bone remodelling. As highlighted in Chapter 5 previous studies have 
reported inconsistent results regarding associations between PWV and BMD with some 
reporting positive associations while others report no association. The reason for the 
disparity with reported results is not clear but the use of different imaging methods to 
measure BMD may account for this. For example, DXA is the most widely used method 
for measuring BMD however previous studies have used QCT – a superior method of 
quantifying BMD – which provides a true volumetric measure of bone which cannot be 
achieved using DXA. This study did not find any association between arterial stiffness 
measured using PWV with AAC measured using lateral VFA scan images but does 
initially report a significant association between PWV and VC measured using CT, 
however this relationship was later found to be confounded by other factors such as age, 
mean arterial pressure, hypertension and body mass index which have all been 
significantly associated with arterial stiffness in this and other research areas. This 
research study also evaluated associations between regulators of bone remodelling – 
circulating Wnt inhibitors sclerostin and Dkk1 – with arterial stiffness as detailed in 
Chapter 6 but reported no association although there was a trend for higher sclerostin 
levels in women with increased arterial stiffness, a finding that has been previously 
reported by others. The role of circulating sclerostin and Dkk1 in the development or 
inhibition of VC and arterial stiffness is a relatively understudied area and there are 
limited data in the literature regarding the associations between circulating sclerostin and 
Dkk1 levels with arterial stiffness in healthy, ambulatory populations, and whether 
arterial stiffness and its contributing factors lead to an increase in circulating sclerostin, 
or increased circulating sclerostin levels result in a reduction of arterial compliance and a 
subsequent increase in PWV remains to be determined. Ultimately further observational 
studies on larger study populations would be required to elucidate the relationships 
between arterial stiffness, BMD and AC/VC.  
 
8.1.4 Bisphosphonates and the effects on AC/VC and aortic stiffness. 
In view of the common underlying mechanisms between VC and bone formation there is 
significant interest in the role of therapies used to treat OP in postmenopausal women 
and the potential therapeutic effects they may have on VC. It is hypothesised that agents 
such as BPs that are widely used to treat OP may slow the rate of progression or even 
inhibit VC. Experimental and animal studies have shown BPs to have a consistent effect 





unequivocal evidence supporting the inhibitory effect of BP. This research project aimed 
to test the hypothesis that BPs have an inhibitory effect on VC using cross-sectional data 
and also from data acquired from the randomised controlled treatment study that ran 
concurrently. This area of research is clinically important as there are currently no 
therapies available that can reverse VC. Chapter 7 reports on the associations between 
VC, aortic stiffness and BP use from the cross-sectional study. Unlike previously 
reported results by others the cross-sectional study results failed to show any 
association between the use of BP therapy with AC. This was mainly attributed to 
possible limitations with imaging methods as previously described and the differences in 
sample size between studies and any possible association between arterial stiffness and 
BP use was confounded by factors associated with arterial stiffness including age and 
hypertension as previously discussed.  Although not presented here, results of the RCT 
also failed to show any significant associations between BP use, AC and arterial 
stiffness although this was likely due to the significantly small sample size. It is important 
to highlight that the pilot RCT started only after the PhD research project had 
commenced and was therefore limited by a small sample size that was not sufficiently 
powered to detect statistically significant change in the outcome measures. Due to the 
significant limitations the RCT data was not included although it served as a useful 
adjunct to the results of the cross-sectional study and results from 24-month data will be 
reported once the RCT study is completed.  
Although this research study employed a comprehensive and stringent list of exclusion 
criterion for the selection of suitable research subjects, as detailed in Section 2.4.1, 
Chapter 2, it did not specify that subjects would not be eligible for enrolment had they 
ever used oestradiol and/or testosterone implants or used percutaneous testosterone 
within the preceding 3-months.  However, each study subject completed a bone health 
questionnaire and was interviewed in order to obtain a comprehensive medical history. It 
is therefore important to note that none of the subjects enrolled onto the study reported 
using these hormone preparations. 
This research project highlighted the importance of patient education regarding the use 
and safety of therapies used to treat OP. For example, many volunteers were reluctant 
to take part in the RCT due to fears surrounding the use of calcium supplementation as 
a result of the reported association between calcium use and CVD frequently published 
in the media.  Furthermore, there was a great lack of understanding with regard to the 
clinical application of BPs and their association with incident oesophageal cancer and 
osteonecrosis of the jaw. Negative reporting in the media and the dissemination of 





RCT resulting in women not wanting to take part for fear of developing cancer and/or 
developing heart disease as a result of taking BP and/or calcium supplementation. In 
conclusion, further large-scale RCTs are required to fully evaluate the vascular effects of 
BPs to establish whether they can provide a concurrent therapy that not only treats OP 
but may also halt the progression of VC in populations that have an increased clinical 
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